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ABSTRACT 
Inhibitory Actions of Ah Receptor Agonists and Indole-Containing Compounds in 
Breast Cancer Cell Lines and Mouse Models. (May 2004) 
Kelcey Manae Becker Walker, B.S., College of William and Mary;  
M.S., Virginia Tech University 
Chair of Advisory Committee:  Dr. Stephen H. Safe 
The aryl hydrocarbon receptor (AhR) binds synthetic and 
chemoprotective phytochemicals, and research in this laboratory has developed 
selective AhR modulators (SAhRMs) for treatment of breast cancer.  Activation 
of the AhR through agonists such as TCDD inhibits hormone activation of 
several E2-responsive genes in breast cancer cell lines.  In this study, inhibition 
of E2-induced proliferation and gene expression by TCDD has been investigated 
in the uterus of wildtype, ERKO and AhRKO mice.  Cyclin D1, DNA polymerase 
α, and VEGF mRNA levels are induced by E2 through ERα in the uterus as 
determined by in situ hybridization studies.  TCDD down-regulated E2-induced 
cyclin D1 and DNA polymerase α expression, but not E2-induced VEGF 
expression, in wild-type mice, but not AhRKO mice, confirming the role of the 
AhR.    Furthermore, protein synthesis was not necessary for induction of cyclin 
D1 or DNA polymerase α gene expression by E2 or inhibition of these 
iv
responses by TCDD.  Therefore, AhR-ERα crosstalk directly regulates the 
expression of genes involved in cell proliferation in vivo. 
AhR agonists induce down-regulation of ErbB family receptors in multiple 
tissues/organs suggesting possible inhibitory interactions with chemotherapeutic 
potential.  Recently, it has been reported that the SAhRM 1,1’,2,2’-
tetramethyldiindolylmethane inhibited DMBA-induced mammary tumor growth in 
rats and also inhibited MAPK and PI3-K pathways in human breast cancer cells.  
BT-474 and MDA-MB-453 cell lines are ErbB2-overexpressing breast cancer 
cells that express functional AhR and exhibit constitutive activation of MAPK and 
PI3-K pathways.  Therefore, 1,1’,2,2’-tetramethyldiindolylmethane-induced 
inhibition of ErbB2 signaling was investigated in these cells lines and in the 
MMTV-c-neu mouse mammary tumor model, which overexpresses ErbB2 in the 
mammary gland.  The growth of ErbB2 overexpressing cell lines and mammary 
tumors was inhibited by 1,1’,2,2’-tetramethyldiindolylmethane; however, 
modulation of MAPK or PI3-K pathways and cell cycle proteins nor induction of 
apoptosis by 1,1',2,2'-tetramethyldiindolylmethane was observed in the ErbB2-
overexpressing cell lines.  Current studies are investigating mitochondrial effects 
of 1,1’,2,2’-tetramethyldiindolylmethane in the ErbB2-overexpressing cell lines, 
as well as continuing studies on gene expression profiles in the mammary 
glands of MMTV-c-neu mice to better understand and identify critical genes that 
are responsible for ErbB2-mediated transformation and growth of cancer 
cells/tumors.     
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1CHAPTER I 
INTRODUCTION
1.1 Breast cancer 
1.1.1 General introduction with statistics   
An estimated 1 in 8 women in the US will develop breast cancer, and it is 
the second leading cause of cancer-related deaths in women of the Western 
world (American, 2003).  The American Cancer Society estimates that 267,000 
new cases of breast cancer will be diagnosed and 39,800 women will die from 
breast cancer this year in the US.  It is the most freqently diagnosed non-skin 
cancer for US women with 5-year survival rates of 97% for local breast cancers, 
78% for regional metastasis and 23% for distant metastasis.  Approximately 
10% of breast cancer cases can be attributed to inheritance of mutations in 
genes such as BRCA1 and BRCA2; however, the majority of cases (~ 90%) 
occur in women with no familial history and the molecular basis and etiology of 
“sporadic” breast cancer is poorly understood (Claus et al., 1996).   
1.1.2 Risk factors for breast cancer 
 A small percentage of all breast cancer cases (~ 10%) have a familial  
_______________ 
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2pattern of incidence resulting from inheritance of germline mutations in high-
penetrance genes such as BRCA1/2 or other low-penetrance genes that have  
yet to be identified.  Inheritance of mutated BRCA1 or BRCA2 carries a lifetime 
risk of 30-70% for cancer incidence with the variation in risk thought to be 
dependent upon genetic background and environmental factors.  The cause of 
the remaining breast cancer cases, ~ 90%, is poorly understood, although 
multiple risk factors have been identified.  The American Cancer Society 
includes increasing age, long menstrual cycle due to early menarche and late 
menopause, obesity after menopause, recent use of oral contraceptives or 
hormone replacement therapy, nulliparity or first pregnancy after the age of 30, 
and the consumption of one or more alcoholic beverages daily as risk factors for 
breast cancer (American, 2003). 
1.1.2.1 Hormonal/environmental risk factors 
 Lifetime exposure to the female hormone estrogen is a major known risk 
factor for the development of breast cancer, and there is much evidence from 
studies of both familial and sporadic breast cancers that support the etiologic 
role of estrogen.  Although few studies have looked at the effect of estrogen on 
the risk of breast cancer development in BRCA1 mutation carriers, there is 
indirect evidence that increased exposure to estrogen increases breast cancer 
risk.  For example, a bilateral prophylactic ovariectomy, which drastically 
decreases circulating estrogen levels in the body, will significantly decrease the 
risk of breast cancer in women that carry the BRCA1 mutation (Rebbeck et al., 
31999).  Other indirect evidence includes increased susceptibility to breast cancer 
from pregnancy  (estrogen levels are 50-100 fold higher during pregnancy) 
(Johannsson et al., 1998; Jernstrom et al., 1999), a 4-fold increase in risk with a 
high body mass index (BMI) at age 12 (adipose tissue is a major source of 
estrogen without ovarian production) (Hilakivi-Clarke et al., 2002), and a 
possible increase in risk of breast cancer when oral contraceptives are taken 
prior to the first pregnancy (Ursin et al., 1997) in either women with a strong 
family history of breast cancer or with mutations in BRCA1/2.   
 There is also evidence that high estrogen exposure increases the risk of 
developing sporadic breast cancer, especially in post-menopausal women.  
Studies have shown that estrogen levels are higher in post-menopausal women 
that develop breast cancer than those that do not (Hankinson et al., 1998) and 
obesity leads to increased estrogen levels in post-menopausal women and this 
increases the risk of breast cancer (Yong et al., 1996).  Multiple studies have 
shown that hormone replacement therapy, whether estrogen or estrogen + 
progestin treatment, during menopause increases the risk of breast cancer 
(Hoover et al., 1976; Colditz and Rosner, 2000; Schairer et al., 2000; Rossouw 
et al., 2002) and increased exposure to estrogen through the menstrual cycle, 
either by early age at menarche or by late age of menopause, increases the risk 
of developing breast cancer (Trichopoulos et al., 1972; Kampert et al., 1988; 
Hulka and Stark, 1995).  Furthermore, a decrease in estrogen levels through a 
4bilateral ovariectomy decreases the postmenopausal risk of breast cancer and is 
a treatment for existing pre-menopausal disease (Kreiger et al., 1999).   
 Research has also investigated the effects of in utero exposure to 
estrogen on the risk of developing breast cancer and the results suggest that 
increased exposure to estrogen in utero also leads to increased risk of breast 
cancer (Trichopoulos, 1990).  High birth weight has been linked to high maternal 
estrogen levels (Gerhard et al., 1987) and multiple studies suggest that high 
birth weight increases the risk of breast cancer development (Michels et al., 
1996; Sanderson et al., 1996), although some studies suggest that this increase 
is observed only in pre-menopausal women (Potischman and Troisi, 1999).  
Maternal estrogen levels are also higher in pregnancies with twins compared to 
singletons (Duff and Brown, 1974), and twins have an increased risk of 
developing breast cancer (Braun et al., 1995; Weiss et al., 1997).  In contrast 
pre-eclampsia and eclampsia during pregnancy are associated with lower 
maternal estrogen levels and offspring have a significantly lower risk of breast 
cancer (Ekbom et al., 1992).  Animal studies have also shown that in utero 
exposure to E2 (Hilakivi-Clarke et al., 1997b), diethylstilbesterol (DES) (Walker, 
1984), genistein (Hilakivi-Clarke et al., 1999), or diets high in n-6 
polyunsaturated fatty acids (Walker, 1990; Hilakivi-Clarke et al., 1997b) 
increases the risk of developing mammary tumors in their offspring.  One 
contradictory study showed that although Asian women have higher estrogen 
levels during pregnancy than Caucasian women, their offspring have a lower risk 
5of developing breast cancer (Lipworth et al., 1999).  Differences in diet and the 
fact that non-pregnant Asian women have 40% lower levels of circulating 
estrogens than Caucasian women (Goldin et al., 1986) may have a more 
dominant effect on risk than the high estrogen levels during pregnancy.    
 Studies investigating a link between estrogen exposure and breast cancer 
risk during the reproductive years, either through menstrual cycling, pregnancy, 
or contraceptive use, have found that increased estrogen exposure is not always 
a risk for breast cancer development.  Estrogens peak twice during the 
menstrual cycle, therefore a shorter cycle would lead to a higher number of 
cycles and more cumulative estrogen exposure.  However, short menstrual cycle 
length dose not increase the risk of breast cancer development or recurrence 
(Garland et al., 1998; Titus-Ernstoff et al., 1998).  Also, multiple studies have 
determined estrogen levels at different stages of the menstrual cycle and have 
found an altered pattern of estrogens during the luteal and follicular stages in 
high-risk women.  In the luteal phase when estrogens peak twice, high risk 
women had lower estrogen levels; in the follicular phase when estrogen are 
normally low, high risk women had increased estrogen levels (Key et al., 1996).   
Estrogen levels are 50-100 fold higher during pregnancy (Murr et al., 
1974); however, some studies have shown that pregnancy is protective against 
breast cancer.  Multiple pregnancies have been shown to decrease risk, and 
there is also a decreased risk for women who have a first full-term pregnancy 
before the age 20 (Murr et al., 1974; Yuan et al., 1988).  Animal studies have 
6confirmed the protective effects of pregnancy.  E2 alone or E2 + progesterone 
treatment to mimic pregnancy protects rats from chemically induced tumors 
(Guzman et al., 1999).  In contrast, the first pregnancy after the age of 30 
increases the risk of breast cancer development (MacMahon et al., 1970) and 
pregnancy after 25 year results in a short term increase in risk with up to a 20 
fold increase during the first year after the pregnancy (Kelsey et al., 1993; Hsieh 
et al., 1994).  It has been suggested that because estrogen during pregnancy 
stimulates ductal branching and extensive formation of more differentiated 
alveolar lobules in the mammary epithelium, pregnancy at a younger age leads 
to more differentiated cell types and this reduces the number of undifferentiated 
cells that could lead to cancer.  However, as women age there is an increasing 
probability of initiated cells present in the mammary gland and estrogen 
exposure during pregnancy could induce these initiated cells to proliferate.  
Other studies have shown that high-birth weight babies, severe 
nausea/vomiting, and DES treatment during pregnancy, all of which are 
associated with increased estrogen exposure, lead to increased risk of breast 
cancer (Depue et al., 1987; Colton et al., 1993; Olsen and Storm, 1998).  In 
contrast, pregnancy-induced hypertension, which is associated with lower 
estrogen levels, decreases the risk of breast cancer development (Hsieh et al., 
1994).  Studies have also shown the protective effects of breastfeeding against 
breast cancer.  According to one study the relative risk of developing breast 
7cancer is decreased by 4.3% for every 12 months a woman breastfed 
(Collaborative, 2002).   
Oral contraceptive use has also been studied as a possible risk factor for 
breast cancer.  The use of oral contraceptives results in constant exposure to 
synthetic estrogens/progestins; however, circulating estrogens such as E2 and 
estrone are lower in these women compared to individuals who do not use oral 
contraceptives (O'Brien et al., 1997).  Oral contraceptives induce proliferation in 
the human breast and long-term use of oral contraceptives leads to a 42-45% 
increase in risk of breast cancer up to the age of 45, but risk is not increased in 
women 45 years or older (Isaksson et al., 2001; Hilakivi-Clarke et al., 2002).   
Environmental factors such as geographic location, diet, bodyweight, 
exercise, alcohol consumption, and exposure to endocrine disruptors have also 
been investigated as possible risk factors for breast cancer.  Breast cancer risk 
is higher for women in Western countries such as the U.S. and the U.K. than for 
far Eastern countries such as Japan, China, and India (McPherson et al., 2000).  
Studies of migrants from Japan to Hawaii indicate that the rates of breast cancer 
for those migrants increased to the rates similar to those observed for breast 
cancer in the U.S. (Brinton and DeVesa, 1996).  The change in breast cancer 
risk has been linked in part to an increase in dietary fat intake of the migrants 
(Kolonel, 1994; Lee et al., 1994).  Most dietary studies have focused on the 
effects of a high-fat diet on breast cancer risk.  Multiple studies have shown that 
a lower intake of fat in the diet decreases serum estrogen levels (Goldin et al., 
81982; Rose et al., 1987; Bennett and Ingram, 1990; Rose et al., 1993); however, 
there are conflicting results on whether a high-fat diet increases the risk of 
breast cancer.  Most case-control studies and animal studies conclude that a 
high-fat diet does promote breast cancer (Freedman et al., 1990; Howe et al., 
1990; Van't Veer et al., 1990; Richardson et al., 1991; Welsch, 1992); however, 
most cohort studies have not found a link between high-fat intake and increase 
risk of breast cancer (Willett et al., 1992; Hunter et al., 1996; Holmes et al., 
1999).  One pooled analysis of cohort studies did find a weak positive 
association between saturated fat intake and relative risk of breast cancer; 
however, no other type of fat was associated with breast cancer risk (Smith-
Warner et al., 2001).  Studies on bodyweight have found an inverse correlation 
between pre-menopausal bodyweight and breast cancer risk (Potischman et al., 
1996; Cleary and Maihle, 1997; Huang et al., 1997; Trentham-Dietz et al., 1997).  
One study showed that a low pre-menopausal body mass index (BMI) results in 
a several fold increase in breast cancer risk.  Furthermore, studies focused on 
bodyweight at puberty have found that lower BMI at puberty increases the risk of 
breast cancer (Hilakivi-Clarke et al., 2001), whereas higher weight or high fat 
consumption leads to a lower risk (Le Marchand et al., 1988; Parent et al., 1996; 
Huang et al., 1997; Magnusson et al., 1998).   
Studies looking at the effects of exercise on breast cancer risk are not 
conclusive as to whether exercise can decrease breast cancer risk.  One study 
does show that exercise can be protective against breast cancer in lean women, 
9but not in heavier women (Thune et al., 1997), and another study found a 
reduced risk of postmenopausal breast cancer associated with exercise early in 
life for women with low BMI at age 18 and those who have gained little or no 
weight in the adult years (Shoff et al., 2000).  However, factors such as diet that 
often correspond with exercise levels could be confounding.  Studies on alcohol 
consumption have shown that alcohol increases serum estrogen levels (Dorgan 
et al., 1994; Ginsburg et al., 1996; Muti et al., 1998; Purohit, 1998) and 
increases the risk of breast cancer development (Longnecker, 1994; Longnecker 
et al., 1995).  Discovery of endocrine disrupting chemicals in our diet and 
environment and the ability of some to mimic estrogen have led to studies on 
whether exposure to endocrine disrupting chemicals affects the risk of 
developing breast cancer.  Studies on organochlorine compounds do not show 
an increase in breast cancer risk with exposure and some studies even show 
lower pesticide levels in cases than in controls (Krieger et al., 1994; Lopez-
Carrillo et al., 1996; Hunter et al., 1997; van't Veer et al., 1997).  Furthermore, a 
meta-analysis on epidemiological studies of high soy intake showed that this 
high soy intake reduced pre-menopausal breast cancer risk (Hilakivi-Clarke et 
al., 2002).   
1.1.2.2 Genetic risk factors 
 Approximately 10% of breast cancer cases can be attributed to familial 
incidence and research has focused on identifying the inherited genes 
responsible.  The breast cancer susceptibility genes BRCA1 and BRCA2 were 
10
identified in 1995 and highly penetrant mutations in these genes can account for 
20-60% of familial breast cancer cases (Nathanson et al., 2001).  First-degree 
relatives of breast cancer patients have a 2-fold greater risk for the development 
of breast cancer over the general population (Pharoah et al., 1997), and this 
cannot be accounted for by BRCA1/2 alone (Peto et al., 1996).  Although 
environmental factors may contribute to an increase in risk, other low-penetrant 
genetic variants may be important (Dunning et al., 1999).  It has been predicted 
that a small number of other genetic variants (~ 4) may account for the 
remainder of familial risk (Easton, 1999).   
 Mutations in BRCA1 or BRCA2 lead not only to an increase in the risk of 
breast cancer, but also increased ovarian, prostate and pancreatic cancers 
(Rahman and Stratton, 1998).  BRCA1/2 mutations are described as highly 
penetrant with a lifetime risk for cancer incidence of 30-70% (Ford et al., 1998), 
some believe that variations in genetic backgrounds lead to the range in risk 
(Nathanson et al., 2001).  Most mutations are small insertions or deletions, 
which are thought to lead to truncated forms of the proteins; however, many 
missense and nonsense mutations have also been described.  Correlations 
between a particular mutation and a disease phenotype have not been 
convincing.  Evidence suggests that the cancer risk associated with BRCA1 and 
BRCA2 mutations is influenced by additional factors, such as genetic 
background and environment and, therefore, particular mutations can not be 
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linked to specific disease phenotypes (Thorlacius et al., 1996; Gayther et al., 
1997; Struewing et al., 1997).   
 BRCA1 and BRCA2 are very different in size and primary sequence; 
however, most evidence suggests they have common biological functions.  They 
have similar patterns of expression and are expressed in many tissues in a cell-
cycle dependent manner (Rajan et al., 1996; Bertwistle et al., 1997; Connor et 
al., 1997; Sharan and Bradley, 1997; Blackshear et al., 1998).  Both proteins are 
localized to the nucleus in somatic cells where they coexist in subnuclear foci 
that redistribute after DNA damage (Chen et al., 1998b).  Studies have 
confirmed a role for both proteins in response to DNA damage and there is 
evidence suggesting a role for BRCA1/2 in DNA double-strand break repair.  
Many studies suggest that BRCA1/2 proteins are important in activation of DNA 
damage checkpoints and that BRCA1 in particular contributes to DNA damage 
responses through interactions with enzymes involved in alterations of chromatin 
and DNA structure as well as transcriptional regulation of other genes involved 
in responses to DNA damage.  Although much evidence points to a role for 
BRCA1/2 in DNA repair, it is still not clear what is the primary cause of mutations 
in the BRCA1/2 genes leading to a disease state.   
 Many studies have investigated multiple other genes for possible low-
penetrance breast cancer susceptibility alleles.  The studies have focused 
mainly on polymorphisms in genes involved in steroid metabolism, such as 
COMT, CYP17, CYP19, ER and PR and carcinogen metabolism, such as 
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CYP1A1, CYP2E1, GSTM1, GSTT1, GSTP1, NAT1 and NAT2, or common 
polymorphism of high-penetrance genes, such as BRCA1 and TP53 (Dunning et 
al., 1999).  Results of these studies on low penetrance genes are inconclusive 
and often result in conflicting conclusions.  Of the genes studied, CYP19,
GSTM1, GSTP1, and TP53 appear to be the strongest possibilities for low-
penetrance breast cancer susceptibility genes (Dunning et al., 1999), although it 
is likely that the major low-penetrance familial risk genes are unknown.   
1.1.3 Breast cancer therapy 
 Advances in early detection and treatment of both initial stage and 
advanced breast cancer have led to significant improvements in patient 
response and survival in recent years (American, 2003).  Primary breast cancer 
is restricted to the breast and regional lymph nodes and can be removed 
surgically.  Once removed adjuvant systemic therapy is generally appropriate 
due to the possibility of micrometastatic tumor deposits in other tissue.  Adjuvant 
therapy can include chemotherapy, radiation therapy or endocrine therapy and 
combinations of at least two of these treatments are commonly prescribed 
(American, 2003).  The basic criterion that determines the appropriate adjuvant 
therapy is the hormone receptor status of the tumor [estrogen receptor (ER) and 
progesterone receptor (PR)].  Receptor negative disease is rarely responsive to 
endocrine therapy and thus chemotherapy and radiation therapy are 
appropriate.  For low risk receptor positive disease, observation or endocrine 
therapy may be appropriate; however, for the majority of receptor positive breast 
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tumors a combination of endocrine therapy and chemotherapy is used 
(Hortobagyi, 2002).  The progression of metastatic breast cancer can vary 
considerably and the therapy of choice often depends on factors such as age, 
extent of metastasis, presence of co-morbid conditions and hormone receptor 
status of the tumors that indicate whether a patient is high or low risk 
(Hortobagyi, 2002).  Low risk, hormone receptor positive disease is generally 
treated with endocrine therapy, whereas, for high-risk patients, chemotherapy in 
combination with endocrine therapy is the treatment of choice (Hortobagyi, 
2002).  Multiple endocrine therapies have been developed and many more are 
being tested.  Due to development of new drugs and acquisition of resistance to 
some endocrine therapies, the most effective sequence for chemotherapeutic 
drug administration is still being determined and will depend on tumor type.  
Standard chemotherapy options include combinations of drugs such as 
cyclophosphamide, methotrexate and 5-fluorouracil (CMF); CMF with vincristine 
and prednisone; 5-fluorouracil, doxorubicin and cyclophosphamide or the 
taxanes paclitaxel and docetaxel.  Many other chemical agents are effective for 
treatment of early and advanced breast cancer and there is extensive ongoing 
research on therapies that target specific molecular pathways of mammary 
tumor growth.   
1.1.3.1 Endocrine therapy  
 In general endocrine therapy is targeted at interrupting estrogen-induced 
proliferation of tumor cells.  The two main objectives of this type of therapy have 
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been to decrease estrogen levels, whether through ovarian ablation in 
premenopausal women or aromatase inhibitors in post-menopausal women, or 
to inhibit ER signaling with chemicals that bind ER directly such as selective 
estrogen receptor modulators (SERMs) (Figure 1.1).  In addition, other 
chemicals indirectly inhibit estrogen receptor signaling through crosstalk with 
other receptors including some nuclear receptors and the aryl hydrocarbon 
receptor.    
Figure 1.1: Structure of SERMs. (Adapted from Howell et al., 2000). 
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1.1.3.1.1 Tamoxifen 
 Tamoxifen was first developed in the 1960’s as a potential anti-fertility 
drug; however, research in the 1970’s discovered its potential as a novel 
antiestrogen for treatment of breast cancer (Harper and Walpole, 1967; Jordan, 
1998; Jordan, 2003).  Tamoxifen was approved by the USDA in 1978, and for 25 
years has been the gold standard for first-line treatment of hormone-sensitive 
metastatic breast cancer and for adjuvant therapy for early breast cancer with 
ER+ tumors after removal.  Tamoxifen is a non-steroidal triphenylethylene 
analog and its active metabolite, 4-hydroxytamoxifen, competes with estrogen 
for binding of the estrogen receptor with high affinity (Dorssers et al., 2001) 
(Figure 1.1).  Because tamoxifen exhibits tissue-specific ER antagonist and 
agonist activity it is considered a SERM.   
Standard 5 year post-operative treatment of breast cancer with tamoxifen 
decreases the annual odds of death by 25% and decreases the incidence of 
new contralateral breast cancer by 50% in ER- and/or PR-positive breast cancer 
(Early, 1998); however, treatment also results in a greater incidence of 
endometrial cancer (Fisher et al., 1996) and thromboembolis disease (Jaiyesimi 
et al., 1995; Fisher et al., 1996).  Responsiveness to tamoxifen treatment is 
partially dependent upon the ER and PR status of the tumors.  The highest 
response rate (70%) is seen in ER- and PR-positive tumors, ER-negative and 
PR-positive tumors have a response rate of 45% and ER-positive and PR-
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negative tumors have a response rate of 34% (Clarke et al., 2001).  Most studies 
report a response rate less than 10% for ER- and PR-negative tumors.   
In advanced breast cancer, over half of the ER-positive tumors show 
some response to tamoxifen treatment (Jaiyesimi et al., 1995).  A minor portion 
of patients treated with tamoxifen respond with complete remission of the 
disease and a majority of patients exhibit a partial remission or a stable disease 
for more than 6 months.  The remaining patients exhibit either a short-term 
stable disease of less than 6 months or immediate disease progression and are 
considered intrinsically resistant to tamoxifen treatment (Howell et al., 1988; 
Robertson et al., 1989; Foekens et al., 1994).  Even those patients initially 
responsive to therapy ultimately develop resistance to tamoxifen treatment and 
must be switched to second and third line endocrine therapy; however, those 
intrinsically resistant to tamoxifen are unlikely to respond to further second or 
third line endocrine therapy (Howell and Dowsett, 1997; Santen and Harvey, 
1999).   
The chemopreventative effects of tamoxifen are also being investigated.  
In one study, preventative treatment of high-risk women with tamoxifen 
decreased the risk of developing breast cancer in both pre-menopausal and 
post-menopausal women (Fisher et al., 1998).   In contrast, two smaller studies 
did not show a similar decrease in breast cancer risk with tamoxifen treatment 
(Powles et al., 1998; Veronesi et al., 1998).  However, differing criteria for 
admission, study design and size could account for the conflicting results and 
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needs to be further examined in order to determine whether tamoxifen is an 
effective chemopreventative agent for breast cancer.   
1.1.3.1.2 Raloxifene  
 Multiple new SERMs have been developed in hopes of replacing 
tamoxifen with a drug that is equivalent or better than tamoxifen as an estrogen 
receptor antagonist in the breast, but that does not have the ER agonist activity 
of tamoxifen in endometrial tissue.  Many of the newer SERMs exhibited activity 
and toxicity similar to or less than tamoxifen and have not been used to replace 
tamoxifen for the treatment of advanced disease (Howell et al., 2003); however, 
one SERM, raloxifene, has shown promise as a possible chemopreventative 
agent for breast cancer.  Raloxifene is a benzothiophene derivative and is 
already approved for the treatment of post-menopausal symptoms of bone loss 
in women (Clarke et al., 2001) (Figure 1.1).  Raloxifene is antiestogenic in both 
breast and endometrial tissue and estrogenic effects in bone, lipid metabolism 
and blood clotting.  In a study of post-menopausal women with osteoporosis, 
raloxifene decreased the risk of invasive breast cancer by 76% during a three-
year treatment.  Also, raloxifene treatment did not increase the rate of 
endometrial cancer, but did increase the incidence of thromboembolic disease 
(Cummings et al., 1999; Cauley et al., 2001).   
1.1.3.1.3 Fulvestrant (ICI 182,780) 
 Fulvestrant, or ICI 182,780, is an estrogen analog with a bulky side chain 
in the 7α position that prevents recruitment of co-activators to the ER complex 
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(Figure 1.1).  Binding of fulvestrant to the receptor results in ubiquitination and 
degradation of the receptor leading to decreased estrogen-responsiveness.  It 
has been termed a “pure” antiestrogen, however, it has been shown to activate 
transcriptional regulation by ERβ (Paech et al., 1997) and to exhibit estrogenic 
activity in normal and neoplastic mammary cells (Hilakivi-Clarke et al., 1997a; 
Kurebayashi et al., 1998).  Fulvestrant is approved for treatment of post-
menopausal women with hormone receptor-positive metastatic cancer following 
progression of the disease with first line endocrine therapy such as tamoxifen.  
Studies have shown that is it effective in 1 in 5 patients with resistance to 
tamoxifen (Howell et al., 2002; Osborne et al., 2002) and is as effective as 
anastrozole, an aromatase inhibitor, in second line treatment for advanced 
disease (Howell et al., 1996; Howell et al., 2003).  Currently, the need for 
intramuscular injections is a limiting factor in the administration of fulvestrant and 
new orally bioactive estrogen analogs, such as ZK191703, are being developed.  
1.1.3.1.4 Aromatase inhibitors 
 Aromatase inhibitors are being developed for the treatment of breast 
cancer in women without functional ovaries, whether through menopause or 
surgical removal.  Aromatase is the enzyme that converts the androgens 
androstenedione and testosterone to the estrogens estrone and estradiol in the 
final step of estrogen synthesis.  Estrogen synthesis occurs in peripheral tissues 
such as fat, muscle, skin, normal breast stromal cells, and breast tumor tissue in 
post-menopausal women, and aromatization is almost completely inhibited by 
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administration of aromatase inhibitors (Geisler et al., 2002) resulting in 
drastically reduced estrogen levels.  However, aromatase inhibitors do not 
decrease estrogen production in the ovaries of pre-menopausal women.  Third-
generation aromatase inhibitors anastrolzole, letrozole and exemestane are very 
specific inhibitors and do not have the adverse effects of the first and second 
generation aromatase inhibitors (Figure 1.2).  Anastrozole and letrozole are 
used in first and second line endocrine therapy for locally advanced and 
metastatic disease, and anastrozole is also used in adjuvant endocrine therapy 
with operable early breast cancer.  Exemestane is used in second line therapy 
after progression of the disease with first line endocrine therapy.   
 There is evidence that third generation aromatase inhibitors are as 
effective or more effective than the traditional second line endocrine therapies, 
such as megestrol acetate and aminoglutethimide, and exhibit less toxicity 
(Buzdar et al., 1996; Jonat et al., 1996; Buzdar et al., 1997; Buzdar et al., 1998; 
Dombernowsky et al., 1998; Gershanovich et al., 1998; Goss et al., 1999; 
Kaufmann et al., 2000).  Further studies showed that anastrozole and letrozole 
are more effective than tamoxifen in postmenopausal women for the treatment 
of advanced breast cancer (Bonneterre et al., 2000; Bonneterre et al., 2001; 
Mouridsen et al., 2001) and that anatrozole treatment as an adjuvant therapy in 
patients with operable breast cancer decreases the incidence of relapse and the 
development of new breast cancer compared to tamoxifen treatment (Baum et 
al., 2002).  However, the third generation aromatase inhibitors are relatively new 
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and the longe term effects on hormone-responsive tissue such as the bone, 
cardiovascular system, pelvic floor, lipids, and brain are not known.  There is 
some evidence that the steroidal exemestane may have lower antiestrogenic 
effects on normal tissue than the non-steroidal anastrozole and letrozole (Goss 
and Strasser, 2001). 
                            
Figure 1.2: Structure of aromatase inhibitors. (Goss and Strasser, 2002). 
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1.1.3.1.6 Arylhydrocarbon receptor (AhR) agonists 
 The arylhydrocarbon receptor (AhR) is part of the basic helix-loop-helix 
family of transcription factors and is the only member that is ligand-activated.  
The AhR was first shown to bind 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an 
environmental toxicant that is a by-product of industrial waste and combustion of 
organic material, and other halogenated aromatic environmental contaminants.  
Ligand-dependent activation of the AhR is associated with a range of 
biochemical and toxic responses including induction of drug metabolizing 
enzymes, disruption of endocrine signaling, hepatotoxic responses such as 
porphyria, immunotoxiicty, developmental and reproductive toxicity, wasting 
syndrome, chloracne, tumor promotion and carcinogenesis (Safe, 2001).  
However, one interesting observation from a long-term feeding study of TCDD 
showed that although liver tumors were higher in female Spraque-Dawley rats, 
TCDD also decreased multiple age-related spontaneous tumors including 
estrogen-dependent uterine and mammary tumors (Kociba et al., 1978).  This 
was one of the first indications that TCDD was able to block estrogen-induced 
responses and subsequent in vitro and in vivo research since has demonstrated 
inhibitory crosstalk between the AhR and ER signaling pathways.  TCDD inhibits 
various E2-induced responses in vitro in breast cancer cell lines including cell 
proliferation, DNA synthesis, gene transcription, and cell cycle progression as 
well as E2-induced responses in the rodent uterus including wet weight 
increase, cell proliferation, gene transcription, peroxidase activity, and PR and 
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ER binding.  The ability of TCDD to inhibit mammary tumor formation and growth 
has been confirmed in various age-dependent, as well as in carcinogen-induced 
mammary tumor models and in athymic nude mice with breast cancer cell 
xenografts.  Furthermore, epidemiology studies of women exposed to TCDD in 
Sevesco, Italy show a lower incidence of breast and endometrial cancer 
(Bertazzi et al., 1993).   
Studies on a series of alternate substituted alkyl polychlorinated 
dibenzofurans (PCDFs) typified by 6-methyl-1,3,8-trichlorodibenzofuran (6-
MCDF) demonstrated that these compounds bind the AhR with moderate affinity 
and exhibit both AhR agonist and antagonist activities (Figure 1.3).  In the rodent 
model 6-MCDF inhibited many of the toxic responses associated with the AhR 
including TCDD-induced CYP1A1, porphyria, immunosupression, and cleft 
palate.  However, 6-MCDF alone exhibited antiestrogenic activity and inhibited 
carcinogen-induced mammary tumor formation in Sprague-Dawley rats.  
Recently, an increasing number of studies have shown that various synthetic 
and structurally diverse naturally occurring compounds also exhibit tissue-
specific AhR agonist and antagonist activites.  These include phytochemicals 
that exhibit multiple chemoprotective and anticarcinogenic activities such as 
flavonoids, carotenoids, indole-3-carbinol and resveratrol (Bjeldanes et al., 1991; 
Jellinck et al., 1993; Chen et al., 1996; Gasiewicz et al., 1996; Gradelet et al., 
1997; Casper et al., 1999; Seidel et al., 2000).   
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Inhibitory AhR-ER crosstalk results in downregulation of several estrogen-
induced genes including pS2, c-fos, cathepsin, PR, and heat shock protein 27.  
Studies have also shown that AhR agonists induce down-regulation of ErbB1 
protein and/or phosphorylation in multiple tissues/organs (Astroff et al., 1990; 
Guyda et al., 1990; Sewall et al., 1995; Zhang et al., 1995).  The antiestrogenic 
properties as well as the possible downregulatory effect on the ErbB family of 
receptors by AhR agonist warrant the further development of selective AhR 
modulators (SAhRMs) for breast cancer chemotherapy where the compounds 
exhibit minimal toxicity but retain the antiestrogenic effects.  Studies in this 
laboratory have focused on two series of SAhRMs: alternate-substituted alkyl 
PCDFs and ring-substituted diindolylmethanes (DIMs) that are able to inhibit 
mammary tumor growth in rodent models while exhibiting relatively low toxicity 
(McDougal et al., 1997; Chen et al., 1998a; McDougal et al., 2000; McDougal et 
al., 2001) (Figure 1.3).   
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Figure 1.3: Structure of SAhRMs. (Safe, 2001). 
1.1.3.2 Molecular targeting 
1.1.3.2.1 Retinoids 
 Retinoids are natural and synthetic vitamin A analogs that possess 
antiproliferative, differentiative, immunomodulatory, and apoptosis-inducing 
properties in many cell types (Yang et al., 2002).  Vitamin A must be acquired 
from the diet either as preformed vitamin A (retinol and retinyl ester) or as 
provitamin A carotenoids that are metabolized to vitamin A in the body, and 
subsequently converted into retinoic acid by oxidative enzymes (Paik et al., 
2003).  The two known natural retinoids are all-trans-retinoic acid and 9-cis 
retinoic acid.  Retinoid signaling is largely through two types of nuclear retinoid 
receptors: retinoic acid receptor (RAR) and retinoid X receptor (RXR) that are 
part of the nulcear receptor superfamily and act as ligand activated transcription 
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factors that bind retinoic acid response elements (RAREs) (Pfahl, 1994; 
Mangelsdorf and Evans, 1995; Chambon, 1996).  Cellular retinoid acid binding 
proteins (CRBP) I and II have also been shown to highly regulate the activity of 
retinoids (Li, 1999).   
 Multiple studies have shown aberrant retinoid signaling in breast cancer.  
(Jing et al., 1996; Widschwendter et al., 1997; Xu et al., 1997; Spinella and 
Dmitrovsky, 2000).  Decreased expression of CRBP has been found both in 
breast cancer cell lines (Jing et al., 1996) and in tumors (Kuppumbatti et al., 
2000), especially in early ductal carcinoma.  Aberrant expression of RARs and 
RXRs has been observed in cultured breast cancer cells and tumors 
(Widschwendter et al., 1997; Xu et al., 1997; Lawrence et al., 1998; Ariga et al., 
2000; Suzuki et al., 2001).  RARβ is consistently downregulated or lost in breast 
cancer (Widschwendter et al., 1997; Xu et al., 1997) and loss of heterozygosity, 
as well as, hypermethylation of the promoter are thought to contribute to the 
silencing (Yang et al., 2001a; Yang et al., 2001b).  Because many of the 
chemopreventative effects of retinoids are due to RARβ induction, RARβ
expression may be used to identify tumors responsive to retinoid treatment and 
RARβ promoter demethylation could be used in therapy for some patients (Yang 
et al., 2002). 
 Epidemiology studies have given inconsistent results with respect to the 
benefits of vitamin A in breast cancer prevention.  A large prospective study 
showed an inverse relationship between dietary vitamin A intake and breast 
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cancer incidence (Hunter et al., 1993); however, two smaller prospective studies 
showed no association between retinol or β-carotene intake and breast cancer 
(Kushi et al., 1996; Verhoeven et al., 1997).  Inconsistancies between the 
studies and difficulties in determining vitamin A intake may account for the 
different results (Paik et al., 2003).  Animal studies of mammary tumor formation 
and growth inhibition by retinoids have identified retinoids that may be effective 
against breast cancer and have defined windows for effective retinoid treatment 
(Paik et al., 2003).  4-Hydroxyphenylretinamide (4-HPR, retinamide), which 
accumulates in mammary tissue, effectively reduces mammary tumor incidence 
and tumor burden in animal models (Moon et al., 1979), and in carcinogen-
induced mammary tumors the window for effective treatment with retinoids is 
early in tumor development as the anti-tumor activity of the retinoids decreased 
markedly when treatment began later in tumor progression (McCormick and 
Moon, 1982) (Figure 1.4).  Combination treatments with retinoids (4-HPR or 9-
cis retinoic acid) and endocrine therapies such as tamoxifen and raloxifene 
exhibit some synergistic effects in prevention of tumor formation in carcinogen-
induced animal models (Ratko et al., 1989; Anzano et al., 1994; Anzano et al., 
1996).   
Clinical trials of retinoids have focused mainly on clinical safety; however,                          
positive results for retinoid treatment are indicated.  One trial of all-trans-retinoic 
acid in combination with tamoxifen indicated an “objective response” in patients 
that previously did not respond to tamoxifen alone.  Another study of all-trans-
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retinoic acid in postmenopausal, advanced, nonmetastatic breast cancer 
showed a reduction in tumor grade and elevated RARβ mRNA in tumors (Toma 
et al., 2000).  A five year trial with 4-HPR treatment of women with stage 1 
breast cancer or ductal carcinoma in situ showed no difference in overall 
recurrence of second breast cancer with or without treatement; however, re-
evaluation which accounted for menopausal status indicated that 4-HPR 
treatment may be beneficial for premenopausal women (Veronesi et al., 1999).  
Further study of retinoid treatment for breast cancer is necessary and ongoing.  
               
Figure 1.4: Structure of retinamide. 
1.1.3.2.2 Angiogenesis 
 Angiogenesis is the process of new blood vessel development from 
existing vasculature.  It is a multistep process in which endothelial cells 
proliferate and become motile, move towards protein angiogenic factors in 
hypoxic tissue, degrade the basement membrane and form primitive vessels 
(Harris, 1997).  All tissues need oxygen and nutrients provided by the 
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vasculature; as tissue proliferates it requires parallel angiogenesis to provide 
oxygen and nutrients to maintain the growth.  Angiogenesis occurs in normal 
tissue, especially during development, wound healing and menstrual cycling 
(Smith, 2001), as well as, in tumor tissue.  New vessel growth is a tightly 
regulated process, especially in adults that is stimulated by numerous vascular 
growth factors, including vascular endothelial growth factor (VEGF), and is 
inhibited by factors such as angiostatin and endostatin (O'Reilly et al., 1994; 
O'Reilly et al., 1997; Ferrara, 2001).  During tumorigenesis a tumor outgrows the 
capacity of the surrounding vasculature to provide oxygen and nutrients, 
therefore the center becomes hypoxic and produces hypoxia-dependent 
angiogenic factors that stimulate new vessel growth.  Studies have shown that 
the growth of a tumor beyond 1-2 mm3 is dependent upon new vascular 
development for growth, and if none is provided then the tumor will go into a 
dormant state (Folkman, 1995).  It has been hypothesized that since 
angiogenesis is relatively low in normal tissue then anti-angiogenic treatment 
would be specific to tumors and significant research has focused on 
development of anti-angiogenic agents for the treatment of cancer.   
 The importance of angiogenesis in breast cancer has been demonstrated 
in multiple in vivo and clinical studies.  One in vivo study showed that normal, 
healthy breast tissue showed no angiogenic potential, where as angiogenesis 
was induced in all of the breast carcinoma samples (Lichtenbeld et al., 1998).  
Furthermore, the use of anti-angiogenic agents such as microtubule disruptors, 
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VEGF receptor tyrosine kinase inhibitors and adenoviral expression of 
angiostatin in animal mammary tumor models have demonstrated the need for 
new vasculature for tumor growth (Klauber et al., 1997; Wedge et al., 2000; 
Gyorffy et al., 2001).  Clinical breast cancer studies looking at angiogenesis as a 
prognostic indicator have shown an association between increased 
angiogenesis, measured by microvessel density, and decreased survival, 
decreased relapse-free survival, and an increase in metastases (Weidner et al., 
1991; Weidner et al., 1992; Heimann et al., 1996).   
 There are three potential molecular targets for the development of anti-
angiogenic agents: proteins and growth factors that stimulate angiogenesis, 
natural inhibitors, and survival factors necessary for maintainence of new 
vasculature.  VEGF is a strong potential target of anti-angiogenic therapy 
because it induces endothelial cell proliferation and motility as well as increasing 
vascular permeability.  One clinical trial treated metastatic breast cancer with a 
humanized recombinant mAb to VEGF (Miller, 2002).  After 22 weeks of 
treatment 17% of the patients were responsive or stable and 3 patients 
continued treatment without progression of disease for over 12 months (Miller, 
2002).  Based on this study, anti-VEGF therapy shows potential as a possible 
treatment for breast cancer.   
 One difficulty in developing anti-angiogenic agents is to identify a 
molecular target that is necessary for disease progression, reliably measure the 
effects of therapy on the molecular target in clinical samples, and correlate that 
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with benefits to the patient.  This is especially difficult with anti-angiogenic 
agents, because a simple measure of angiogenesis is not available.  
Furthermore, clinical trials on the benefits of anti-angiogenic agents must be 
carfully designed.  Preclinical studies have shown that anti-angiogenic agents 
have the greatest potential as adjuvant therapy where prevention and delay in 
disease progression are the prime objectives (Miller, 2002).  In contrast, anti-
angiogenic therapy for metastatic disease may not result in a classical objective 
response and tumor involution seen with cytotoxic drugs since disease 
stabilization is the most likely outcome for these agents (Miller, 2002).   
1.1.3.2.3 ErbB2  
 The human epidermal growth factor receptor (HER) family, also known as 
the ErbB family of receptors, is involved in normal growth and differentiation of 
the breast (Carraway et al., 1997) and has also been implicated in 
carcinogenesis (Slamon et al., 1989).  The family includes genes that encode 
four tyrosine kinase, cell membrane receptors, ErbB1 (HER1), ErbB2 (HER2), 
ErbB3 (HER3), and ErbB4(HER4) that are expressed at various levels in a 
variety of tissues.  The receptors bind a range of growth factor ligands and 
activation via the tyrosine kinase region of the receptors mediates cell 
proliferation, differentiation, and survival (Salomon et al., 1995; Schlessinger, 
2000; Simon, 2000).  Dysregulation of ErbB signaling pathways can result from 
receptor gene amplifications or mutations that lead to an increase in receptor 
transcription, translation, or stabiltity altering the receptor protein expression 
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levels in the cells.  ErbB2 overexpression in observed in 20-30% of breast 
tumors (van de Vijver et al., 1987; McCann et al., 1991) and is associated with 
aggressive tumor behavior and poor prognosis (Hynes and Stern, 1994).  
Patients with ErbB2 overexpressing tumors have a significantly shorter overall 
survival rate and time to relapse than patients with tumors that lack ErbB2 
overexpression (Slamon et al., 1987; Slamon et al., 1989; Berchuck et al., 
1990).  One study showed that 92% of overexpression of ErbB2 in breast cancer 
was due to gene amplification (Pauletti et al., 1996), and overexpression is 
found in all stages of tumor development, but not in benign tissue (Allred et al., 
1992).  Much research has focused on the use of ErbB2 as a prognostic and 
predictive factor as wells as a target for breast cancer therapy.   
 Multiple approaches have been attempted to target the ErbB receptors 
including anti-ErbB specific monoclonal antibodies (mAbs), small molecular 
tyrosine kinase inhibitors, cytotoxic or immunoreactive agents coupled to anti-
ErbB mAbs, and antisense technology targeted to the receptors.  The mAb 
trastuzumab (Herceptin) has been the focus of most research targeting ErbB2 
and is approved for use as a single agent for the treatment of patients with 
metastatic breast cancers that express ErbB2.  Trastuzumab binds to the 
extracellular domain of ErbB2 with high affinity and causes internalization and 
degradation of the receptor and antibody-dependent cytotoxic responses 
depending on the level of ErbB2 expression (Baselga et al., 2001).  One study of 
trastuzumab treatment in patients with high level ErbB2 tumor expression 
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showed 23% of patients had tumor shrinkage of 50% or more and an additional 
8% developed stable disease for a period greater than 6 months (Seidman et al., 
2001).  Small molecular weight inhibitors of the tyrosine kinase activity of ErbB2 
are also being investigated in animal models (Zhang et al., 1999); however, a 
second generation of more specific ErbB2 inhibitors are currently being 
developed for future use in clinical trials.   
1.1.3.4 Peroxisome proliferator-activated receptor γ (PPARγ)
PPARγ is a member of the nuclear hormone receptor superfamily and is a 
ligand-activated receptor that heterodimerizes with RXR.  The resulting 
heterodimer acts as a transcription factor that binds to peroxisome proliferator 
response elements (PPREs) in target gene promoters (Lehmann et al., 1995; 
Lemberger et al., 1996; Saltiel and Olefsky, 1996; Schoonjans et al., 1996b).  In 
addition, RXR ligands in combination with PPARγ agonists increase 
transcriptional activity (Mukherjee et al., 1997).  Two isoforms of PPARγ
(PPARγ1 and PPARγ2) are produced from alternate promoter usage.  PPARγ1 is 
expressed in multiple tissues including the breast and PPARγ2 is specific for 
adipocytes (Mueller et al., 1998).  Natural ligands for PPARγ include the 
eicosanoid 15-deoxy-∆12,14-prostaglandinJ2 (PGJ2) and certain unsaturated fatty 
acids.  Multiple synthetic ligands called thiazolidinediones (TZDs) including 
rosiglitazone, pioglitazone, and troglitazone are currently used for the treatment 
of type II diabetes melitis (Figure 1.5).  TZDs decrease insulin resistance by 
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increasing glucose uptake in peripheral tissue and decreasing hepatic glucose 
output.   
                                 
Figure 1.5: Structure of TZDs. (Martens et al., 2002). 
Activation of PPARγ leads to transcriptional activation of numerous 
genes, especially those involved in metabolism and transport, differentiation of 
preadipocytes to adipocytes, as well as transcriptional repression of certain 
genes (Tontonoz et al., 1994a; Tontonoz et al., 1994b; Schoonjans et al., 1996a; 
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Jiang et al., 1998; Ricote et al., 1998; Li et al., 2000; Marx et al., 2000; Chawla 
et al., 2001).  Antiproliferative and prodifferentiation activities of PPARγ ligands 
have been demonstrated in multiple cancers including breast cancer, however 
the target genes involved are unknown (Koeffler, 2003).  Studies in different 
cancer cell lines have demonstrated that PPARγ agonists increased expression 
of cyclin-dependent kinase inhibitors p21waf1 and p27kip1, decreased cyclin D1 
expression, decreased expression or activation of inflammatory cytokines and 
transcription factors such as TNF, IL-4, IL-1, and NFκB, and induced apoptosis 
(Karin and Delhase, 2000; Joyce et al., 2001).  Furthermore, studies have 
shown that PPARγ-independent effects of PGJ2 and TZDs may also contribute 
to their anticarcinogenic effects.  In PPARγ-/- ES cells TZDs deplete calcium 
stores causing activation of protein kinase R that phosphorylates and inactivates 
the α-subunit of eukaryotic initiation factor 2 (Palakurthi et al., 2001).  A 
decrease in activity of translation initiation factors such as eukaryotic initiation 
factor 2 could contribute to the antiproliferative effects of these compounds.  
Furthermore, PGJ2 inhibits the NFκB pathway in PPARγ-negative cells (Rossi et 
al., 2000; Straus et al., 2000).  Therefore, PPARγ-dependent and independent 
pathways contribute to the anticarcinogenic effects of PPARγ ligands and 
contributions of these pathways may vary with cell context. 
Breast cancer cells often express high levels of PPARγ and multiple in 
vitro and in vivo studies have demonstrated the potential for applications of 
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PPARγ ligands in treatment of breast cancer.  TZDs inhibit proliferation and 
induce differentiation-like changes and can act synergistically with retinoids to 
inhibit proliferation and induce apoptosis in breast cancer cell lines in vitro and in 
xenografts on nude mice (Muller et al., 1988; Elstner et al., 1998).  In vivo 
studies with carcinogen-induced mammary tumor models have shown that 
GW7845, a PPARγ ligand, inhibits tumor development in rats (Suh et al., 1999) 
and troglitazone inhibited tumor formation in mice.  Combined treatment with 
retinoids plus troglitazone enhanced the inhibition of tumor formation (Mehta et 
al., 2000).  Furthermore, carcinogen treatment of mice with a heterozygous 
germ-line deletion of PPARγ leads to a higher incidence of mammary tumor 
formation compared to wild-type mice, suggesting a protective role for PPARγ in 
the mammary gland (Girnun et al., 2002).  These and other studies demonstrate 
the potential application of PPARγ ligands in breast cancer therapy, especially in 
conjunction with retinoid treatment.   
1.1.3.5 Vitamin D3 analogs 
 Vitamin D3 is synthesized in the skin by the action of ultraviolet light and 
is then transformed by two metabolic steps in the liver and kidney to the 
biologically active 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) (Figure 1.6).  
Adequate synthesis of vitamin D3 and dietary intake of calcium is necessary for 
skeletal health, and the active form of vitamin D3 stimulates intestinal absorption 
of calcium and phosphate.  The historical geographic distribution of rickets, a 
disease caused by vitamin D3 deficiency, parallels that for some cancer rates 
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and enhanced sun exposure is also associated with lower mortality rates from 
prostate, breast and colon cancer (Garland and Garland, 1980; Garland et al., 
1990; Gorham et al., 1990; Emerson and Weiss, 1992; Hanchette and Schwartz, 
1992; Garland et al., 1999) implying a link between vitamin D3 and cancer 
development.  1,25(OH)2D3 acts through the vitamin D receptor (VDR), a 
member of the nuclear receptor superfamily.  Ligand bound VDR 
heterodimerizes with other nuclear receptors, preferentially RXR, and regulates 
gene transcription by binding to vitamin D receptor response elements (VDREs) 
in gene promoters (Carlberg, 1995).  Although the majority of VDR action is 
thought to be mediated through genomic pathways, non-genomic, rapid 
responses through a putative membrane receptor have been described (Nemere 
et al., 1998).   
 The VDR is expressed in normal breast tissue and is highly regulated 
during pregnancy and lactation (Mezzetti et al., 1987; Berger et al., 1988; 
Colston et al., 1988).  Multiple studies have implicated a role for 1,25(OH)2D3 in 
differentiation and milk production in the mammary gland (Mezzetti et al., 1988; 
Colston and Hansen, 2002).  A high proportion of breast cancer tumors also 
express VDR (Freake et al., 1984; Eisman et al., 1986; Berger et al., 1987) and 
studies have reported a positive relation between VDR expression and disease-
free survival (Colston et al., 1989; Berger et al., 1991).  Epidemiology studies 
have also linked vitamin D3 and breast cancer risk.  Studies have shown that 
vitamin D3 deficiency is associated with an increase in breast cancer risk 
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(Janowsky et al., 1999) and disease activity (Mawer et al., 1997) and that 
vitamin D3 intake and breast cancer risk have an inverse relationship (John et 
al., 1999; Shin et al., 2002).  Furthermore, multiple studies have reported a link 
between polymorphisms of VDR and breast cancer risk (Curran et al., 1999; 
Lundin et al., 1999; Ingles et al., 2000; Bretherton-Watt et al., 2001).   
 The ability of 1,25(OH)2D3 to inhibit the growth of multiple cancer cell 
lines including breast cancer cell lines in vitro led to development of a wide 
variety of synthetic analogs with the majority of modifications on the C,D-ring 
and the C-17 side chain (Hansen et al., 2001a; Colston and Hansen, 2002).  The 
goal is to separate the growth regulation of the compound from the calcium 
mobilization and develop an analog with enhanced growth regulatory activity 
compared to the native compound but a weaker effect on calcium metabolism.  
Multiple analogs inhibit growth of breast cancer cells and various mechanisms of 
action have been reported including: regulation of cell cycle progression with 
arrest in G0/G1 (James et al., 1996; Simboli-Campbell et al., 1997; Wu et al., 
1997; Hansen et al., 2001b), induction of morphological and biochemical 
features of apoptosis (Welsh, 1994; James et al., 1995; Simboli-Campbell et al., 
1996; Narvaez and Welsh, 1997; Hansen et al., 2001b), modification of growth 
factor signaling [EGF (Koga et al., 1988; Desprez et al., 1991), amphiregulin 
(Akutsu et al., 2001), TGFβ (Koli and Keski-Oja, 1995; Mercier et al., 1996), and 
IGF-1 (Vink-van Wijngaarden et al., 1996; Xie et al., 1997; Xie et al., 1999a; 
Pirianov and Colston, 2001)], and a decrease in invasiveness and angiogenesis 
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(Oikawa et al., 1990; Majewski et al., 1993; Hansen et al., 1994; Majewski et al., 
1996; Iseki et al., 1999).   
 EB1089 is a second-generation analog that has shown potential for 
breast cancer therapy (Figure 1.6).  EB1089 has a conjugated double bond 
system in the side chain region and is 50 time more active than 1,25(OH)2D3 in 
vitro but has reduced activity on calcium metabolism in vivo (Colston et al., 
1992; Mathiasen et al., 1993).  Mulitple studies in carcinogen-induced and 
breast cancer cell xenograft models in rodents have demonstrated a decrease in 
tumor progression after treatment with EB1089 (Colston et al., 1992; 
VanWeelden et al., 1998).  Some have reported tumor regression and indicators 
of apoptosis (James et al., 1998; VanWeelden et al., 1998), as well as enhanced 
activity when combined with paclitaxel (Koshizuka et al., 1999a) or retinoic acid 
(Koshizuka et al., 1999b).  Animal models for bone metastasis have also shown 
increased survival and decreased metastasis when treated with EB1089 (El 
Abdaimi et al., 2000).  One phase I safety trial for EB1089 which included 
patients with advance breast cancer and colorectal cancer determined the 
maximum tolerated dose and found that 10 of the 36 patients developed 
hypercalceamia that later was resolved (Gulliford et al., 1998).  Also, while no 
clear anti-tumor activity was observed, 4 of the 25 breast cancer patients 
showed disease stabilization for more than 3 months.  Additional trials of 
EB1089 are underway and, in common with other vitamin D analogs, the biggest 
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obstacle for clinical applications is the level of hypercalcemic effects at the 
effective anticarcinogenic dose.   
Figure 1.6: Structure of vitamin D3 analogs. (Adapted from Guyton et al., 2003). 
1.1.4 Mammary carcinogenesis 
The process of carcinogenesis involves the three basic steps of initiation, 
promotion and progression.  Initiation occurs when DNA is damaged and not 
properly repaired.  DNA damage occurs regularly through exposure to 
chemicals, radiation and viruses and the majority of damage is eliminated 
through repair mechanisms or cell death.  However, a minor portion of DNA 
damage that is not repaired can lead to permanent genetic damage that alters 
gene expression and results in the formation of neoplastic cells.  Promotion 
occurs when a neoplastic cell is induced to proliferate and forms a premalignant 
lesion.  The mechanism by which promotion leads to a growth advantage for 
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neoplastic cells is not clearly understood; however, tumor promoters usually 
alter signal transduction pathways that could result in dysregulation of growth 
signals.  In the final step of progression mechanisms such as altered mitotic 
apparatus, telomere function (Blackburn, 1994), DNA hypomethylation, 
recombination, and gene transposition (Cheng and Loeb, 1993) lead to changes 
in chromosome structure (insertions, deletions, strand breaks) and genetic 
instability.  These steps lead to formation of cancer cells, which exhibit 
uninhibited growth and the potential for metastasis.  Cancer cells acquire several 
alterations that lead to malignant growth and these include: self-sufficiency in 
growth signals, insensitivity to growth inhibition, evasion of apoptosis, limitless 
replicative capability, angiogenic ability, and invasiveness (Hanahan and 
Weinberg, 2000).  
Mammary carcinogenesis is also a progression through defined 
pathological stages that begins with atypical epithelial hyperplasia in which the 
epithelial cells proliferate and form multiple cell layers from the single cell 
layered epithelium (Figure 1.7).  This progresses to in situ carcinoma in which 
the epithelial cells continue to proliferate and fill the mammary duct or lobule; 
however, with in situ carcinoma the basement membrane of the structure 
remains intact.  Invasive carcinoma occurs when the basement membrane 
breaks down and epithelial cells invade the surrounding fatty and connective 
tissue where they can then spread to other parts of the body such as the lung, 
bone, or lymph nodes.  Ductal epithelial cells are the most common targets for 
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development of breast cancer and ductal carcinoma in situ is estimated to 
account for 85% of the new in situ carcinoma cases in 2003 (American, 2003).  
The other major target for breast cancer development is the lobular epithelial cell 
and lobular carcinoma in situ accounts for most of the other 15% of new in situ 
carcinoma cases (American, 2003).   
Figure 1.7: Progression of mammary carcinogenesis. (Polyak, 2001). 
Hormones are involved in normal mammary development throughout 
gestation, puberty, pregnancy and lactation, and their involvement in 
development of breast cancer has also been established.  Studies in 
carcinogen-induced and spontaneous mammary cancer models in rodents have 
shown that both estrogen and progesterone are able to initiate and promote 
mammary tumor formation and growth (Jabara et al., 1973; Welsch, 1985; 
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Robinson and Jordan, 1987).  There are multiple possible mechanisms for 
hormonal initiation and promotion of mammary cancer.  One mechanism for the 
initiation of mammary cancer by estrogen and other hormones is through 
metabolic activation of the hormones into reactive intermediates that are capable 
of adducting to DNA.  One study demonstrated that in ER-negative cells 
treatment with E2 and DES resulted in chromosomal damage consistent with 
that observed in breast tumors (Russo, 2001).  Therefore, E2 and DES are 
capable of DNA damage that may initiate tumor development in actual breast 
cancer cases and the damage is independent of ER signaling.  Another 
mechanism for promotion of mammary tumor growth by estrogen is through the 
induction of epithelial cell proliferation.  Multiple studies have demonstrated that 
estrogen induces mammary epithelial cell proliferation through the ER (Osborne 
et al., 1985; Katzenellenbogen et al., 1987).  Premalignant atypical epithelial 
hyperplasia is characterized by intense epithelial cell proliferation and 
expression of ER in the presence of estrogen could give these cells a growth 
advantage (Hansen and Bissell, 2000).  However, not all early lesions express 
ER so other unknown mechanisms of promotion must also contribute to breast 
cancer development.  
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1.2 Estrogen and estrogen receptors 
1.2.1 Physiological role of E2  
E2 is an important steroid hormone required for normal development and 
function of multiple organ systems including the reproductive, cardiovascular, 
and immune systems, as well as in aberrant growth such as mammary and 
uterine cancers.  In the reproductive system, E2 functions in the synchronized 
phases of proliferation and differentiation in the uterus and in folliculogenesis 
and steroid production in the ovary.  In the mammary gland, E2 is involved in 
ductal growth and stimulates formation of terminal end buds and proliferation of 
ductal epithelium.   
1.2.1.1 Uterus  
The uterus undergoes cyclic changes during the reproductive cycle in 
preparation for implantation of the embryo. Upon implantation the uterus 
undergoes massive differentiation of the stroma surrounding the implanted 
embryo.  The uterus develops from the Mullerian ducts, which also give rise to 
the infundibula, oviducts, cervix, and anterior vagina (Gray et al., 2001).  The 
uterine wall is composed of two compartments, the outer myometrium and the 
endometrium.  The myometrium is the smooth muscle component of the uterine 
wall and consists of an inner circular smooth muscle layer and an outer 
longitudinal smooth muscle layer.  The endometrium forms the mucosal lining of 
the uterus and is comprised of a stromal component and epithelial cells.  The 
endomentium contains two types of epithelial cells the luminal and glandular 
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epithelial cells that form a single cell layer lining the lumen and glands of the 
uterus (Gray et al., 2001).   
 Preparation of the uterus for implantation is a complex process that 
involves synchronization of the embryo and is dependent on the multifunctional 
effects of both estrogen and progesterone on the uterine endometrium (Couse 
and Korach, 1999).  Estrogen production that peaks at ovulation primes the 
uterus by inducing differentiation and proliferation of the luminal and glandular 
epithelial cells and increasing PR expression in the stroma and myometrium.  
The release of progesterone from the corpus luteum along with a physical 
stimulus of the uterine lining results in subsequent induction of decidualization of 
the stroma.  Decidualization is a process of massive proliferation and 
differentiation of the stroma and localized increases in vascular permeability and 
edema leading to a swelling of the uterine stroma.  Finally, attachment of the 
embryo to the uterine wall in the mouse is thought to be dependent upon a 
secondary increase in levels of E2.   
1.2.1.2 Ovaries 
The ovary can be divided into three main functional units: follicles, corpus 
lutea, and interstitial/ stromal tissue.  A maturing follicle is comprised of an outer 
thecal layer surrounding multiple granulosa cell layers that together they act to 
encase the maturing oocyte.  The follicles differentiate into corpus lutea after 
ovulation and the corpus lutea are vascularized structures that contain terminally 
differentiated thecal and granulosa cells.  The interstitial or stromal tissue is the 
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matrix in which the follicles and corpus luteua are suspended and is the source 
of undifferentiated cells that eventually will form thecal and granulosa cells.  
Dedifferentaited thecal and granulosa cells from atretic follicles and regressed 
corpus luteua are also part of the stromal tissue.  (Baird, 1984; Couse and 
Korach, 1999).  
The two main functions of the ovaries are steroid production and 
folliculogenesis, and together they can be divided into two separate phases: the 
follicular phase of follicle maturation and E2 synthesis and the luteal phase that 
begins with ovulation in which the corpus luteum synthesizes large amounts of 
progesterone as well as E2.  At the beginning of the follicular phase primordial 
follicles are recruited to form the primary follicles that grow and prepare for 
ovulation.  Primary follicles develop through secondary, tertiary, and atretic or 
graffian stages that are each characterized by defined structure and function.  
The selection of follicles for ovulation in which some secondary-tertiary follicles 
will undergo atresia and others will continue development to the graffian or 
ovulatory stage is not well understood.  A surge in the gonadotrophins LH and 
FSH leads to rupturing of the follicle and ovulation, the remaining thecal and 
granulosa cells of the follicle terminally differentiate to form a corpus luteum and 
the luteal phase begins (Richards, 1980; Couse and Korach, 1999).   
Steroid synthesis occurs in the granulosa and thecal cells of the follicles, 
as well as the interstitial tissue, and is highly regulated by the gonadotropins 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) that regulate the 
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expression and activity of the steroidogenic enzymes within the cells.  For E2 
production, LH stimulates the synthesis of androgens (androstenedione and 
testosterone) from cholesterol in the thecal cells through transcriptional and 
translational regulation of cholesterol side chain cleavage enzyme and 17α-
hydroxylase/C17-20 lyase (Couse and Korach, 1999).  Androgens pass through 
the basement membrane to the granulosa cells where FSH stimulation and 
signaling from the oocyte regulate the aromatase-dependent conversion of 
androstenedione and testosterone to estrone and estradiol, respectively 
(Vanderhyden et al., 1993; Vanderhyden and Tonary, 1995; Vanderhyden and 
Macdonald, 1998).  Estradiol is released into the follicular fluid and passes 
through the basement membrane to enter circulation.  When ovulation occurs, 
luteinization of the follicle and differentiation of the thecal and granulosa cells 
leads to formation of the corpus luteum and altered expression and activity of 
the steroidogenic enzymes which now produce high levels of progesterone.   
Numerous studies have described the effects of high levels of locally 
synthesized estrogen in the ovary that are thought to be essential for normal 
ovarian function.  Multiple estrogenic effects have been described in granulosa 
cells including DNA synthesis and proliferation, increased ER expression, 
synthesis of IGF-1, increased gap junction size and number, attenuation of 
apoptosis and follicular atresia, and augmented response to FSH (Richards, 
1975; Richards et al., 1976; Rao et al., 1978; Burghardt and Anderson, 1981; 
Farookhi and Desjardins, 1986; Hernandez et al., 1989; Wang and Greenwald, 
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1993; Hsueh et al., 1994; Bley et al., 1997).  Overall, the effects of estrogen 
seem to increase the response of the follicles to gonadotrophins, resulting in 
increased estrogen synthesis (Zhuang et al., 1982; Wang and Greenwald, 
1993).  Thus estrogen appears to work in both autocrine and paracrine fashion 
in conjunction with gonadotrophins to regulate ovarian responses.   
1.2.1.3 Mammary gland 
The mammary gland is a dynamic structure that is continually changing 
throughout the reproductive life of females to form an extensive ductal gland 
capable of milk production.  Development of the mammary gland is divided into 
5 stages: embryonic/fetal, neonatal/prepubertal, pubertal, sexually mature adult, 
and pregnancy/lactation (Hovey et al., 2002).  During embryonic and fetal 
development mammary epithelium invades from the nipple into a pad of fatty 
tissue called the mammary fat pad and forms a rudimentary, branched ductal 
network in the proximal corner of the fat pad.  During the neonatal and 
prepubertal time period the mammary epithelium remains a rudimentary ductal 
network and grows isometrically with the rest of the body.  At puberty ovarian 
hormones are released and terminal end buds (TEB) form from the distal ends 
of the mammary ducts that swell into the bulbous TEB structures with multiple 
layer of cuboidal epithelial cells.  The TEBs proliferate and invade into the 
mammary fat.  Growth and branching of the ductal network through bifurcation at 
the TEB or lateral bud formation from side branching continues until the extent of 
the fat pad is reached.  Once the ends of the fat pad are reached the TEBs 
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regress.  In sexually mature adult females the mammary gland is characterized 
by limited growth and lobule development or alveolar budding followed by 
regression with each menstrual or estrous cycle. Final maturation and 
differentiation of the mammary gland occurs during pregnancy and lactation.  
The mammary epithelium expands and differentiates into secretory, milk-
producing, lobular alveoli and the fat cells dedifferentiate into preadipocytes.  
With cessation of suckling, the mammary gland regresses by apoptosis in a 
process called involution to return to the pre-pregnancy, adult stage of the 
mammary gland.   
 The ductal network of the mammary gland is composed of a single layer 
of luminal epithelial cells that lay on a layer of myoepithelial cells.  A basement 
membrane separates the myoepithelial and luminal epithelial cells from the 
stromal tissue, which consists of stromal fibroblast cells, adipocytes, immune 
cells, and vasculature.  The terminal end buds that form during puberty are 
bulbous structures that have muiltple layers of epitheial cells called body cells 
covered by a single layer of epithelial cells called cap cells that sit on a minimal 
basement membrane (Wiseman and Werb, 2002).  
 Mammary gland development from the pubertal stage to pregnancy and 
lactation is highly regulated by both reproductive and metabolic hormones 
(Neville et al., 2002).  Estrogen is thought to play a major role in ductal 
morphogenesis during puberty, especially in TEB formation and cellular 
proliferation of the ductal epithelium resulting in ductal elongation (Neville et al., 
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2002).  Estrogen is also important for lobular and alveolar development during 
the adult reproductive cycle.  Studies in ovariectomized mice have shown that 
exogenous treatment with E2 and progesterone induce proliferation in ductal 
and TEB epithelial cells leading to alveolar and ductal side branching as 
observed during the estrous cycle (Bresciani, 1968; Haslam, 1988). 
1.2.2 ER subtypes  
Estrogens modulate cellular changes through steroid hormone receptors 
called ERs.  Thus far two ERs have been identified, ERα and ERβ (Figure 1.8).  
Separate genes located on different chromosomes encode the two receptors 
(Kuiper et al., 1996; Tremblay et al., 1997).  Both receptors contain the A-F 
functional domains described for members of the nuclear receptor superfamily; 
however, the homology between the two ERs varies among these domains.  The 
DNA binding region is highly conserved between ERα and ERβ, whereas the N’-
terminal A/B domain that contains activation function-1 (AF-1) is not (Enmark et 
al., 1997).  Amino acid residues critical for function of AF-2 are conserved 
between the receptors in the mouse and mutations lead to ligand-independent 
activation of both receptors (Tremblay et al., 1997; Giguere et al., 1998; 
Tremblay et al., 1998).  Also, the site in the AF-1 region necessary for the 
ligand-independent activation of ERα by mitogen-activated protein kinase 
(MAPK) is present and functional in ERβ (Tremblay et al., 1997; Tremblay et al., 
1998).   
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Figure 1.8: Schematics of human ERα and ERβ. (Katzenellenbogen et al., 
2000). 
Both receptors bind E2 and interact with ERE sequences; however 
distinct ligand binding profiles have been described (Katzenellenbogen and 
Katzenellenbogen, 2000; Katzenellenbogen et al., 2001; Meyers et al., 2001; 
Mortensen et al., 2001; Shiau et al., 2002) and the transactivation potential 
differs between the two receptors (Kuiper and Gustafsson, 1997; Paech et al., 
1997; Barkhem et al., 1998; Kuiper et al., 1998; Montano et al., 1998; Hall and 
McDonnell, 1999).  In most contexts, ERβ exhibits lower activity than ERα.  Two 
studies have shown that 4-hydroxytamoxifen does not induce agonist activity 
with ERβ as it does with ERα (Tremblay et al., 1997; Watanabe et al., 1997) and 
studies on transcriptional activation through an AP-1 site showed that 
antiestrogens exhibited inhibitory activity with ERα and exhibited agonist activity 
with ERβ (Paech et al., 1997).  Studies investigating ER activation of GC-rich 
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sites through Sp1 have also shown differential activity between ERα and ERβ
(Saville et al., 2000).  
Multiple studies have shown potential cooperative activity between ERα
and ERβ through formation of heterodimers in vitro (Cowley et al., 1997; 
Pettersson et al., 1997; Tremblay et al., 1997; Ogawa et al., 1998); however, the 
significance of the findings depends upon identifying coexpression of the 
receptors in tissue.  ERα and ERβ are expressed in the uterus, ovaries, lungs, 
male reproductive tract, thyroid, adrenals, bone, heart, and various regions of 
the brain; the prostate and the ovaries are the only tissues in which ERβ
expression is higher than ERα (Shughrue et al., 1996; Arts et al., 1997; Byers et 
al., 1997; Couse et al., 1997; Kuiper et al., 1997; Brandenberger et al., 1998; 
Pau et al., 1998).  ERα is also expressed in the pituitary, mammary gland, 
kidney, liver and skeletal muscle (Couse et al., 1997).  Differences in expression 
patterns between species have also been found.  ERβ is detected in the pituitary 
of the rat, human, and rhesus monkey, but not in the mouse (Couse et al., 1997; 
Mitchner et al., 1998; Pau et al., 1998; Petersen et al., 1998; Shupnik et al., 
1998; Wilson et al., 1998); in the human mammary gland, ERβ has been 
detected in both normal and neoplastic human tissue and cell lines, whereas 
ERα is predominantly expressed in the mouse mammary gland (Couse et al., 
1997; Dotzlaw et al., 1997; Enmark et al., 1997; Moore et al., 1998; Vladusic et 
al., 1998; Dotzlaw et al., 1999).  Furthermore, in tissues such as the ovaries and 
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prostate where significant levels of ERβ expression have been found, the two 
receptors have distinct patterns of expression within particular cell types.  In the 
ovaries ERβ is expressed in the granulosa cells whereas ERα is expressed in 
the thecal and interstitial regions (Hiroi et al., 1999; Rosenfeld et al., 1999).  
Similarly, in the prostate ERβ expression is detected in the epithelium and ERα
is detected in the stroma (Kuiper et al., 1996).  In contrast, one study has found 
co-localization of ERα and ERβ expression in the rat forebrain (Shughrue et al., 
1998). 
1.1.2.1 Generation of ER knockout mice 
The generation of mice deficient in ERα (ERKO), ERβ (βERKO) and both 
receptors (αβERKO) have aided in deciphering the role of each receptor in the 
reproductive system and mammary gland of the mouse.  ERKO and βERKO 
mice were generated through homolgous recombination.  Targeted insertion of a 
1.8 kb NEO sequence into exon 2 approximately 270 bp downstream of the 
translational start site resulted in disruption of the ERα gene (Lubahn et al., 
1993).  Similarly, for ERβ a 1.8 kb NEO sequence was inserted into exon 3 of 
the gene resulting in disruption of the sequence coding for the first zinc finger, 
which is necessary for the proper function of the receptor (Krege et al., 1998a).  
αβERKO mice were generated by mating of heterozygous mice from the ERKO 
and βERKO lines (Couse et al., 1999b).   
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Splice variants of the disrupted genes that may code for receptors with 
decreased functional activity have been detected in small amounts in both the 
ERKO and βERKO models and could complicate interpretation of data from the 
all the ERKO models (Couse et al., 1995; Krege et al., 1998b).  One study 
comparing the ERKO model described here and a model generated by deletion 
of exon 2 (ERα∆2KO) demonstrated that the ability of E2 to increase uterinte 
weights and induce production of nitric oxide was totally abrogated in the 
ERα∆2KO mice, but was partially (uterine weights) or totally (nitric oxide) 
preserved in the ERKO mice (Pendaries et al., 2002).  Furthermore, two splice 
variants with partially deleted A/B domains were detected in the uterus and one 
was detected in the aorta of the ERKO mice and could account for the partial 
response to E2.  
1.1.2.2 Phenotypes of ER knockout mice 
1.1.2.2.1 Uterus 
 Estrogen signaling is involved in preparation of the uterus for embryo 
implantation and for the actual implantation process.  ERα is expressed in all 
compartments of the uterus and low levels of ERβ expression have also been 
described (Couse et al., 1997; Kuiper et al., 1997).  Uteri from all three ERKO 
models possess normal structure with a myometrial compartment and an 
endometrial compartment consisting of both stroma and epithelium (Hewitt and 
Korach, 2003); however the ERKO and αβERKO uteri are immature and 
hypoplastic with fewer glands than the wild-type mice (Lubahn et al., 1993; 
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Couse et al., 1999b).  Therefore, ERα and ERβ are not necessary for normal 
development of the uterus, but ERα is needed for maturation of the uterus.  Uteri 
from ERKO and αβERKO mice are also not responsive to estrogen.  Studies in 
ERKO mice have demonstrated that treatment with E2 does not induce typical 
uterine responses including increased weight, water imbibition or hyperemia, cell 
proliferation and DNA synthesis, or induction of estrogen responsive genes such 
as PR and lactoferrin (Lubahn et al., 1993; Couse et al., 1995).  In contrast, 
βERKO mice undergo cyclic changes with ovarian hormones; however, the 
immature uterus has increased proliferative markers and exaggerated 
responses to estrogen (Krege et al., 1998a).  These data indicate that ERα is 
necessary for estrogen-induced responses in the uterus, whereas ERβ may play 
an inhibitory role. 
 Multiple studies have described cross-talk between ER signaling and 
growth factor signaling in the uterus.  Estrogen treatment increases epidermal 
growth factor (EGF) and its receptor (EGFR) (DiAugustine et al., 1988; Huet-
Hudson et al., 1990), insulin-like growth factor-1 (IGF-1) (Couse and Korach, 
1999), and transforming growth factor-α (TGF-α) (Nelson et al., 1992) and 
activates the IGF-1 signaling pathway (Richards et al., 1996) in the uterus.  
Furthermore, cotreatment with antibodies to EGF attenuates the uterine 
response to estrogen (Nelson et al., 1991) and treatment of IGF-1 knockout 
mice with E2 does not result in uterine epithelial cell mitosis (Adesanya et al., 
1999), indicating that both EGF and IGF-1 are involved in the uterine response 
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to estrogen.  Conversely, treatment with either EGF or IGF-1 results in 
estrogenic-like responses that include epithelial cell proliferation, induction of 
target genes, and increase in uterine weights (Nelson et al., 1991; Ignar-
Trowbridge et al., 1992), and the estrogen antagonist ICI 164,384 decreases the 
uterine response to EGF (Ignar-Trowbridge et al., 1992).  Therefore, ERKO mice 
were treated with EGF and IGF-1 to determine whether ERα is necessary for the 
growth factor-induced responses in the uterus.  Although the ERKO mice 
express the growth factor receptors and c-fos induction indicated that the EGF 
signaling pathway was intact, neither EGF nor IGF-1 induced a mitogenic 
response in the uterine epithelium, indicating that ERα is necessary for the 
response (Curtis et al., 1996; Klotz et al., 2002).   
 Progesterone is essential for the decidual response in the mouse uterus 
and PR expression is highly regulated by estrogen; therefore the ability of the 
uterus to respond to progesterone was investigated in the ERKO mice.  
Although PR protein levels were approximately 60% of that seen in wild-type 
mice, progesterone treatment resulted in induction of progesterone-responsive 
genes in the uterus (Curtis et al., 1999).  Furthermore, uterine decidualization 
can be experimentally induced with an estrogen-progesterone treatment 
regimen and injection of oil to induce ‘trauma’ to the epithelium and mimic 
implantation.  Decidualization was observed in ERKO mice and progesterone 
alone also induced this response (Curtis et al., 1999).  Therefore, the 
progesterone signaling pathway for gene expression and decidualization in the 
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uterus is functional without ERα.  The ability of progesterone to induce 
decidualization in the ERKO uterus without estrogen ‘priming’ could be due to 
the inherently impaired uterine epithelium of the ERKO mice that is more 
sensitive to induced ‘trauma’ with oil injection than wild-type mice.  Trauma to 
the uterus has been shown to induce decidualization without estrogen priming 
(Finn, 1965; Finn, 1966).   
 Estrogen signaling is also involved in implantation of the embryo in the 
uterus.  Embryo implantions in ERKO mice utilized experimental transfer of 
donor embryos and hormone-priming because ERKO mice are anovulatory.  
Implantations were observed in control but not ERKO mice, indicating that 
ERα is necessary for implantation (Hewitt and Korach, 2003).   
Many of the estrogenic effects induced in the adult uterine epithelium are 
highly dependent upon stormal-epithelial interactions.  Estrogenic responses are 
observed in uterine epithelial cells that lack ERα (Couse and Korach, 1999).  
The generation of ERKO mice led to the development of tissue recombination 
experiments in which wild-type and ERKO tissue were combined to determine 
the cell types required to express ERα for estrogen action.  Tissue 
recombination studies in the adult uterus have shown that ERα expression is 
required in the stromal tissue and not in the epithelium for E2-induced epithelial 
cell proliferation (Cooke et al., 1997) and that ERα expression in required in both 
the stromal and epithelial tissue for E2-induced secretion of lactoferrin and 
complement component C3 (Buchanan et al., 1999).  
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1.1.2.2.2 Ovaries 
 Estrogen and gonadotrophins coordinately induce steroid hormone 
production and folliculogenesis in the ovaries.  Multiple studies have 
demonstrated ERα and ERβ expression in the ovaries with ERβ localizing 
mainly to the granulosa cells of growing follicles and ERα localizing to the 
interstitial and thecal regions (Hiroi et al., 1999; Rosenfeld et al., 1999; Sar and 
Welsch, 1999).  The three ERKO models have been used to investigate the 
roles of ERα and ERβ in the ovaries.   
 The ovaries of neonatal and prepubertal ERKO female mice appear 
grossly normal and mature ovaries have a normal compliment of primordial 
follicles indicating that fetal and neonatal ovarian development and germ cell 
generation and migration are not dependent on ERα (Schomberg et al., 1999).  
In contrast mature ovaries are anovulatory with no corpus lutea present and 
exhibit enlarged, hemorrhagic and cystic follicles in ERKO mice (Schomberg et 
al., 1999).  The cystic structures in the ERKO ovaries are also seen in mice that 
overexpress LHβ (Risma et al., 1995), and the development of the phenotype in 
ERKO mice was blocked by inhibtion of LH production (Couse et al., 1999b).  
Therefore, the increased LH levels seen in the ERKO mice are probably 
responsible for the cystic phenotype of the ovaries as opposed to a direct effect 
due to loss of ERα in the ovaries.  Superovulation studies in ERKO mice have 
also shown that although ovulation cannot be induced in mature ovaries, 
immature ovaries can be induced to ovulate, although to a lesser extent than 
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observed in ovaries from wild-type mice (Couse et al., 1999a).  Furthermore, 
follicles in the tertiary and pre-antral stages are present in the mature ovaries of 
ERKO mice indicating that recruitment of primordial follicles and the early stages 
of folliculogenesis do not require ERα.  Attenuation of apoptosis and induction of 
LH receptors in granulosa cells of antral follicles, which are thought to be 
estrogen mediated, were also observed in ovaries of ERKO mice indicating that 
this response is also not mediated by ERα (Schomberg et al., 1999).  Studies 
also examined the steroidogenic function of the ovaries and demonstrated that 
serum progesterone levels in ERKO mice were normal, whereas serum estrogen 
levels were increased (Couse and Korach, 1999).   
 Ovaries from βERKO mice are normal in size and morphology with a 
relatively normal intersitial/stromal compartment that contains follicles from 
various stages of follicular development.  This indicates that like ERα, ERβ is not 
required for germ cell development or migration or for normal ovarian 
development.  There was an increase in early atretic follicles and few corpus 
lutea indicating a reduction in complete folliculogenesis.  Superovulation studies 
in βERKO mice showed that exogenous gonadotrophins induced ovulation; 
however, the ovulatory capacity was dramatically decreased compared to wild-
type mice.  The ovaries from superovulated βERKO mice contained numerous 
preovulatory, unruptured follicles suggesting that ovaries respond to the 
proliferative stimulation, but do not luteinize and rupture.  The steroidogenic 
function of ovaries from βERKO mice appear to be normal, serum progesterone 
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and estrogen levels were similar to wild-type levels (Couse and Korach, 1999).  
The reduced ability of both the ERKO and βERKO mice to ovulate indicates that 
both receptors are required for efficient ovulation, although reduced ovulation 
was possible in the absence of each recpetor.   
αβERKO mice exhibited an ovarian phenotype distinct from both the 
ERKO and βERKO mice.  Normal follicles are present in the ovaries; however, 
follicles that lack oocytes and contain Sertoli-like cells and structures that are 
intermediate with characteristics of both types of follicles are observed (Couse et 
al., 1999b).  It appears that the oocyte degenerates with age and the normal 
follicle transdifferentiates into a seminiferous tubule-like follicle.  Simiar 
structures have been reported in aromatase knockout mice that are not able to 
produce estrogen and in mouse models that lack germ cells (Behringer et al., 
1990; Britt et al., 2001).  Therefore, ERα and ERβ may coordinately act to 
maintain oocyte integrity and prevent follicular degeneration.   
1.1.2.2.3 Mammary gland 
 Estrogen is required for proper ductal morphogenesis of the mammary 
gland during puberty and may also play a role in alveolar development during 
the cycle and pregnancy (Neville et al., 2002).  At birth the mammary gland of 
female ERKO mice exhibits the same rudimentary ductal tree structure with the 
epithelial and stromal portions as well as the connective tissue that is observed 
in wild-type mice, demonstrating that ERα is not required for normal gestational 
mammary gland development.  During puberty the rudimentary ductal tree of the 
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mammary gland responds to hormones and elongates and branches to fill the 
mammary fat pad; however, the mammary gland of ERKO mice does not 
develop beyond the rudimentary ductal tree (Couse and Korach, 1999).  
Therefore, ERα is necessary for mammary gland elongation and growth during 
puberty.  Maturation of the mammary gland during pregnancy involves further 
ductal growth and branching and development of lobular alveolar structures.  
However, the lack of ovulation in ERKO mice results in decreased progesterone 
levels that are insufficient for development of the lobular alveolar structures.  
Treatment of ERKO mice with progesterone showed that the ERKO mammary 
gland responds to progesterone and develops lobular alveolar structures (Hewitt 
and Korach, 2000) indicating that the ERKO mammary gland possesses tissue 
components necessary for further development but lack stimuli downstream of 
ERα. βERKO mice exhibit normal mammary gland development and βERKO 
mothers are able to nurse their pups (Couse and Korach, 1999).  These data 
suggest that ERα is necessary for mammary gland elongation and development 
during puberty, and that ERβ is not required for mammary gland development or 
function.  
 Stromal-epithelial interactions are important for ductal elongation in the 
mammary gland.  TEB formation and outgrowth in mice are dependent on 
interactions between epithelial cells and adipocytes or stromal fibroblasts (Daniel 
et al., 1984).  Futhermore, the outermost proliferating cap cells of the TEB do not 
express ERα indicating that estrogen acts indirectly on the proliferating epithelial 
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cells either through the stromal or non-proliferating epithelial cells (Daniel et al., 
1987).  Tissue recombination studies using mammary gland epithelium and 
stroma from wild-type and ERKO mice have also shown that ERα expression in 
the stroma but not the epithelium is necessary for ductal growth (Cunha et al., 
1997). 
The role of estrogen in breast cancer is noted above (Section 1.1.2.1) and 
expression of ER and estrogen-dependent growth of human breast tumors is 
well established.  The role of ERα in mammary tumorigenesis was investigated 
by crossing the ERKO mice with MMTV-Wnt-1 mice.  MMTV-Wnt-1 is a 
transgenic line that expresses the Wnt-1 protooncogene in the mammary gland 
and nearly 100% incidence of mammary hyperplasia and lobuloalveolar 
adenocarcinoma is observed in one year-old females (Tsukamoto et al., 1988).  
The lobuloalveolar hyperplasia seen in the wild-type MMTV-Wnt-1 mice was 
also observed in ERKO-Wnt-1 mice; however, the extensive hyperplasia of the 
ductal epithelium and ductal elongation seen in the wild-type-Wnt-1 mice was 
decreased in ERKO-Wnt-1 mice.  Expression of the Wnt-1 gene induced tumor 
formation on the ERKO background, but a 50% tumor incidence was seen in 
twice the time required for the response in wild-type-Wnt-1 mice.  Therefore, the 
induction of hyperplasia and tumorigenesis in the mammary gland by Wnt-1 
does not require ERα, however, ERα plays a role in promotion of the 
phenotypes and terminal end bud formation and ductal morphogenesis are ERα-
dependent.    
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1.1.2.2.4 Hypothalamic-pituitary axis 
 The hypothalamus is located at the base of the brain above the pituitary 
and translates neuronal signals from the brain into humoral factors such as 
gonadotrophin releasing hormone (GnRH) that stimulate the function of the 
anterior pituitary via the hypothalamo-hypophyseal portal system (Couse and 
Korach, 1999).  The pituitary produces and secretes the gonadotrophins follicle 
stimulating hormone (FSH) and luteininzing hormone (LH), the lactotroph 
prolactin (PRL), as well as other peptide hormones.  The gonadotrophins 
stimulate gametogenesis and synthesis of steroid and peptide hormones in the 
gonads that then feed back to the hypothalamus and the pituitary to regulate 
FSH and LH production and secretion.  FSH and LH are negatively regulated by 
estrogen (Gharib et al., 1990; Shupnik, 1996; Couse and Korach, 1999) and 
expression of ERα and ERβ in the pituitary and regions of the brain has been 
shown, although the levels vary between species (Couse et al., 1997; Mitchner 
et al., 1998; Pau et al., 1998; Petersen et al., 1998; Shupnik et al., 1998; Wilson 
et al., 1998).  Female ERKO and αβERKO mice exhibit increases in FSHβ and 
LHβ mRNA levels in the pituitary and a similar increase in serum LH levels 
(Scully et al., 1997; Couse and Korach, 1999).  In contrast the LH and FSH 
levels in βERKO females are normal indicating that ERα mediates the negative 
feedback of estrogen that regulates LH levels.   
 PRL acts on the female reproductive system to affect differentiation and 
function of the lactating mammary gland and to promote blastocyst implantation 
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through luteinization of the corpus luteum; furthermore, E2 regulates PRL 
synthesis and secretion (Maurer et al., 1990; Stefaneanu, 1997).  Pituitary and 
serum hormone PRL mRNA levels are decreased in ERKO mice compared to 
wild-type animals indicating that ERα is required for PRL synthesis and 
secretion (Scully et al., 1997).   
1.1.2.2.5 Bone 
 Bone is a dynamic tissue that is under constant absorption as a mineral 
source for the body and remodeling to maintain skeletal structure and strength.  
A link between estrogen and the dynamics of bone has been known since 
decreased estrogen levels are associated with osteoporosis, a disease 
characterized by loss of bone mass and strength due to a disruption of the 
equilibrium between bone absorption and remodeling (Couse and Korach, 
1999).  The beneficial effects of estrogen replacement therapy on the bone in 
postmenopausal women are well established (Barrett-Connor and Grady, 1998; 
Komm and Bodine, 1998); however, the mechanisms of estrogen action on the 
bone are unclear.  Expression of ERα and ERβ in bone cell cultures (Arts et al., 
1997; Onoe et al., 1997; Couse and Korach, 1999) and ERKO and βERKO mice 
have distinguished between the roles of both receptors in estrogen action on 
bone.  In both males and females, differential effects on bone growth are seen in 
the three ERKO models.  A decrease in long bone growth is seen in ERKO 
females; an increase in growth is seen in βERKO females and αβERKO females 
exhibit intermediate growth of long bones (Couse and Korach, 1999; Lindberg et 
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al., 2001) indicating a stimulatory role for ERα and inhibitory role for ERβ in long 
bone growth in females.  Another study demonstrated an increase in cortical 
bone mineral associated with radial bone growth in βERKO females indicating a 
repressive role for ERβ in regulation of bone growth in females (Windahl et al., 
1999).  βERKO females are partially protected from age-related trabecular bone 
loss indicating a repressive action of ERβ in regulation of trabecular bone 
growth, and ERβ is not required for the protective effects of E2 on trabecular 
bone mineral density (Windahl et al., 1999; Windahl et al., 2001).  Male βERKO 
mice do not exhibit any bone abnormalities, whereas, ERKO and αβERKO 
males exhibit decreased longitudinal and radial skeletal growth associated with 
decreased IGF-1 levels during growth and maturation (Windahl et al., 1999; 
Vidal et al., 2000) indicating that ERα has a stimulatory effect and ERβ does not 
have a role on bone growth in males.   
1.1.2.2.6 Cardiovascular system 
 The protective effects of estrogen against cardiovascular disease has 
been demonstrated in various animal models and in multiple epidemiology 
studies documenting the reduced incidence of cardiovascular disease in 
postmenopausal women receiving estrogen replacement therapy (Nathan and 
Chaudhuri, 1997; Barrett-Connor and Grady, 1998).  However, recent evidence 
from multiple trials and observational studies using estrogen/progestin 
combination therapy has shown an increase in cardiovascular disease including 
coronary heart disease, stroke and pulmonary embolism (Grodstein et al., 2000; 
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Simon et al., 2001; Viscoli et al., 2001; Grady et al., 2002; Rossouw et al., 
2002).  The increased risk of cardiovascular disease with combination 
estrogen/progestin therapy in postmenopausal women may be due to the 
prothrombotic and proinflammatory effects of progestins that outweigh any 
protective effects due to estrogen (Fletcher and Colditz, 2002).  However, the 
mechanisms of the protective effects of estrogen vs. the detrimental effects of 
estrogen/progestin on the cardiovascular system are unclear.   
 Estrogen is thought to lower cholesterol through increased clearance of 
low-density lipoproteins (LDLs) from circulation via a mechanism that is 
dependent upon apoE protein expression (Nathan and Chaudhuri, 1997).  
Studies in ERKO mice have shown that ERα is necessary for E2-induced 
increases in apoE protein expression in serum (Srivastava et al., 1997).  Multiple 
studies have investigated the role of the ERs and estrogen for inhibition of 
responses to vascular injury.  E2 inhibits multiple types of responses to vascular 
injury in βERKO mice, but not in the ERα∆2KO mice indicating the ERα and not 
ERβ is necessary for estrogen-dependent protection from response to vascular 
injury (Karas et al., 1999; Brouchet et al., 2001; Pare et al., 2002).  Another 
study in ERKO mice demonstrated that ERα also mediates induction of nitric 
oxide production and inhibition of acetylcholine-elicited relaxation in the aorta by 
E2 (Darblade et al., 2002).  βERKO mice have exhibited abnormalities in ion 
channels of vascular smooth muscle cells, the development of sustained systolic 
and diastolic hypertension due to age, as well as increased vasorelaxation and 
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augmented vasoconstricition with E2 treatment in blood vessels (Nilsson et al., 
2000; Zhu et al., 2002).   
1.2.3 Function of ER domains 
 ERα and ERβ contain the 6 functional domains characteristic of the 
nuclear receptor superfamily of transcription factors (Figure 1.9).  The N’-
terminal A/B domain is the least conserved between members of the 
superfamily; for example there is only 17% identity between human ERα and 
ERβ (White et al., 1987; Evans, 1988; Danielian et al., 1992; Enmark et al., 
1997).  The A/B domain is also known as AF-1 and is a ligand-independent 
transactivation domain.  AF-1 interacts with the basal trancription machinery 
(Sadovsky et al., 1995) and several different coactivators (Endoh et al., 1999; 
Kobayashi et al., 2000; Wang et al., 2001a; Wu et al., 2001) and is a region of 
kinase-dependent phosphorylation required for ligand-independent activation of 
ER (Shibata et al., 1997).  The C domain is the DNA-binding domain (DBD) and 
contains two zinc fingers that form a helix-loop-helix structure necessary for 
protein-DNA interactions between the receptor and DNA response elements.  
The first zinc finger fits into the major groove of DNA and is responsible for 
specific amino acid contacts with DNA and the second zinc finger is important 
for receptor homo- or heterodimerization and phosphate backbone contacts 
(Tsai and O'Malley, 1994).  The DBD is the most highly conserved domain with 
97% homology between the zinc finger regions of human ERα and ERβ (Enmark 
et al., 1997; Tremblay et al., 1997; Couse and Korach, 1999).  The D domain is 
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approximately 30% conserved between the human ERs and contains the 
receptor nuclear localization signal (Enmark et al., 1997).  
               
Figure 1.9: Functional domains of ER. (Shupnik, 2002). 
The E domain contains the ligand binding domain (LBD) and AF-2 and 
has many functions including receptor dimerization, ligand binding (LBD), 
transcriptional activation (AF-2), and coactivator/corepressor binding.  The E 
domain contains twelve α-helices arranged in an antiparallel sandwich with the 
insertion of a small β-sheet.  Receptor dimerization is necessary for activation 
and mutational studies have shown that dimerization is mediated through helices 
7-10 (Fawell et al., 1990; Lees et al., 1990).  Ligand binding involves the β-sheet 
and helices 3,5,11,and 12 and the pocket formed for ligand binding contains a 
highly conserved region for stability and a highly variable region for ligand 
68
specificity (Renaud and Moras, 2000).  The AF-2 region, specifically helix 12, is 
critical for ligand-dependent transactivational activity (Danielian et al., 1992; 
Saatcioglu et al., 1993; Barettino et al., 1994; Durand et al., 1994).  Ligand 
binding leads to repositioning of helix 12 and allows coactivator association 
(Renaud and Moras, 2000).   
The C’-terminal F domain is not well conserved in the superfamily nor 
among ERs of different species; there is only 18% homology between human 
ERα and ERβ (Enmark et al., 1997).  The function of the F domain is not well 
defined.  Some studies indicate a role in transactivation of certain ligands 
through coregulatory function or dimerization (Montano et al., 1995; Peters and 
Khan, 1999).  The proximity of the F domain to helix 12 indicates possible 
involvement in transactivation when helix 12 is repositioned upon ligand binding.   
1.2.4 Mechanisms of ER action   
Recent studies have provided evidence for multiple mechanisms of ER 
action (Figure 1.10).  In the classic genomic pathway, E2 diffuses into the cell 
and binds to ER associated with heat shock protein 90 (hsp90).  Ligand-bound 
ER undergoes conformational changes that lead to release of hsp90 and 
receptor homodimerization.  The resulting ER dimers then bind to conserved 
palindromic estrogen response elements (EREs) in promoters of E2-responsive 
genes and along with a complex of other proteins and these interactions lead to 
induced gene expression (Kumar and Chambon, 1988).  However, it has been 
shown that the classical pathway of ER activation does not explain E2-  
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Figure 1.10: Multiple mechanisms of ER signaling. (Hall et al., 2001). 
dependent gene expression (Paech et al., 1997; Saville et al., 2000), particularly 
for genes that do not contain consensus EREs.  ER binds various transcription 
factors to modulate gene expression by protein-protein interactions (Day et al., 
1990; Porter et al., 1997).  E2 also induces rapid responses such as Ca2+ fluxes 
and kinase activation that are independent of the genomic pathway and involve 
membrane receptors (Revelli et al., 1998; Kelly and Levin, 2001).  Moreover, 
growth factors induce kinase cascades that lead to phosphorylation and 
activation of ER in the absence of ligand (Katzenellenbogen and Norman, 1990; 
Kato et al., 1995; El-Tanani and Green, 1997).  Multiple mechanisms of ER 
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action explain the wide range of cellular and genomic responses to ER 
activation.   
1.2.4.1 Genomic 
1.2.4.1.1 ER/Sp1 
Signaling by multiple nuclear receptors (androgen receptor (Lu et al., 
2000), PR (Gao et al., 2001), RARα receptor (Merchiers et al., 1999; Suzuki et 
al., 1999; Husmann et al., 2000), RXR receptor (Krey et al., 1995; Horie et al., 
2001)) including the ER (Krishnan et al., 1994; Porter et al., 1996; Sun et al., 
1998; Dong et al., 1999; Duan et al., 1999; Wang et al., 1999; Xie et al., 1999b; 
Vyhlidal et al., 2000; Xie et al., 2000; Castro-Rivera et al., 2001; Samudio et al., 
2001) are mediated by nuclear receptor/Sp1 interaction with guanine-cytosine 
(GC)-rich promoter sequences.  Specificity protein 1 (Sp1) is a housekeeping 
zinc-finger protein that contains three DNA binding regions that recognize GC-
rich sites in the DNA with the core GGCGGG element.  These GC-rich sites 
have been found in multiple promoters in the region between the transcription 
start site and 200 bp upstream and genome wide analysis indicates that the GC-
rich sites are primarily found in regions associated with transcription initiation 
(Hapgood et al., 2001).   
Early studies of estrogen responsive genes identified promoter regions 
that did not contain concensus or nonconcensus EREs but were still responsive 
to E2 [c-myc (Dubik and Shiu, 1992), cathepsin D (Krishnan et al., 1994), hsp 27 
(Porter et al., 1996), and TGFα (Vyhlidal et al., 2000), c-fos (Duan et al., 1998), 
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adenosine deaminase (Xie et al., 1999b) and retinoic acid receptor α1 (Sun et 
al., 1998)].  In many of these genes, a DNA motif containing an ERE half-site 
and a GC-rich sequence that interacts with Sp1 was identified.  It was 
hypothesized that E2-responsiveness was associated with cooperative 
interactions of ER and Sp1 [c-myc (Dubik and Shiu, 1992)].  Subsequent 
analysis of the cathepsin D and TGFα promoters demonstrated that both the 
ERE-half site and GC-rich site were necessary for estrogen responsiveness and 
ligand bound ER interacts with Sp1 proteins and the complex binds to the ERE-
half and GC-rich sites, respectively [cathepsin D (Krishnan et al., 1994), TGFα
(Vyhlidal et al., 2000)].  However, analysis of the hsp27 promoter showed that 
the ERE half-site was not necessary for activation by estrogen (Porter et al., 
1996) and several genes that are E2-responsive require only GC-rich sites [c-fos 
(Duan et al., 1998), adenosine deaminase (Xie et al., 1999b), and retinoic acid 
receptor α1 (Sun et al., 1998), bcl-2 (Dong et al., 1999), DNA polymerase 
α (Samudio et al., 2001), thymidylate synthase (Xie et al., 2000), cyclin D1 
(Castro-Rivera et al., 2001), and E2F1 (Wang et al., 1999)].  Studies of these 
promoters showed that ligand bound ER interacted with Sp1and regulated 
transcription through Sp1-binding to GC-rich promoter elements.  Therefore, two 
mechanisms of ER/Sp1 transcriptional activation have been demonstrated: one 
dependent upon ER-DNA binding at ERE half-sites and one independent of ER 
binding to DNA.  Since these early studies several laboratories have identified 
both ER-DNA binding dependent and independent activation of estrogen 
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responsive proteins by ER/Sp1 complexes [low density lipoprotein receptor (Li et 
al., 2001), human PR A (Petz and Nardulli, 2000), rabbit uteroglobulin gene 
(Scholz et al., 1998), vitellogenin A1 IO (Batistuzzo de Medeiros et al., 1997)].   
Multiple studies have investigated protein-protein interactions between 
ER and Sp1.  Initial studies used glutathione-S-transferase (GST)-fusion protein 
pull-down assays to show that ER interacts primarily with the C-terminal region 
of Sp1, and Sp1 interacts with multiple regions of ER including the AF1 and AF2 
domains (Porter et al., 1997).  Further studies demonstrated that the AF1 
domain of ERα was necessary for transactivation of a GC-rich promoter element 
by ER and that the AF1 region of ERα functionally interacts with the zinc-finger 
region of Sp1 to form an active ERα/Sp1 complex (Saville et al., 2000).   
1.2.4.1.2 ER/AP-1 
 AP-1 is a transcription factor and members of the AP-1 transcription 
factor family are referred to as immediate early genes because of their role in 
rapid transcriptional responses to extracellular signaling and their role in the 
transition from G0 to G1 phase of the cell cycle (Cohen and Curran, 1988; 
Lamph et al., 1988; Morgan and Curran, 1988).  AP-1 is formed by 
homodimerization of Jun proteins, heterodimerization of Fos and Jun proteins, or 
heterodimerization of Fos-related antigen and Jun proteins.  Several estrogen-
responsive genes contain AP-1 promoter elements and E2 is able to increase or 
decrease transcriptional activation of these genes depending upon the promoter 
and cell context (Tzukerman et al., 1990; Doucas et al., 1991; Shemshedini et 
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al., 1991; Tzukerman et al., 1991; Webb et al., 1995; Kushner et al., 2000) 
(Figure 1.10).   
Initial studies on activation of AP-1 promoter elements by E2 used the 
collagenase promoter in which the estrogen responsive region was identified as 
an AP-1 promoter element (Tzukerman et al., 1991; Webb et al., 1995).  It was 
shown that ER activated the promoter without directly binding to DNA 
(Tzukerman et al., 1991) and that the activation at the AP-1 element involved ER 
interactions with Jun protein but not Fos protein or DNA (Webb et al., 1995).  In 
vitro protein-protein interaction studies using co-immunoprecipitation and GST-
fusion protein pull down assays have shown that the hinge region (amino acids 
259-302) of ER interacts with the C’-terminal region of Jun; however, ER 
interaction with Fos has not been demonstrated.  Furthermore, loss of ER-Jun 
interactions by disruption of amino acids 259-302 leads to loss of transcriptional 
activity and members of the p160 transcriptional coactivator family can enhance 
the activity of the complex (Teyssier et al., 2001).  Also, recent identification of a 
coactivator of AP-1, CAPER, that specifically interacts with E2-bound ER, Jun 
and activating signal cointegrator-2 suggests biological significance for ER-Jun 
interactions (Jung et al., 2002).  Evidence from these promoter and protein-
protein interaction studies suggest that ER interacts with the Jun protein of the 
AP-1 transcription factor and activates AP-1 promoter elements in an ER-DNA 
binding independent manner.  However, the mechanism of ER activation of AP-1 
promoter elements is also ligand dependent and E2, tamoxifen, and ICI 164,384 
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all activate AP-1 promoter elements in HeLa cells.  The regions of the ER that 
are necessary for ER/AP-1 activity are ligand-dependent.  For example, 
tamoxifen required the DBD of ER for activation of the AP-1 element, whereas 
E2-dependent activation is also observed for ER containing deletion of the DBD 
(Webb et al., 1995).   
1.2.4.2 Non-gemomic   
The rapid induction of several E2-mediated responses may be due to a 
membrane associated ER that is responsible for multiple non-genomic 
mechanisms of action (Figure 1.10).  Studies in various cell lines have described 
Ca2+ fluxes (Tesarik and Mendoza, 1995; Picotto et al., 1999; Stefano et al., 
1999; Kelly and Levin, 2001), generation of cyclic nucleotides (Ropero et al., 
1999; Teoh and Man, 2000), and activation of kinase cascades (Le Mellay et al., 
1997; Doolan et al., 2000) that occur within seconds or minutes after treatment 
with E2.  Recent studies have shown that ERα and ERβ rapidly activate the 
RAS-RAF-MAPK pathway through interactions with src (Migliaccio et al., 2000) 
and E2 induces phosphatidylinositol-3 kinase (PI3-K) activity which is inhibited 
by ICI182,780 in vascular endothelial cells (Simoncini et al., 2000).  Rapid E2-
dependent activation of nitric oxide synthase (NOS) has also been described in 
multiple cell types (Chen et al., 1999; Russell et al., 2000) and induction of NOS 
in vascular cells involves E2-dependent activation of MAPK and Akt pathways 
(Chen et al., 1999; Mendelsohn, 2000; Russell et al., 2000; Simoncini et al., 
2000).  Furthermore, a study using the c-fos promoter demonstrated that E2-
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dependent activaiton of the serum response element (SRE) occurs through 
upregulation of the MAPK and PI3-K pathways resulting in phosphorylation and 
DNA binding of Elk-1 and Srf, respectively (Duan et al., 2001; Duan et al., 2002).   
 Although there is clear evidence for the existence of a membrane 
associated ER, convincing localization and isolation of an endogenous 
membrane-based ER has not been reported.  It is not clear whether the 
membrane associated ER is ERα, ERβ or a new receptor.  Associations of this 
receptor with the membrane have not been determined and it is noteworthy that 
neither ERα nor ERβ contain the hydrophobic, membrane-spanning regions or 
sites for post-translational lipid modification.  One study in COS-1 cells 
demonstrated that transfected ERα and ERβ were able to incorporate into the 
cell membrane and mediate ligand-dependent activation of kinase cascades 
(Razandi et al., 1999) and multiple studies using antibodies to ER or E2-
conjugated with BSA have shown punctate staining of the cell membrane 
(Norfleet et al., 2000; Russell et al., 2000; Duan et al., 2001).  Furthermore, 
studies in MCF-7 cells have isolated receptors from plasma membrane extracts 
with antibodies to ERα and have identified 130, 110, 92 and 67 kDa proteins 
(Powell et al., 2001).    
1.2.4.3 Ligand-independent ER activation 
Ligand independent activation of ER by growth factors has also been 
reported (Figure 1.10).  Growth factors activate kinase pathways such as MAPK, 
PI3-K, c-Jun N-terminal kinase (JNK), protein kinase A, B, or C (PKA, PKB, 
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PKC), and insulin receptor substrate 1 (IRS-1) and induce a multitude of cellular 
responses including cell cycle progression, cell proliferation, cell survival, and 
apoptosis.  The ability of serum, insulin and insulin-like growth factor to activate 
ERα and an ERE-promoter construct without hormone treatment was the first 
indication of growth factor activation of ER (Katzenellenbogen and Norman, 
1990) and this observation has been supported by subsequent studies.  For 
example it has been shown that pS2 and PR mRNA levels are induced after 
treatment of MCF-7 cells with E2 or IGF-1 and both responses are inhibited by 
ICI 182,780 and wortmanin, a PI3-K inhibitor, indicating that induction is 
dependent on the PI3-K pathway and involves ER.  Another study using an 
adensone deaminase (ADA) promoter reporter construct, which is activated via 
ER/Sp1 complexes, showed that gene activity was induced by EGF, IGF-1, and 
TGFα in MCF-7 cells transfected with ERα (Xie et al., 2001).  Specific inhibitors 
of the MAPK pathway and overexpression of dominant-negative Ras, as well as 
mutation in serines 118 and 167 of ER inhibited IGF-1-dependent induction of 
the reporter construct indicating that IGF-1 activated ERα through the MAPK 
pathway (Xie et al., 2001) and serines 118 and 167 in ERα were required.  
Other studies have demonstrated that activation of ER by EGF and IGF-1 were 
AF-1 dependent and required phosphorylation of serine 118 (Kato et al., 1995; 
Bunone et al., 1996; Karas et al., 1999) and Akt, downstream of PI3-K, is 
involved in AF-1-dependent phosphorylation of ER.  In contrast, studies with 
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cAMP analogs have reported AF-2-dependent activation of ER in various cell 
types (El-Tanani and Green, 1997).   
 Several studies have investigated activation of ERα by growth factors and 
this has also been observed for ERβ.  For example, EGF induced reporter gene 
activity in cells transfected with an ERβ expression plasmid and an ERE reporter 
construct and the response was inhibited by antiestrogens and MAPK inhibitors 
(Tremblay and Giguere, 2001).  This indicates that ligand-independent activation 
of ERβ by growth factors also involves kinase pathways, similar to that observed 
for ERα.  Furthermore, in vitro assays have shown that ERβ is phosphorylated in 
the AF-1 domain, as has been reported for ERα.
 In vivo animal studies also provide evidence for growth factor activation of 
ER.  In studies with adult ovariectomized mice, EGF induces estrogen-like 
responses in the uterus including increased DNA synthesis, phosphatidylinositol 
turnover, PR, and lactoferrin (Nelson et al., 1991; Ignar-Trowbridge et al., 1992; 
Curtis et al., 1996) and cotreatment with ICI 182,780 reduces the uterine 
response to EGF (Ignar-Trowbridge et al., 1992) indicating the need for ER in 
EGF–induced uterine responses.  Furthermore treatment of ERKO mice with 
EGF did not result in increased DNA synthesis or PR in the uterus; however, 
other EGF-mediated responses such as c-fos gene expression were observed in 
ERKO mice.  These studies indicate that although the EGF signaling pathway is 
intact induction of estrogen-like responses by EGF require ERα and are not 
observed in ERKO mice (Curtis et al., 1996).   
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1.3 Aryl hydrocarbon receptor (AhR) 
1.3.1 Structure and mechanism of action   
The AhR is a ligand-activated transcription factor that binds a structurally 
diverse range of chemicals.  It was initially identified as a receptor that bound 
hydrophobic environmental contaminants such as polycyclic aromatic 
hydrocarbons (PAHs) and halogenated aromatic hydrocarbons (HAHs); 
however, recent studies have identified many naturally-occurring plant products 
including flavonoids, carotenoids, and phenolics that are AhR ligands.  The AhR 
is a member of the basic-helix-loop-helix (bHLH)-Per,Arnt,Sim (PAS) family of 
transcription factors.  The bHLH motif is located in the N-terminal region of the 
protein and is involved in DNA binding, heterodimerization, and interaction with 
the heat shock protein 90 (hsp90) (Figure 1.11).  The nuclear localization signal 
(NLS) and nuclear export signal (NES) are also located within the bHLH region 
of the receptor.  Adjacent to the C-terminal end of the bHLH motif is the PAS 
domain.  It includes 2 imperfect repeats of 50 amino acids that are termed PAS 
A and PAS B.  PAS A and PAS B form an interactive surface for 
heterodimerization and PAS B is also involved in ligand binding and hsp90 and 
Sp1 protein interactions.  The C-terminal half of the receptor contains the Q-rich 
region which mediates the transactivation activity of the receptor and involves 
recruitment of CBP/p300 and RIP 140 coactivators.   
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Figure 1.11: Functional domains of AhR. (Mimura and Fujii-Kuriyama, 2003). 
The mechanism of AhR action is similar to that described for other ligand-
activated receptors and was derived from early studies on AhR-mediated 
induction of CYP1A1 gene expression (Swanson and Bradfield, 1993; Whitlock, 
1993; Whitlock et al., 1996; Wilson and Safe, 1998) (Figure 1.12).  The unbound 
hepatic AhR is located in the cytosol as a multi-protein complex containing two 
hsp90 molecules, the X-associated protein 2 (XAP2) (Meyer et al., 1998), and 
co-chaperone protein p23 (Kazlauskas et al., 1999).  Following ligand binding 
the receptor undergoes a conformational change that exposes the NLS and 
results in translocation into the nucleus (Hord and Perdew, 1994; Pollenz et al., 
1994).  In the nucleus the ligand:AhR dissociates from the protein complex and 
heterodimerizes with a closely related nuclear bHLH-PAS protein called AhR 
nuclear translocator (Arnt) protein (Probst et al., 1993; Hankinson, 1995).  The 
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heterodimer has a high affinity for DNA and binds dioxin response elements 
(DREs) in promoters of responsive genes.  The consensus DRE contains an N 
T/G TGCGTG A/C C/G A/T A/G G/C N sequence in which the pentanucleotide 
core (GCGTG) is necessary for AhR/Arnt binding and the flanking sequence in 
important for transcriptional activation (Safe, 2001).  Binding of the heterodimer 
to DNA leads to chromatin and nucleosome disruption, increased promoter 
accessibility, and ultimately gene transcription (Denison et al., 1988; Denison et 
al., 1989; Whitlock, 1999; Denison et al., 2002).  Studies have demonstrated that 
other transcription factors such as Sp1 and coactivators such as CBP/p300, 
RIP140, and Src-1 are involved in the AhR/Arnt transcriptional activity (Ko et al., 
1996; Kobayashi et al., 1996; Kobayashi et al., 1997; Kumar and Perdew, 1999; 
Kumar et al., 1999).  The NES is responsible for cytoplasmic shuttling of 
receptors that do not bind Arnt or DNA and results in ubiquitination and 
proteasome degradation (Roberts and Whitelaw, 1999).  The AhR-related factor, 
termed the AhR repressor (AhRR), has also been identified (Mimura et al., 
1999).  The AhRR is localized in the nucleus and forms heterodimers with Arnt 
that bind DREs but act as transcriptional repressors.  The promoter region of 
AhRR also contains functional DREs and is inducible through the AhR, 
indicating that AhR and AhRR may form a regulatory feedback loop (Mimura et 
al., 1999). 
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Figure 1.12: AhR signaling. (Mimura and Fujii-Kuriyama, 2003). 
1.3.2 Biological responses to AhR agonists 
The most potent and best-characterized ligand for the AhR is 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), an HAH that is a byproduct of industrial 
processes and combustion of organic material.  TCDD binds with high affinity to 
the AhR and induces a wide variety of biological and toxic responses.  Most 
research has used TCCD as the prototypical AhR ligand to study the biological 
responses mediated by the AhR.  TCDD indcues phase I and phase II xenobiotic 
metabolizing enzymes (XMEs) including cytochrome P450 (cyp) 1A1, cyp 1A2, 
cyp 1B1, NADP(H):oxidoreductase, class 3 aldehyde dehydrogenase, NAD(P)H: 
quinone reductase 1 and 2, glutathione-S-transferase Ya subunit, and UDP-
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glucuronosyl transferase.  Many of these induction responses involve AhR 
interactions with XREs in the promoters of the inducible genes (Paulson et al., 
1990; Favreau and Pickett, 1991; Asman et al., 1993; Jaiswal, 1994).  PAHs and 
HAHs that induce XMEs are often the substrates for some of the induced 
enzymes and the AhR mediated responses may have evolved to decrease the 
cellular levels of these compounds.  Many of the induced metabolic pathways 
also generate electophilic intermediates from PAH substrates and these 
metabolites can be genotoxic.  The induction of multiple genes involved in other 
cellular processes including cell proliferation (TGF-β, IL-1β, PAI-2), cell cycle 
regulation (p27, jun-B), apoptosis (Bax), DNA synthesis (DNA polymerase k), 
and AhR signaling (AhRR) by AhR agonists has also been described 
(Hankinson, 1995; Sogawa and Fujii-Kuriyama, 1997; Hahn, 1998; Kolluri et al., 
1999; Mimura et al., 1999; Matikainen et al., 2001; Ogi et al., 2001).  A 
microarray study in HepG2 cells showed that 108 genes were upregulated by 
TCDD (in the presence of cycloheximide) indicating that TCDD induces many 
other genes that have previously not been characterized (Frueh et al., 2001).   
TCDD induces multiple cellular responses that are dependent on cell 
context.  For example, TCDD induces cell proliferation and terminal 
differentiation in keratinocytes (Milstone and LaVigne, 1984; Choi et al., 1991; 
Gaido et al., 1992; Gaido and Maness, 1994) and both increases and decreases 
in proliferation rates in hepatocytes (Wiebel et al., 1991; Wolfle et al., 1993; 
Moolgavkar et al., 1996).  TCDD induces apoptosis in thymocytes (McConkey et 
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al., 1988; McConkey and Orrenius, 1989; Kamath et al., 1997) and apoptosis as 
well as inhibition of UV-induced apoptosis in hepatocytes (Moolgavkar et al., 
1996; Worner and Schrenk, 1996).  Furthermore, the AhR can form protein 
complexes with retinoblastoma protein and these complexes lead to inhibition of 
cell cycle progression (Ge and Elferink, 1998; Puga et al., 2000; Elferink et al., 
2001).   
TCDD induces several well-characterized acute and chronic toxic 
responses including craniofacial abnormalities such as cleft palate in mice 
(Courtney and Moore, 1971) and a range of other embryotoxicities in other 
species including resorption, fetal mortality, and decreased fetal weights 
(Couture et al., 1990).  Induction of cleft palate in mice by TCDD alters the 
proliferation and differentiation of the medial edge epithelium (Pratt et al., 1984; 
Abbott and Birnbaum, 1989), possibly through regulation of TGF-β3 (Pratt et al., 
1985).  TCDD induces thymic involution and immunosuppression at levels below 
those that cause systemic toxicity.  Thymic atrophy can be induced with single 
low dose of TCDD and involution of the thymus is dependent upon AhR 
expression (Poland and Glover, 1980).  Supression of cell-mediated immunity is 
also observed after treatment with low doses of TCDD and this response is 
mediated by non-lymphoid tissue (Nagarkatti et al., 1984).  TCDD alters 
maturation and decreased mitogenic activity of thymic epithelium and it has 
been suggested that this may lead to the suppression of cell-mediated immunity 
(Greenlee et al., 1985).  TCDD also affects humoral immunity through 
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suppression of B lymphocyte responses.  TCDD treatment is required early in B 
cell activation; however, the inhibitory effects are seen later in the differentiation 
of B cells into plasma cells (Luster et al., 1988).  TCDD induces tumors in 
various rodent models and the pattern of tumors is dependent upon the animal 
species and strain.  Using the two-stage model of liver carcinogenesis, treatment 
with TCDD results in tumor promotion (Pitot et al., 1980) and chronic dietary 
studies in rats have shown that TCDD induces squamous cell carcinoma of the 
lungs, hard palate/nasal turbinates and tongue as well as hepatocellular 
carcinoma (Kociba et al., 1978; Goodman and Sauer, 1992).  TCDD is not 
genotoxic (Poland and Glover, 1979; Geiger and Neal, 1981) and therefore the 
mechanism of TCDD induced carcinogenesis is unclear.  TCDD could increase 
metabolism of other chemicals into carcinogens, increase lipid peroxidation, or 
alter cell proliferation.  TCDD induces other toxic responses including altered 
lipid metabolism, epithelial hyperplasia and metaplasia, altered reproductive and 
endocrine function, porphyria, and wasting syndrome (Poland and Knutson, 
1982; Bjerke et al., 1994; Kerkvliet, 1995; Oughton et al., 1995).   
Although the molecular mechanisms for the induction of XMEs and 
multiple other genes involved in cell proliferation, differentiation, and apoptosis 
are known, the mechanisms by which the AhR mediates many toxic responses 
are unknown.  PAHs and HAHs induce parallel dose-response curves for 
induction of XMEs whereas, only HAHs such as TCDD induce the toxic 
responses indicating that molecular mechanisms for the induction of XMEs and 
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toxicity may be different.  One mechanism of TCDD-induced toxicity may be due 
to persistent transcriptional activation of genes regulated by the AhR; however, 
critical genes required for induced toxicity have not yet been identified.  
Furthermore, degenerate DREs or other low-affinity AhR DNA binding sites may 
be present in other genes and the persistent and potent HAHs such as TCDD 
may preferentially modulate expression of these genes.  In addition, the 
molecular mechanisms may not be direct transcriptional regulation by AhR.  Arnt 
also forms dimers with HIF-1α, a transcription factor involved in hypoxic 
responses and persistent activation of the AhR could sequester Arnt or other 
coactivators and decrease other signaling pathways such as hypoxia.   
AhR agonists also cause tissue-specific inhibition of estrogen-induced 
responses (Kociba et al., 1978; Safe et al., 1998; Safe and McDougal, 2002) 
and SAhRMs have been developed for the treatment of breast cancer.  Kociba 
and coworkers (Kociba et al., 1978) initially reported that age-dependent 
spontaneous mammary and uterine tumor formation in Sprague Dawley rats was 
inhibited in rats receiving TCDD in the diet.  These correlated with epidemiology 
studies in Sevesco, Italy in which women accidentally exposed to TCDD 
exhibited lower rates of breast and endometrial cancer (Bertazzi et al., 1993; 
Bertazzi et al., 2001).  Subsequent research in several laboratories has 
demonstrated that TCDD inhibits estrogen-induced responses in the rodent 
uterus, carcinogen-induced rodent mammary tumors and human 
breast/endometrial cancer cell lines.  In the uterus TCDD and other AhR 
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agonists inhibit E2-induced increase in wet weight, cell proliferation, PR and 
EGF receptor binding, peroxidase activity, and EGF receptor and c-fos mRNA 
expression.  In vitro work in breast cancer (MCF-7, T47D, MDA-MB-468) and 
endometrial cancer cell lines (ECC1, HEC1A) have shown that the AhR is 
expressed and agonists induce cyp1A1 expression.  Studies in MCF-7 and 
T47D cells showed that TCDD inhibits E2-induced cell proliferation, DNA 
synthesis, PR mRNA and protein expression, pS2 mRNA and protein 
expression, cathepsin D mRNA and protein expression, prolactin receptor 
mRNA expression, vitelogenin A2 promoter activity and creatine kinase B 
promoter activity.  TCDD also inhibited certain E2-induced cell cycle responses 
such as G0/G1 to S transition, retinoblastoma phosphorylation, cyclin-dependent 
kinase 2 and 4 phosphorylation, and cyclin D1 protein expression (Wang et al., 
1998).   
Multiple mechanisms of cross-talk between the AhR and ER signaling 
pathways have been proposed.  Induction of cyp1A1 and cyp1A2 by TCDD 
results in rapid metabolism and cellular depletion of E2 in cell culture; however, 
the same effect was not observed in in vivo rodent studies (Gierthy et al., 1988; 
Badawi et al., 2000).  TCDD also activates proteasome-dependent degradation 
of ERα (Wormke et al., 2000; Wormke et al., 2003) and cotreatment with E2 and 
TCDD results in low levels of ERα which may be limiting for transactivation 
(Figure 1.13).  Several estrogen responsive genes contain inhibitory DRE (iDRE)  
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Figure 1.13: AhR-ER crosstalk through proteasome-mediated degradation.
(Wormke et al., 2003). 
sequences that interact with the AhR complex and this results in decreased E2-
induced transactivation.  Mutation of the core pentanulceotide DRE sequence 
leads to loss of inhibitory AhR-ER cross-talk (Gillesby et al., 1997; Duan et al., 
1999; Porter et al., 2001; Wang et al., 2001b).  However, several E2-induced 
genes inhibited by TCDD (eg. RARα1) do not have iDRE sequences in the 
promoters (Safe et al., 1998).  It has also been suggested that competition for 
coactivators and other transcription factors or direct interactions between the 
AhR and ER may contribute to the inhibition of E2-induced responses by AhR 
agonists (Klinge et al., 2000; Carlson and Perdew, 2002; Ohtake et al., 2003).   
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1.3.3 Phenotype of AhR knockout (AhRKO) mice  
 AhRKO mice have been generated in several laboratories and the 
resulting animals develop some similar phenotypes and also a number of 
distinctive phenotypes (Fernandez-Salguero et al., 1995; Schmidt et al., 1996).  
The Gonzalez laboratory generated AhRKO mice by replacing exon 1 with a 
neomycin resistance gene resulting in the deletion of the translational start site 
and a protion of the basic amino acids involved in DNA binding (Fernandez-
Salguero et al., 1995).  The Bradfield laboratory generated AhRKO mice by 
replacing exon 2 with a neomycin resistance gene and the result was the 
deletion of the bHLH domain involved in heterodimerization and DNA binding 
(Schmidt et al., 1996).  Both laboratories utilized ES cells from the 129 mouse; 
however, different substrains were utilized.  C57BL/6 micewere also used in 
these studies; however, different breeding sources were utilized.  In order to 
compare the two models the Gonzalez mice will be designated d1/d1 and the 
Bradfield mice will be designated d2/d2 based on the exon that was deleted in 
generation of the transgenic mice.    
 Certain phenotypes such as decreased liver size at 3-4 weeks of age and 
subtle hepatic portal fibrosis were seen in both transgenic models.  Decreased 
constitutive expression of certain xenobiotic metabolizing enzymes (XMEs) and 
decreased body size during the first four weeks of age were observed in both 
the d2/d2 and d2/d2 AhRKO mice.  Decreased fertility with difficulty in 
maintaining pregnancy, lactation, and rearing of pups to weaning was also 
89
observed in these transgenic mice (Abbott et al., 1999).  Induction of biological 
responses by TCDD and related AhR agonists was not seen in either AhRKO 
models.  Cyp1A1 is not induced by TCDD in either the d1/d1 or d2/d2 AhRKO 
mice (Fernandez-Salguero et al., 1996; Schmidt et al., 1996) and a third AhRKO 
model was resistant to TCDD-induced teratogenesis and benzo(a)pyrene-
induced carcinogenesis (Mimura et al., 1997; Shimizu et al., 2000).  These 
studies indicate that the AhR is necessary for induction and basal expression 
and is also required for the teratogenic and chemical carcinogenic effects 
induced by TCDD and benzo(a)pyrene, respectively.  It also indicates a role for 
the AhR in liver development and possibly some aspects of fertility.   
 Significant differences in phenotypic traits were also observed between 
the d1/d1 and d2/d2 AhRKO mice.  Normal Mendelian distribution of the pups 
suggests that embryonic mortalities should not be observed in these mice; 
however, d1/d1 mice had a high mortality rate within the first 2 weeks of age 
whereas the d2/d2 had survival rates similar to their wild-type littermates 
(Fernandez-Salguero et al., 1995; Schmidt et al., 1996).  Livers of the d1/d1 
mice exhibited eosinophilia of the periportal hepatocytes, centrilobular 
hypercellularity, glycogen depletion, and inflammation of the bile duct, whereas 
livers of the d2/d2 mice exhibited prolonged extramedullary hematopoiesis and 
extensive microvesicular fatty metamorphosis within hepatocytes that completely 
resolved by 4-5 weeks of age (Fernandez-Salguero et al., 1995; Schmidt et al., 
1996).  The immune system of the d1/d1 mice also developed altered 
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pheonotypes (Fernandez-Salguero et al., 1995).  The periarterial lymphatic 
sheaths of the spleen were small compared to wild-type mice and splenocyte 
numbers were decreased at 2-3 weeks and appeared to recover by week 8 and 
decreased again in mice 25-32 weeks of age.  There were also fewer lymphoid 
cells in the peripheral lymph nodes in the d1/d1 mice.  In contrast the spleens of 
the d2/d2 mice appeared normal except at 6 weeks of age when some mice 
exhibited high splenocyte numbers (Schmidt et al., 1996).  Multiple factors could 
account for differences between d1/d1 and d2/d2 mice including the timing of 
these observations, the different targeting strategies leading to differential 
effects on the expression of neighboring genes, different substrain of ES cells, 
breeding of chimeras leading to different genetic backgrounds, and different 
environmental exposure of the colonies to xenobiotics and infectious agents 
(Lahvis and Bradfield, 1998).  The discrepancies between the two AhRKO 
mouse models make if difficult to determine the role of the AhR in the different 
phenotypes.   
 d2/d2 AhRKO mice have been used to investigate the role of the AhR in 
mediating inhibition of estrogen-induced responses by TCDD in the uterus.  
TCDD inhibits estrogen-induced lactoferrin mRNA expression and proliferation in 
the luminal epithelium of the uterus in wild-type mice; however, TCDD does not 
inhibit either the increase in lactoferrin mRNA expression or increased labeling 
index in the epithelial cells induced by estrogen in the uterus of d2/d2 AhRKO 
mice (Buchanan et al., 2000).  Furthermore, tissue recombination studies using 
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uterine cells from the d2/d2 AhRKO mice, as described with the ERKO mice, 
have shown that AhR expression in the stroma is necessary for TCDD-
dependent inhibition of E2-induced proliferation of epithelial cells (Buchanan et 
al., 2000).  
1.3.4 Diversity of agonists    
An increasing number of studies have shown that the AhR binds 
structurally diverse compounds including phytochemicals that exhibit multiple 
chemoprotective and anticarcinogenic activities (Bjeldanes et al., 1991; Jellinck 
et al., 1993; Chen et al., 1996; Gasiewicz et al., 1996; Gradelet et al., 1997; 
Casper et al., 1999; Seidel et al., 2000).  In general, the compounds can be 
divided into synthetic compounds or naturally occurring compounds that are 
produced in biological systems through natural processes.  The naturally 
occurring compounds are primarily dietary phytochemicals or endogenous 
biochemicals.   
1.3.4.1 Synthetic ligands  
 The planar, hydrophobic HAHs such as polyhalogenated dibenzo-p-
dioxins, dibenzofurans, and biphenyls and PAHs such as 3-methylcholanthrene, 
benzo(a)pyrene, benzanthracene, and benzoflavones are the most extensively 
studied classes of AhR agonists (Figure 1.14).  Moreover, many of these 
compounds are high affinity ligands for the AhR (Poland and Knutson, 1982; 
Gillner et al., 1993; Kafafi et al., 1993).  The more stable HAHs are the most 
potent AhR agonists with binding affinities in the pM to nM range, whereas the 
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more labile PAHs have binding affinities in the nM to µM range.  Structure-
activity studies with these compounds initially demonstrated that AhR ligands 
tend to be co-planar with dimensions that fit within 14 A X 12 A X 5 A and high 
affinity binding was dependent upon particular electronic, steric and 
thermodynamic characteristics (Kafafi et al., 1993; Bonati et al., 1995; Waller 
and McKinney, 1995; Tuppurainen and Ruuskanen, 2000; Mhin et al., 2002).  
However, a large number of synthetic compounds such as SKF71739, 
2(methylmercapto)aniline, omeprazole, and YH439 with structures and 
physiochemical properties different from the HAHs and PAHs also to bind the 
AhR and activate AhR-dependent gene expression (Denison and Heath-
Pagliuso, 1998; Nagy et al., 2002).  Therefore, the range of potential synthetic 
and natural AhR ligands has been continually expanding and includes diverse 
structural classes of compounds (Denison and Nagy, 2003). 
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Benzo(a)pyrene β-Naphthoflavone3-Methylcholanthrene
2,3,7,8-Tetrachlorodibenzo-p-dioxin 3,4,3’,4’,5-Pentachlorobiphenyl 2,3,7,8-Tetrachlorodibenzofuran
Figure 1.14: Structure of synthetic AhR ligands. (Adapted from Denison and 
Nagy, 2003). 
1.3.4.2 Natural ligands 
1.3.4.2.1 Dietary 
 A variety of naturally occurring dietary compounds activate or inhibit the 
AhR signaling pathways have also been reported.  Dietary phytochemicals such 
as indole-3-carbinol (I3C) (Bjeldanes et al., 1991; Gillner et al., 1993), 7,8-
dihydrorutacarpine (Gillner et al., 1989), dibenzoylmethanes (MacDonald et al., 
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2001), curcumin (Ciolino et al., 1998), carotinoids (Gradelet et al., 1996a; 
Gradelet et al., 1996b) and flavonoids (Canivenc-Lavier et al., 1996; Ashida et 
al., 2000; Allen et al., 2001) competitively bind the AhR and/or activate AhR-
dependent gene expression (Figure 1.15).  Furthermore, dietary indoles such as 
I3C and tryptophan (Trp) can be converted in the mammalian digestive tract to 
more potent AhR ligands (Bjeldanes et al., 1991; Perdew and Babbs, 1991).  
Acid-catalyzed condensation of I3C results in the formation of indolo-[3,2-b]-
carbazole (ICZ), which among the dietary compounds has perhaps the highest 
affinity for the AhR and is a potent inducer of AhR-dependent gene expression.  
3,3’Diindolylmethane a dimeric condensation product of I3C is also an AhR 
agonist (Bjeldanes et al., 1991; Gillner et al., 1993; Jellinck et al., 1993). 
 Flavonoids such as flavones, flavanols, flavanones, and isoflavones are 
the largest group of dietary phytochemical AhR ligands.  The majority of the 
flavonoids exhibit AhR antagonist activity; however, numerous agonists have 
also been identified (Canivenc-Lavier et al., 1996; Ashida et al., 2000; Allen et 
al., 2001).  These compounds are found in fruits, vegetables, and teas and blood 
levels of flavonoids have been reported at concentrations sufficient to induce or 
inhibit AhR-dependent activity (Nakagawa et al., 1997; Paganga and Rice-
Evans, 1997; de Vries et al., 1998).   
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Figure 1.15: Structure of naturally occurring and endogenous ligands of the AhR.
(Denison and Nagy, 2003). 
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1.3.4.2.1 Endogenous 
 Although numerous synthetic and natural dietary ligands for the AhR have 
been identified, an endogenous, physiological ligand for the AhR has not been 
reported.  The promiscuous ligand binding activity of the AhR suggests that 
there may be multiple endogenous ligands.  Observations of AhR activation and 
receptor-dependent responses in the absence of endogenous ligand suggest 
that an endogenous ligand does exist.  Nuclear AhR complexes have been 
identified in cells and tissue sections that have not been exposed to exogenous 
ligands (Abbott et al., 1994; Singh et al., 1996; Chang and Puga, 1998) and 
hydrodynamic shear stress conditions as well as methylcellulose suspensions of 
multiple cell types induce cyp1A1 expression (Sadek and Allen-Hoffmann, 1994; 
Monk et al., 2001; Denison et al., 2002).  Also, disruption of the AhR through 
anti-sense or iRNA techniques results in decreased mouse blastocyst 
development and altered cell cycle regulation in cell culture (Paine, 1976; Peters 
and Wiley, 1995; Goerz et al., 1996; Abdelrahim et al., 2003).  Furthermore, 
development of abnormalities in the liver and possibly the immune system of the 
AhRKO mice suggests that there is an endogenous ligand for the AhR in the 
mouse (Fernandez-Salguero et al., 1995; Schmidt et al., 1996).  
 Several structurally diverse endogenous biochemicals that bind the AhR 
and/or activate AhR-dependent gene expression have been identified.  
Endogenous compounds which contain indole structures activate the AhR and 
the majority are formed from Trp through biological or physiochemical 
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processes.  Several Trp photooxidation products competitively bind the AhR and 
activate AhR-dependent gene expression (Rannug et al., 1987; Wei et al., 
1999).  One of the photoxidation products was identified as FICZ, a compound 
very similar in structure to ICZ which is formed from I3C (Bjeldanes et al., 1991; 
Denison and Nagy, 2003).  It has been suggested that FICZ and other 
photooxidation products of Trp may be novel chemical messenger of light similar 
to other Trp-derived molecules such as indole acetic acid (involved in plant 
growth regulation) and seratonin (involved in circadian rhythms of mammals) 
(Wei et al., 1999).  The AhR may be similar to other members of the PAS 
superfamily that are activated by light.   
 Trp metabolites such as tryptamine, indole acetic acid, and kyneurinines 
also activate the AhR signaling pathway.  Although they have weak activity and 
normal blood concentrations are low, in abnormal conditions such as inhibition of 
monoamine oxidase activity levels of these compounds are sufficient to activate 
AhR signaling (Miller, 1997; Heath-Pagliuso et al., 1998).  Indigo and indirubin 
are metabolites of Trp that can also be formed from cyp2A6/2C19/2E1-
dependent metabolism of indoles (Gillam et al., 1999; Gillam et al., 2000).  They 
were isolated from human urine and exhibited AhR activity in a yeast cell 
bioassay (Adachi et al., 2001).  Although levels of these compounds in human 
serum have not been established, indigo and indirubin levels in fetal bovine 
serum were sufficient to activate the AhR in the yeast cell bioassay (Adachi et 
al., 2001).   
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 Tetrapyroles such as bilirubin and biliverdin are another group of 
endogenous compounds that bind and activate the AhR (Figure 1.15).  
Persistent cyp1A1 expression in congenitally jaundiced Gunn rats suggested the 
presence of an endogenous AhR ligand (Kapitulnik and Gonzalez, 1993).  
Bilirubin, the primary breakdown product of heme, was present at high levels in 
the blood of Gunn rats and is sufficient to induce cyp1A1 expression and DRE-
dependent activity in cultures at physiologically relevant concentrations 
(Kapitulnik and Gonzalez, 1993; Sinal and Bend, 1997; Phelan et al., 1998).  
Biliverdin, a precursor for bilirubin, also activates DRE-dependent gene 
transcription (Denison et al., 2002).  Higher induction potency was observed for 
bilirubin and biliverdin in cells compared to in vitro systems suggesting these 
compounds may be converted to more potent metabolites in vivo (Denison et al., 
2002).   
 Some arachidonic acid (AA) metabolites activate the AhR.  Lipoxin A4, a 
lipoxygenase product of AA, binds the AhR and induces cyp1A1 and DRE-
dependent gene expression at concentrations near physiological levels (Serhan 
and Sheppard, 1990; Schaldach et al., 1999) (Figure 1.15).  Several 
prostaglandins, including prostaglandin G2, also bind the AhR and activate AhR-
dependent gene expression, although only at concentrations >1 µM, which is 
much higher than physiological concentrations (Smith, 1989; Seidel et al., 2001) 
(Figure 1.15).  However, it has been reported that prostaglandin concentrations 
can reach 5-10 µM near hepatocytes due to their secretion into the narrow 
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space of the Disse (Neuschafer-Rube et al., 1993).  Studies have also 
demonstrated that several prostaglandins induced reporter expression 2-5 fold 
higher than the maximum inducing dose of TCDD, suggesting that 
prostaglandins may activate other pathways that augment AhR signaling.   
 Carotenoids including canthaxanthin, astaxanthin, and β-apo-8’-carotinal 
also induce cyp1A1 and other AhR-dependent gene expression (Astorg et al., 
1994; Gradelet et al., 1996a; Gradelet et al., 1996b; Gradelet et al., 1997) 
(Figure 1.15).  Although none of the endogenous retinoids exhibited AhR-
dependent activity, synthetic retinoids activate the AhR and AhR-dependent 
gene expression, suggesting that endogenous retinoids or retinoid-like 
compounds may also affect AhR signaling (Soprano et al., 2001; Gambone et 
al., 2002).  The endogenous oxysterol, 7-ketocholesterol competitively binds the 
AhR and act as an AhR antagonist (Savouret et al., 2001).  Furthermore, 
concentrations of 7-ketocholesterol found in the blood are sufficient to inhibit 
TCDD-induced gene expression in culture (Savouret et al., 2001).    
1.4 ErbB2 and ErbB receptor family 
1.4.1 Structure and function   
The epidermal growth factor receptor (EGFR) family, also known as the 
ErbB receptor family, plays a critical role in normal development and physiology 
as well as the growth of multiple human cancers including breast cancer.  The 
ErbB family is comprised of 4 genes that encode 4 homologous tyrosine kinase 
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receptors, namely ErbB1 (EGFR), ErbB2, ErbB3 and ErbB4 (Menard et al., 
2000; Mendelsohn and Baselga, 2000; Olayioye et al., 2000; Sweeney et al., 
2001).  These receptors are phosphoglycoprotein transmembrane receptors that 
contain an extracellular ligand-binding domain, a single membrane-spanning 
region and an intracellular protein tyrosine kinase domain (Figure 1.16).  The 
four receptors are differentially expressed in normal and cancerous tissues.  
ErbB2 plays a key role in coordinating with the other ErbBs in a complex 
signaling network that regulates cell growth, differentiation and survival (Yarden, 
2001).  ErbB2 is expressed in a wide variety of tissue except those of 
hematopoietic origin and is overexpressed in multiple types of cancer including 
breast cancer.  ErbB2 is necessary for normal development and is expressed in 
the nervous system, bone, muscle, skin, heart, lungs, and intestinal epithelium of 
the human fetus (Coussens et al., 1985; Quirke et al., 1989).  In the absence of 
ErbB2 in the mouse during development the trabeculae of the heart will not 
develop and the mice die during gestation (Meyer and Birchmeier, 1995).  ErbB2 
is also involved in normal mammary gland development and growth.  ErbB 
ligands stimulate lobulo-alveolar development in the mouse mammary gland in 
expalnt cultures and in vivo (Yang et al., 1995; Jones et al., 1996; DiAugustine 
et al., 1997; Normanno and Ciardiello, 1997). 
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Figure 1.16: Stucture of the ErbB receptors. (Adapted from Harris et al., 2003). 
1.4.2 ErbB ligands 
Ligands for the ErbB family of receptors are members of the EGF-like 
peptide growth factor family that are produced as transmembrane precursors.  
The ectodomains are processed by proteolysis resulting in formation of soluble 
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growth factors.  ErbB ligands contain an EGF-like motif of 50-55 amino acids 
with 6 highly conserved cysteine resudies that confer binding specificity.  They 
can be divided into 3 classes of lignds based on receptor specificity.  EGF, 
amphiregulin (AR), and TGFα bind ErbB1; beta cellulin (BTC), heparin-binding 
EGF (HB-EGF), and epiregulin (EPR) bind ErbB1and ErbB4; and neuregulins 
can be divided into two sub classes: neuregulins 1 and 2 bind ErbB3 and ErbB4 
whereas neuregulins 3 and 4 bind ErbB4.  Direct ligands for ErbB2 have not 
been described and studies suggest that differences in regions of the 
extracellular domain that contact the ligands between ErbB2 and the other 
ErbBs may account for their differences in ligand binding specificity (Cho and 
Leahy, 2002; Ogiso et al., 2002).  Although ligands for ErbB2 have not been 
described ErbB2 is a coreceptor for many of the known ErbB ligands and is 
transactivated by many of the EGF-like ligands (Pinkas-Kramarski et al., 1996; 
Pinkas-Kramarski et al., 1997).  ErbB ligands are bivalent molecules with two 
binding sites for the receptor.  Neuregulin –1 contains a high affinity, narrow 
specificity binding site in the N-terminal region and a low-affinity, broad 
specificity binding site in the C-terminal region and ErbB2 preferentially binds the 
low affinity binding site (Tzahar et al., 1996; Yarden, 2001).  This suggests that 
the ligands have high affinity binding sites that bind ErbB1, ErbB3, or ErbB4 and 
a low affinity site that recruits homo- or heterodimerization partners.  Homo- and 
heterodimeric interactions between the ligand-bound ErbBs are not random; 
ErbB2 is the preferential dimerization partner for the ligand-bound ErbBs 
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(Tzahar et al., 1996; Burden and Yarden, 1997; Graus-Porta et al., 1997; 
Pinkas-Kramarski et al., 1998).  Furthermore, dimerization with ErbB2 leads to 
higher ligand binding affinity as well as stonger and more sustained activation of 
signaling pathways compared to dimers that do not contain ErbB2 (Sliwkowski et 
al., 1994; Beerli et al., 1995; Graus-Porta et al., 1995; Karunagaran et al., 1996).   
1.4.3 Activation of ErbB signaling pathways 
Activation of ErbB pathways have been described as a signal 
transduction network with 3 layers: the input layer of ligands or growth factors; 
the cellular information processing layer of receptors, SH2-proteins, enzyme 
cascades, and trancription factors; and the output layer of cell growth 
differentiation or migration (Yarden, 2001).  Ligand binding to ErbB family of 
receptors leads to homo- or heterodimerization and activation of the intrinsic 
kinase domain.  Kinase activation results in phosphorylation of specific tyrosine 
residues on the cytoplasmic tail of the receptor that acts as docking sites for 
various signaling molecules.  The signaling molelcules then activate signal 
transduction pathways such as the MAPK pathway and the PI-3K pathway 
(Beerli et al., 1995; Tzahar et al., 1996) (Figure 1.17).  Studies using cell lines 
stably transfected with combinations of the ErbB receptors demonstrate that 
ErbB2-ErbB3 heterodimers give the highest mitogenic activity (Pinkas-Kramarski 
et al., 1996).  ErbB3 lacks a functional kinase activation domain and, therefore, 
ErbB3 homodimers are catalytically inactive (Guy et al., 1994; Pinkas-Kramarski 
et al., 1996).  However, the cytoplasmic tail of ErbB3 contains many docking 
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sites for signaling molecules.  The lack of kinase activity may prevent 
overactivation of ErbB3 and the requirement of heterodimerization with ErbB2 
for activity leads to increased control over signal transduction (Pinkas-Kramarski 
et al., 1996; Waterman et al., 1999).   
Figure 1.17: ErbB2 signaling pathways. (Citri et al., 2003). 
The prolonged signaling of ErbB2-containing heterodimers is partly due to 
the balance between the degradation and recycling pathways for the receptors.  
Ligand-bound receptors are endocytosed and the vesicles form early 
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endosomes.  In the endosome the receptor and ligand are separated and sorting 
occurs in which the receptor is either recycled to the membrane or transported 
with the ligand to a lysosome for degradation (Yarden, 2001).  An adapter 
protein c-Cbl controls the recycling/degradation pathway (Thien and Langdon, 
1998).  Along with the ligand, c-Cbl induces degradation of receptors in the early 
endosome by associating with the receptor and leading to ubiquitination and 
subsequent degradation in the lysosome (Levkowitz et al., 1998).  ErbB1 
homodimers are generally degraded by the lysosome, however, ErbB1 
heterodimerized with ErbB2 is recycled to the cell membrane (Lenferink et al., 
1998).  c-Cbl binds strongly to ErbB1 and only weakly interacts with ErbB2, 
resulting in the differing balance in the degradation and recycling pathways 
(Levkowitz et al., 1996).   
1.4.3.1 MAPK pathway 
 The MAPK signaling pathway is one of the main kinase cascades 
activated by ErbB receptors and is involved in signaling for both cell proliferation 
and apoptosis.  The phosphyorylated tyrosines on the cytoplasmic tails of the 
receptors act as docking sites and form high affinity complexes with signaling 
molecules that link the receptor signaling to kinase cascades (Santen et al., 
2002) (Figure 1.18).  For example, the adaptor protein Shc can bind to the 
phosphorylated tyrosine residues, become phosphorylated, then further complex 
with the adaptor protein Grb-2.  The guanine nucleotide exchange factor SOS 
then enters the complex and catalyzes the conversion of Ras-GDP to Ras-GTP.  
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Ras-GTP then initiates the signaling of the MAPK pathway.  Ras-GTP interacts 
with and phosphorylates the first kinase in the MAPK pathway, Raf-1 or MAP 
kinase kinase kinase.  Activated Raf-1 phosphorylates MEK 1/ 2 or MAP kinase 
kinase on two serine residues in the active loop resulting in activation of the 
kinase.  MEK1/ 2 then activates MAP kinase or ERK1/2 through phosphorylation 
on tyrosine and threonine residues in the activation loop (Santen et al., 2002).  
Active ERK1 and 2 can then stimulate multiple downstream events involved in 
gene regulation including phosphorylation of other protein kinases, such as RSK 
proteins and MAP kinase interacting kinases 1 and 2, as well as transcription 
factors that lead to induction of cell proliferation.  Active ERK 1 and 2 translocate 
to the nucleus and activate Elk-1, an ETS family domain protein that binds 
serum response elements and mediates transcription.  ERK 1 and 2 also 
catalyze phosphorylation of c-Jun, c-Fos, and activating transcription factor-2 
(Santen et al., 2002).   
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Figure 1.18: MAPK signaling pathway. (Santen et al., 2002). 
1.4.3.2 PI3-K / Akt pathway 
 Activation of Akt, or protein kinase B (PKB), through the PI3-K pathway is 
the other major kinase signaling pathway activated by ErbB receptors.  Akt is 
involved in signaling for cell survival and cell proliferation.  The 85 kDa subunit of 
PI3-K binds phosphorylated tyrosine residues on cytoplasmic tails of activated 
ErbB receptors by a src homology 2 (SH2) domain and the 110 kDa catalytic 
subunit rapidly phosphorylates PIP2 to give PIP3 (Figure 1.19).  Both 
phosphatidylinositol-dependent kinase (PDK) and Akt bind PIP3 through 
pleckstrin homology (PH) domains that recognize inositol lipids and PDK 
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phosphorylates Akt on threonine and serine residues.  Activated Akt then 
translocates into the nucleus and phosphorylates target proteins involved in cell 
survival and cell proliferation.  Glycogen synthase kinase (GSK) 3β
phosphorylates cyclin D1 targeting it for degradation and inhibiting the cell cycle.  
Akt phosphorylates GSK 3β targeting it for degradation and allowing cyclin D1 to 
induce cell cycle progression.  Akt also phosphorylates the protein BAD, 
preventing its binding to BCL-X and this resulting in inhibition of apoptosis and 
promotion of cell survival.   
Figure 1.19: PI3-K/Akt signaling pathway. (Physiomics, 2003). 
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1.4.4 ErbB2 mouse mammary tumor models 
ErbB2 overexpression has been observed in multiple tumor types 
including breast cancer, and is associated with high constitutive kinase activities.  
As discussed previously, ErbB2 overexpression has been reported in 20-30% of 
primary breast tumors (van de Vijver et al., 1987; McCann et al., 1991) and is 
associated with aggressive tumor behavior and poor prognosis (Hynes and 
Stern, 1994); however, the role of ErbB2 in tumor formation in unclear.  
Transgenic mice provide a useful model for assessing the role of an oncogene in 
tissue-specific tumor induction and growth in vivo.  To study the role of a 
particular oncogene in mammary tumor formation, this gene can be fused to the 
mouse mammary tumor virus (MMTV) promoter, which drives expression in 
mammary tissue.  The contruct can be introduced into the genome of mice and 
mammary tumor formation can be assessed.  Transgenic mice carrying MMTV-
c-myc and MMTV-v-Ha-ras fusion contructs develop solitary mammary 
adenocarcinomas in a stochastic manner that appears clonal in origin (Stewart 
et al., 1984; Leder et al., 1986; Sinn et al., 1987).  This suggests that expression 
of c-myc or v-Ha-ras alone is not sufficient for transformation of mammary 
epithelial cells, and additional events are necessary for malignant 
transformation.   
The rat homologue of ErbB2 was originally isolated from chemically-
induced rat neuroblastoma and identified as c-neu (Shih et al., 1981).  C-neu 
was isolated as an activated form that contained a single amino acid (valine to 
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glutamic acid) substitution in the transmembrane region of the receptor resulting 
in increased tyrosine kinase activity by inducing ligand-independent receptor 
dimerization (Bargmann et al., 1986).  C-neu can also be activated by deletions 
in the extracellular region (Bargmann and Weinberg, 1988) or by overexpression 
(Di Fiore et al., 1987; Hudziak et al., 1987), as observed in human breast 
tumors.  Therefore, multiple groups have used activated and wild-type c-neu 
fused to the MMTV promoter to develop transgenic mice and determine the role 
of neu in mammary tumor formation and growth (Muller et al., 1988; Bouchard et 
al., 1989; Guy et al., 1992).   
The first studies developed transgenic mice expressing activated c-neu in 
the mammary epithelium using a recombinant plasmid with the MMTV LTR and 
cDNA encoding the activated c-neu protein (Muller et al., 1988).  Four transgenic 
founder lines were produced and the transgene was passed onto the progeny 
and two of the lines expressed the transgene in organs assayed (Muller et al., 
1988).  Expression of c-neu in the mammary gland, parotid gland, Harderian-
lacrimal gland and epididymis of the transgenic mice was consistent with 
previous studies using the MMTV promoter.  The line designated TG.NF showed 
uniform expression of the transgene throughout the mammary gland and 
lactational defects were developed and followed by synchronous mammary 
tumor formation involving all mammary glands in all mice at 13-14 weeks of age 
(Muller et al., 1988).  Examination of the surrounding mammary tissue showed a 
lack of normal mammary epithelium in the mammary glands of these transgenic 
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mice.  The second line designated TG.NK expressed the transgene in a non-
uniform, stochastic pattern of expression in mammary epithelium in the same 
gland and stochastic tumor formation adjacent to normal mammary epithelium 
starting around 25 weeks of age in female mice (Muller et al., 1988).  However, 
while normal epithelium did not express the transgene, expression of the 
trangene within affected cells correlated morphologically with dysplasia and 
tumor formation.  The kinetics of tumor formation and the lack of normal 
epithelium in the TG.NF, which has uniform expression of the transgene, 
suggest that the expression of activated c-neu is sufficient for transformation of 
the mammary epithelium (Muller et al., 1988).  Mice from the TG.NK line are 
available from Charles River Laboratories and were used for our studies.   
A second group also developed transgenic mice expressing the activated 
c-neu on the MMTV promoter; however, the kinetics of tumor formation differed 
from mice reported in the first study (Bouchard et al., 1989).  Mammary tumors 
developed after 5 to 10 months of age in the majority of females in all transgenic 
lines established.  The mammary tumors developed independently and 
ashynchronously, differing in size (Bouchard et al., 1989).  Furthermore, 
transgene mRNA levels were highly expressed in morphologically normal 
mammary glands before the appearance of visible tumors (Bouchard et al., 
1989).  These results suggest that an additional genetic event is necessary for 
transformation of mammary epithelium that expresses activated c-neu.  The 
contrasting results from the two studies could be due to the difference in the 
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structure of the transgene used to develop the mice.  The transgene from the 
first group contained the rat 30 S sequence for the Harvey murine sarcoma viral 
gemone between the MMTV LTR and the cDNA for c-neu; in contrast the MMTV 
LTR and the c-neu cDNA were adjacent to each other in the transgene used by 
the second group (Bouchard et al., 1989).  Furthermore, undetected 
modifications to the transgene could have been generated during manipulation 
and changed the biological properties of one of the transgenes (Bouchard et al., 
1989).   
 Studies of transgenic mice with the wild-type c-neu gene on the MMTV 
promoter have shown that overexpression of unactivated c-neu in the female 
mammary epithelium resulted in focal mammary tumor formation that 
metastasized with high frequency (Guy et al., 1992).  The pattern of tumor 
formation and high level transgene expression in normal mammary epithelium in 
these studies suggest that additional events are necessary for transformation of 
mammary epithelial cells that overexpress unactivated c-neu (Guy et al., 1992).  
However, results showing that mammary tumors express higher tyrosine kinase 
activity than the surrounding normal epithelium together with results from the 
first MMTV-c-neu transgenice mice (that express activated c-neu) indicate that 
activation of c-neu leading to higher tyrosine kinase activity could lead to 
transformation (Muller et al., 1988; Guy et al., 1992).   
Transgenic mice overexpressing oncogenes in knockout mice have been 
used to determine the role of cyclin D1 in transformation of the mammary 
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epithelium.  Cyclin D1 is involved in the transition from G0/G1 to S phase of the 
cell cycle and both the ras and neu oncogenes regulate cyclin D1 expression 
through the MAPK pathway (Filmus et al., 1994; Albanese et al., 1995; Liu et al., 
1995; Lavoie et al., 1996; Lee et al., 2000).  One study crossed the MMTV-v-Ha-
ras, MMTV-c-neu, MMTV-c-myc, and MMTV-Wnt-1 transgenic mice with cyclin 
D1 knockout mice to determine whether cyclin D1 expression was necessary for 
tumor formation in the mice (Yu et al., 2001).  MMTV-v-Ha-ras and MMTV-c-neu 
mice that did not express cyclin D1 did not develop mammary tumors, whereas 
the MMTV-c-myc and MMTV-Wnt-1 mice that did not expresss cyclin D1 did 
develop mammary tumors (Yu et al., 2001).  Similarly, tumors and mammary 
epithelial cells from the MMTV-v-Ha-ras and MMTV-c-neu did not express cyclin 
D2, whereas tumors and mammary epithelial cells from MMTV-c-myc and 
MMTV-Wnt-1 mice expressed cyclin D2 (Yu et al., 2001).  These studies 
indicate that while the oncogenes c-myc and Wnt-1 bypass the need for cyclin 
D1 expression for cell cycle progression, most likely through the expression of 
cyclin D2, c-neu and v-Ha-ras oncogenes are dependent upon cyclin D1 
expression for cell cycle progression.  This is probably due to their inability to 
induce the expression of cyclin D2 or other cyclins that compensate for cyclin 
D1.  Further studies in mice show that replacement of cyclin D1 with cyclin E on 
the cyclin D1 promoter and overexpression of ras and c-neu on the MMTV 
promoter induced mammary tumor formation (Yu et al., 2001).  These results 
indicate that cyclin E can compensate for cyclin D1 in ras- and c-neu- induced 
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cell cycle progression when the cyclin D1 promoter was used for expression of 
cyclin E.     
1.5 Objectives 
1.5.1 Objective 1 
 E2-induced cell proliferation is well characterized in vitro in breast cancer 
cells and in vivo in the rodent uterus, and this is accompanied by induction of 
several genes associated with cell proliferation such as c-myc, c-fos, ornithine 
decarboxylase, and cyclin D1.  Recently, it has been shown that E2 induces 
several genes associated with purine/pyrimidine and DNA synthesis, as well as 
the growth factor VEGF in breast cancer cells.  Therefore, the immature mouse 
uterus will be used as an in vivo model to investigate E2-induced expression of 
genes involved in cell proliferation.  The organ structure and multiple cell types 
of the uterus complicate gene expression studies, compared to in vitro studies 
which involve a single cell type.  In order to localize changes in expression to 
specific regions or cell types, gene expression in the uterus will be analyzed by 
in situ hybridization.  There is evidence in the uterus that E2 binds ER in stromal 
or epithelial cells and induces expression of paracrine factors that then induce 
proliferation in neighboring cells or other cell types.  In order to differentiate 
direct induction of gene expression by E2 from indirect induction of gene 
expression by a paracrine factor, protein synthesis will be inhibited by 
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cycloheximide prior to E2 treatment.  Furthermore, to determine whether ERα is 
necessary for E2-induced gene expression, ERKO mice will also be used.   
Crosstalk between AhR and ER has been characterized in vitro in breast 
cancer cell lines.  Activation of the AhR through agonists such as TCDD down-
regulate induction of several E2-responsive genes including those required for 
cell proliferation.  Therefore, E2-induced proliferation in the immature mouse 
uterus will be used as a model to determine whether AhR agonists inhibit 
induction of gene expression by E2 in vivo.  Furthermore, AhRKO mice will be 
used to determine whether AhR is necessary for these responses and 
cycloheximide-dependent inhibition of protein synthesis will determine whether 
new protein synthesis is necessary for AhR-mediated inhibitory responses. 
1.5.2 Objective 2  
Overexpression and amplification of ErbB2 have been implicated in 
development of aggressive forms of human breast cancer.  In vitro studies in 
BT-474 ErbB2 overexpressing human breast cancer cells indicate that 
modulation of cyclin D1 and p27 through both the MAPK and PI3K/Akt pathways 
allows G1 to S phase transition; in vivo studies crossing MMTV-c-neu and cyclin 
D1-/- mice indicate that cyclin D1 is necessary for ErbB2 induced mammary 
tumor formation (Lenferink et al., 2001; Yu et al., 2001).  However the 
mechanism of ErbB2 transformation and growth of cells is not completely 
understood.  The MMTV-c-neu mouse mammary tumor model expresses a 
mutated form of the rat c-neu (ErbB2) protein under the mouse mammary tumor 
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virus resulting in a well established progression of mammary carcinogenesis 
with palpable mammary tumors forming around 25 weeks of age (Muller et al., 
1988).  Therefore, gene expression profiles during the progressive stages of 
mammary carcinogenesis in MMTV-c-neu mice will be analyzed to better 
understand how ErbB2 overexpression transforms cells and results in tumor 
formation. 
Previous studies have shown that AhR agonists induce down-regulation 
of ErbB1 protein and/or phosphorylation in multiple tissues/organs (Astroff et al., 
1990; Guyda et al., 1990; Sewall et al., 1995; Zhang et al., 1995), suggesting 
possible inhibitory interactions with chemotherapeutic potential.  Several ErbB2-
overexpressing breast cancer cells such as the BT-474 and MDA-MB-453 cell 
lines express a functional AhR and exhibit constitutive activation of both the 
MAPK and PI3K pathways.  Recently, it has been reported that the SAhRM 
1,1’,2,2’-tetramethyldiindolylmethane (1,1’,2,2’-tetraMethDIM, Figure 1.20) 
inhibited DMBA-induced mammary tumor growth in rats and also inhibited 
MAPK and PI3K pathways in MCF-7 human breast cancer cells.  The proposed 
studies will investigate inhibitory AhR-ErbB2 interactions of 1,1’,2,2’-
tetraMethDIM in these cells lines and investigate the mechanism of growth 
inhibition.  A parallel approach using MMTV-c-neu transgenic mice that 
overexpress ErbB2 in the mammary gland will also be carried out to determine 
the inhibitory effects of 1,1’,2,2’-tetraMethDIM on ErbB2-induced tumor 
formation.   
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Figure 1.20: Structure of 1,1’,2,2’-tetraMethDIM.
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CHAPTER II  
MATERIALS AND METHODS 
2.1 Animals 
Female B6C3F1 mice and MMTV-c-neu mice were obtained from Charles 
River Laboratories (Wilmington, MA).  Twenty-five day old female AhRKO and 
ERKO mice were obtained from in house colonies.  The mice were kept in 
temperature controlled conditions room with a 14 h light and 10 h dark 
photocycle.  Rodent chow and water was supplied ad libitum.   
2.2 Treatment and tissue processing
For uterine studies, twenty-five day-old mice were injected 
intraperitoneally with either 200 ng of E2 (Sigma, St Louis, MO) in 100 µl of corn 
oil, 1 µg of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in 100 µl oil, E2 + TCDD, 
or corn oil alone.  Some mice also received 75 mg/kg of cycloheximide (Sigma) 
prior to treatment with E2 and TCDD.  One, three, six, or twelve hours after 
treatment the mice were euthanized by CO2 asphyxiation.  The uteri were 
removed, fixed in 4% paraformaldehyde (EMS, Fort Washington, PA) overnight, 
washed with 70% ethanol and paraffin embedded.  For MMTV-c-neu studies, 
female MMTV-c-neu and FVB mice at 6, 12, and 18 weeks of age were 
euthanized by CO2 asphyxiation and mammary glands were removed or twenty-
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two week old MMTV-c-neu mice were treated with 10 mg/kg 1,1’,2,2’-
tetraMethDIM or corn oil by gavage and palpable mammary tumor were 
measured every other day.  After 28 days the mice were euthanized by CO2
asphyxiation and mammary gland and lungs were removed, fixed in 4% 
paraformaldehyde or 10% formaldehyde (Sigma) and paraffin embedded. 
2.3 Probe synthesis for in situ hybridization   
Radiolabeled cRNA probes were generated from linearized cDNA 
plasmids using in vitro transcription by T7, T3 or SP6 RNA polymerases 
(Promega, Madison, WI) with [35S]-UTP (NEN, Boston, MA).  The cyclin D1 
cDNA in pBluescript was a gift from Dr. Charles Sherr (St. Jude Children's 
Research Hospital, Memphis, TN) and the pcDEB-M180K DNA polymerase α
cDNA construct was a gift from Dr. Fumio Hanaoka (The Institute of Physical 
and Chemical Research, RIKEN, Saitama, Japan).  The DNA polymerase α
cDNA fragment was cloned into pcDNA3.0 and then used to make cRNA 
probes.  The VEGF cDNA fragment was amplified by RT-PCR, cloned into 
pcDNA3.0, and sequenced in this lab.     
2.4 In situ hybridization   
Sections (0.5 µM) of paraffin-embedded tissue were placed on positively 
charged slides.  The sections were deparaffinized with three 5 min washes with 
the xylene substitute Hemo-De (Fisher Scientific, Pittsburgh, PA), re-hydrated 
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with a graded series of 5 min ethanol baths (100% x 3, 95% x 2, 70% X1) and 
post-fixed with 4% paraformaldehyde in PBS for 20 min.  The sections were then 
digested with proteinase K (Roche, Indianapolis, IN)(20 µg/ml) in a digestion 
buffer (50 mM Tris, 5 mM EDTA, pH 8) for 7.5 min, re-fixed for 5 min with 4% 
paraformaldehyde in PBS, washed with DEPC-treated water for 30 sec, rinsed in 
PBS, and dehydrated with a graded series of ethanol baths and air dried at room 
temperature.  Sense and antisense radiolabeled cRNA probes were denatured 
in hybridization buffer (50% formamide, 0.3 M NaCl, 20 mM Tris-HCl [pH 8], 
5mM EDTA [pH 8], 10 mM sodium phosphate [pH 8], single-strength Denhardt’s 
solution, 10% dextran sulfate, 0.5 mg/ml yeast RNA, 100 mM dithiothreitol) at 
70oC for 10 min and added to sections. Slides were hybridized with the cRNA 
probes (5 x 106 cpm/slide) for 18 h at 55oC in a humidified chamber containing 
50% formamide/5X SSC.  Slides were washed for 30 min in 5X SSC/10 mM β-
mercaptoethanol (βME) at 55oC, 20 min in 50% formamide/2X SSC/50 mM βME 
at 65oC, 10 min in 1X TEN (0.05 M NaCl, 10 mM Tris [pH 8], 5 M EDTA) at room 
temperature, and three 10 min changes of 1X TEN at 37oC.   Slides were 
digested with DNase-free RNase (Promega) (10 µg/ml) in 1X TEN at 37oC for 10 
min to remove nonspecifically bound probe, then washed for 15 min in 1X TEN 
at 37oC, 20 min in 50% formamide/2X SSC/50 mM βME at 65oC, 15 min in 2X 
SSC at room temperature, 12 min in 0.1X SSC at room temperature, 5 min in 
70% ethanol/0.3 M ammonium acetate at room temperature, 1 min in 95% 
ethanol/0.03 M ammonium acetate at room temperature, and two 1 min changes 
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in 100% ethanol.  Slides were coated with Kodak NTB-2 liquid photographic 
emulsion (Eastman Kodak, Rochester, NY), developed 3-4 weeks later with 
Kodak D-19 developer (Eastman Kodak), counterstained with Harris Modified 
Hematoxylin (Fisher Scientific), dehydrated with a graded series of ethanol to 
Hemo-De, and fixed with cover slips by Permount (Fisher Scientific).  The slides 
were evaluated by both brightfield and darkfield microscopy with a Zeiss 
Axioplan 2 Photomicroscope (Carl Zeiss Inc, Thornwood, NY) and digital images 
were captured.  Representative photomicrogrphs are shown for each probe and 
treatment group. 
2.5 Histopathology  
Animals were euthanized by CO2 asphyxiation and the #1 and #3 
mammary glands were removed, fixed in 4% paraformaldehyde, and processed 
by the Hisotpathology Lab.  Stained tissue sections were analyzed by a board 
certified Pathologist.   
2.6 Microarray analysis 
Animals were euthanized by CO2 asphyxiation and the #4, #5, and part of 
#3 mammary glands were removed.  RNA was extracted using Trizol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer protocol, resuspended 
in RNA Storage Solution (Ambion, Austin, TX), and concentration and purity 
determined by spectrophotometry.  Microarray analysis was determined using 
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Affymetrix MG-U74Av2 chip according to manufacturers protocol.  Gene 
expression data was analyzed using GeneSpring version 6.0 (Silicon Genetics, 
Redwood City, CA).  Genes up-regulated or down-regulated greater than two-
fold were grouped based on known gene ontology using DAVID a web-based, 
client/server application (http://david.niaid.nih.gov/david/upload.asp) that allows 
users to access a relational database of functional annotations (Dennis et al., 
2003).  Functional annotations are derived primarily from LocusLink and the 
annotation data used by DAVID is updated weekly.  It should be noted that 
DAVID may classify genes under more than one category since many genes are 
known to have more than one function. 
2.7 Cell culture   
All cell lines were obtained from ATCC (Manassas, VA).  BT-474 human 
breast cancer cells were cultured in DME/F-12 medium (Sigma) supplemented 
with 10% fetal bovine serum (FBS) (Sigma), sodium bicarbonate (1.5 g/L), 
glucose (4.5 g/L), sodium pyruvate (0.11 g/L), insulin (10 mg/L), and 
antibiotic/antimyotic solution.  MDA-MB-453 cells were maintained in RPMI 
medium (Sigma) supplemented with 10% fetal bovine serum, sodium 
bicarbonate (1.5 g/L), Hepes (2.38 g/L), sodium pyruvate (0.11 g/L), glucose (4.5 
g/L), and antibiotic/antimyotic solution.  All cells were maintained at 37C in a 5% 
CO2 atmosphere.   
123
2.8 Cell proliferation  
Cells were seeded for experiments in DME/F-12 medium without phenol 
red (Sigma) containing 2.5% charcoal-stripped FBS, sodium bicarbonate (1.5 
g/L), glucose (4.5 g/L), sodium pyruvate (0.11 g/L), insulin (10 mg/L), and 
antibiotic/antimyotic solution in triplicate in 6 or 12 well plates.  Twenty-four 
hours after seeding cells were dosed with 1,1’,2,2’-tetraMethDIM at 2.5, 5.0 and 
10.0 µM either in DME/F-12 media without phenol red supplemented with 2.5% 
or 5.0% charcoal-stripped FBS or in the medium in which the cells were 
maintained.  Dosing medium was changed every 48 h throughout the assay and 
throughout the time course each well of cells was trysinized, placed in Isoton II 
(Fisher Scientific), and counted by the Coulter Z1 cell counter in duplicate.  
Results are expressed as means ± SE for three replicate experiments for each 
treatment group. 
2.9 Cell cycle analysis  
Cells were seeded for experiments in DME/F-12 medium without phenol 
red containing 2.5% charcoal-stripped FBS, sodium bicarbonate (1.5 g/L), 
glucose (4.5 g/L), sodium pyruvate (0.11 g/L), insulin (10 mg/L), and 
antibiotic/antimyotic solution in triplicate in 6 well plates.  Twenty-four hours after 
seeding cells were treated with 2.5, 5.0 and 10.0 µM 1,1’,2,2’-tetraMethDIM in 
2.5% DME/F-12 and dosing medium was changed every 48 h.  Forty-eight hours 
after treatment the cells were collected and place in propidium iodide staining 
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solution [sodium citrate 4 mM, triton X-100 0.1%, propidium iodide 50 mg/ml 
(Sigma), RNase One 30U/ml (Promega)] for 10 min at 37oC in the dark.  NaCl 
was then added for a final concentration of 0.15 M and samples stored at 4oC in 
the dark until analyzed by flow cytometry.  Results are expressed as means ±
SE for three replicate experiments for each treatment group. 
2.10 Western blot analysis  
Cells were seeded in DME/F-12 medium without phenol red containing 
2.5% charcoal-stripped FBS.  After treatment for 12 and 24 hours, cells were 
harvested in 60 to 200 µl of 1X Laemmli buffer (50 mM Tris-Cl (pH 6.8), 2% 
SDS, 0.1% bromophenol blue, 10% glycerol, and 100 mM DTT) depending upon 
experiments and equal volumes of whole cell lysates were boiled for 5 min and 
used for Western blots.  After 40 hour and 4 day treatments, cells were lysed in 
ice cold lysis buffer (50 mM HEPES, pH 7.5, 500 mM NaCl, 10% (v/v) glycerol, 
1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA) supplemented with protease 
inhibitor cocktail (Sigma).  Cells lysates were scraped into 1.5 ml eppendorf 
tubes and incubated on ice for 1 hour with intermittent vortexing.  Cell lysates 
were then centrifuged for 15 min at 40,000 x g and the supernatants used for 
Western blot analysis.  Protein concentrations were measured with Bradford 
reagent according to standard protocol and equal amounts of protein from each 
treatment group were boiled in 1X Laemmli buffer for 2 min prior to loading.  
Proteins from both lysis protocols were separated by 10% SDS-PAGE, and 
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electrophoresed to PVDF membrane (BioRad, Hercules, CA).  Membranes were 
blocked in Blotto [5% milk +TBS (10 mM Tris-HCl, pH 8.0, 150 mM NaCl) + 
0.05% Tween 20] and probed with primary antibodies ErbB2 (neu), p-ERK1/2, 
ERK1/2, p-Akt, Akt, cyclin D1, p27, ERα (G-20), AhR (H-211), and cyp1A1 at 
1:1000 in Blotto or p21 (rabbit polyclonal) at 1:400 in Blotto (antibodies were 
purchased from Santa Cruz Biotechnologies, Santa Cruz, CA).  Membranes 
were washed with TBS + 0.05% Tween 20 and following incubation with 
peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnologies) at 
1:5000 in Blotto, immunoglobins were visualized using the ECL detection system 
(Perkin Elmer, Boston, MA).  For Western blots with PARP antibody (Santa Cruz 
Biotechnologies) membranes were blocked in 1% bovine serum albumin (BSA) 
+ 1X PBS + 0.04% Tween 20, probed with the PARP antibody at 1:200 dilution 
in 1% BSA + 1X PBS + 0.04% Tween 20 overnight, washed with 1X PBS + 
0.04% Tween 20, probed with peroxidase-conjugated mouse IgG2a (Santa Cruz 
Biotechnologies) at 1:5000 in 1% BSA + 1X PBS + 0.04% Tween 20 for 4 h and 
immunoglobins were visualized using the ECL detection system (Perkin Elmer).   
2.11 Immunoprecipitation 
Cells were seeded in DME/F-12 medium without phenol red containing 
2.5% charcoal-stripped FBS.  After 24 h cells were treated with 10 µM 1,1’,2,2’-
tetraMethDIM, 10 nM E2, 10 µM U0126, or 10 µM LY294002 and treatment 
media was changed after 48 h.  Fours days after the beginning of treatment, the 
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media was removed and cells were lysed in ice-cold lysis buffer (50 mM HEPES, 
pH 7.5, 500 mM NaCl, 10% (v/v) glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 
mM EGTA) supplemented with protease inhibitor cocktail (Sigma).  Cells lysates 
were scraped into 1.5 ml eppendorf tubes and incubated on ice for 1 hour with 
intermittent vortexing.  Cell lysates were then centrifuged for 15 min at 40,000 x 
g and the supernatants used for immunoprecipitations.  Protein concentrations in 
the supernatants were measured using Bradford reagent according to standard 
protocols.  For immunoprecipitations, 350 mg of protein was precleared with 30 
µl of Protein A/G-agarose Plus beads (Santa Cruz Biotechnologies) in 1 ml 1X 
phosphate buffered saline (PBS) rocking for 1 hour and 15 min at 4oC.  Beads 
were centrifuged at 700 x g for 3 min and 1200 µl of supernatant was transferred 
to a new tube.  Two micrograms of ErbB2 (Santa Cruz Biotechnologies) or 
normal rabbit IgG (Santa Cruz Biotechnologies) antibody plus 30 µl of Protein 
A/G-agarose Plus beads were added to the samples and incubated overnight at 
4oC with gentle shaking.  For washing, the beads were centrifuged at 700 x g for 
3 min, supernatant removed, 1 ml RIPA buffer [50 mM Tris-HCl (pH 7.5), 15mM 
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS] added, and 
rocked for 30 sec.  The wash was then repeated with 1 ml of 1X PBS, the beads 
were pelleted again at 700 x g for 3 min, supernatant removed, and 50 µl of 1X 
Laemmli buffer (50 mM Tris-Cl (pH 6.8), 2% SDS, 0.1% bromophenol blue, 10% 
glycerol, and 100 mM DTT) was added to each sample.  Immunoprecipitated 
samples were boiled for 5 min prior to loading and 50 µg of the total protein for 
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each sample was loaded in 1X Laemmli buffer after boiling for 2 min.  The 
proteins were separated on a 10% SDS-PAGE gel and electrophoresed to 
PVDF membrane (BioRad).  Membranes were blocked in 1% milk + 1% BSA 
+TBS (10 mM Tris-HCl, pH 8.0, 150 mM NaCl) + 0.05% Tween-20, probed with 
anti-p-Tyr antibodies (Santa Cruz Biotechnologies) at 1:1000 for 4 h, washed 
with TBS + 0.05% Tween 20, probed with peroxidase-conjugated anti-mouse 
IgG (Santa Cruz Biotechnologies) antibodies at 1:5000 for 3 h, washed with TBS 
+ 0.05% Tween 20, and immunoglobins were visualized using the ECL detection 
system (Perkin Elmer).  Membrane was stripped for 45 min at 65oC in stripping 
solution (62.5 mM Tris-HCl, 2% SDS, 10 mM β-mercaptoethanol, pH 6.8), rinsed 
with dH2O, incubated in dH2O overnight at 4
oC, and reprobed with ErbB2, p-
ERK1/2, ERK1/2, p-Akt, and Akt antibodies as described above for Western 
blots.   
2.12 Caspase-3 apoptosis assay 
Cells were seeded for experiments in DME/F-12 medium without phenol 
red containing 2.5% charcoal-stripped FBS, sodium bicarbonate (1.5 g/L), 
glucose (4.5 g/L), sodium pyruvate (0.11 g/L), insulin (10 mg/L), and 
antibiotic/antimyotic solution in triplicate in 96 well plates.  Twenty-four hours 
after seeding, cells were treated with 2.5, 5.0 and 10.0 µM 1,1’,2,2’-
tetraMethDIM; 0.1 µM okadaic acid; or 3 µM camptothecin in 2.5% DME/F-12.  
After 24, 48, and 72 h the cells were washed with 1X PBS and lysed with cell 
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lysis buffer (10 mM Tris-HCL, 10 mM NaH2PO4/NaHPO4 (pH7.5), 130 mM NaCl, 
1% triton X-100, 10 mM NaPPi) for 30 min on ice.  Ac-DEVD-AMC fluoroganic 
substrate (BD Biosciences, San Jose, CA) at a final concentration of 20 µM and 
protease assay buffer (20 mM HEPES (pH 7.5), 10% glycerol, 2 mM DTT) were 
added to the cell lysates and incubated for 1 hour at 37oC in the dark.  The 
release of AMC by cleavage with active caspase-3 in the cell lysates was 
measured with an excitation wavelength of 390 nm and an emission wavelength 
of 460 nm.  Results are expressed as means ± SE for three replicate 
experiments for each treatment group. 
2.13 Lactose dehydrogenase (LDH) cytotoxicity assay 
Cells were seeded for experiments in DME/F-12 medium without phenol 
red containing 2.5% charcoal-stripped FBS, sodium bicarbonate (1.5 g/L), 
glucose (4.5 g/L), sodium pyruvate (0.11 g/L), insulin (10 mg/L), and 
antibiotic/antimyotic solution in triplicate.  Twenty-four hours after seeding cells 
were treated with 2.5, 5.0 and 10.0 µM 1,1’,2,2’-tetraMethDIM  or 0.005, 0.05, or 
5 mM phenol in 2.5% DME/F-12.  Two or 4 days after treatment 20 µl of 
supernatant was removed from each well to be assayed.  Three control wells 
were lysed with 0.3% Triton X-100 3 to 6 h prior to assay to measure maximum 
release of LDH into the supernatant.  Total lysis of cells was confirmed under the 
microscope.  Two hundred microliters of phosphate buffer (NaH2PO4/NaHPO4,
pH7.5) with 1.22 mM pyruvate (Sigma) and 8 µl of NADH (Sigma) at 12.4 mg/ml 
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were added to the cell supernatant and incubated at 37oC for 30 min.  The 
absorbance at 390 nm was measured to determine the decrease in NADH 
concentration resulting from LDH converting pyruvate to lactate.  Controls of 
pyruvate alone, pyruvate + NADH alone, and pyruvate + NADH + DME-F-12 
without cells were used for baseline measurements of minimum and maximum 
absorbance and wells lysed with Triton X-100 were used to measure the 
maximum decrease in absorbance due to total cell lysis.  Results are expressed 
as means ± SE for three replicate experiments for each treatment group. 
2.14 Mammalian one-hyrbrid transfections 
 Cells were seeded for experiments in DME/F-12 medium without phenol 
red containing 2.5% charcoal-stripped FBS, sodium bicarbonate (1.5 g/L), 
glucose (4.5 g/L), sodium pyruvate (0.11 g/L), insulin (10 mg/L), and 
antibiotic/antimyotic solution in 12 well plates.  Twenty-four hours after seeding 
cells were transfected by the calcium phosphate method with 100 ng of the 
empty pM, Elk1-Gal4, SRF-Gal4, SMAD2-Gal4, or SMAD4-Gal4 fusion protein 
expression plasmids and 1 µg of the Gal4-luciferase reporter vector.  Five hours 
after transfection the cells were washed with 1X PBS, shocked with 25% 
glycerol in 1X PBS for 15 sec, rinsed once with 1X PBS and treated for 36 h.  
Cells were harvested by scraping the plates in 100 µl of 1X lysis buffer.  Twenty 
microliters of the cell lysate was used for performing luciferase assays 
(Promega) on a Lumicount Luminometer (Packard Instrument Co., Downers 
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Grove, IL).  Total protein in each sample was measured with Bradford reagent 
and normalized luciferase values were calculated by dividing the luciferase value 
by total protein for a given sample.  Results are expressed as means ± SE for 
three replicate experiments for each treatment group.  
2.15 Statistical analysis 
Statistical significance was determined by analysis of variance and 
student’s t-test.  Treatment groups were considered statistically different if p < 
0.05.  Results are expressed as means ± standard error (SE) for at least three 
replicate experiments for each treatment group. 
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CHAPTER III  
RESULTS 
3.1 ERα-AhR crosstalk in uterine gene expression  
3.1.1 E2-induced expression of genes involved in cell proliferation in the mouse 
uterus 
E2-induced cell proliferation is well characterized in vitro in breast cancer 
cells and in vivo in the rodent uterus and is associated with the induction of 
several genes including c-myc, c-fos, ornithine decarboxylase, and cyclin D1 
(Dubik and Shiu, 1992; Duan et al., 1998; Castro-Rivera et al., 2001).  Recently, 
it has been shown that E2 induces several genes associated with 
purine/pyrimidine and DNA synthesis, as well as the growth factor VEGF, in 
breast cancer cell lines (Samudio et al., 2001; Stoner et al., 2004).  In order to 
investigate in vivo induction of gene expression by E2 and to localize the 
expression within the uterus the immature mouse uterus was used as an in vivo 
model for studying hormonal regulation of cell proliferation.  The organ structure 
and multiple cell types of the uterus can complicate gene expression studies 
using whole organ extracts, compared to in vitro studies that involve single cell 
types and lack organ structure.  Therefore in situ hybridization was used to 
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localize changes in mRNA levels to specific regions or cell types in the rodent 
uterus. 
Initial studies investigated the time course induction of gene expression 
by E2 by determining increased mRNA levels in specific regions of the uterus.  
Inbred B6C3F1 mice were treated with E2 by intraperitoneal injection and the 
uterus was removed 1, 3, 6, and 12 hours later for analysis.  Induction of cyclin 
D1 by E2 is well characterized in breast cancer cell lines and previous studies 
have used whole organ extracts to investigate induction of cyclin D1 by E2 in 
vivo in the uterus (Geum et al., 1997; Wang et al., 1998; Castro-Rivera et al., 
2001; Buchanan et al., 2002).  This study localized the highest induction of 
cyclin D1 gene expression to the luminal epithelium.  Three hours after 
treatment with E2 cyclin D1 probes showed a generalized staining of the cyclin 
D1 mRNA throughout the stroma of the uterus that was consistently higher than  
133
observed in tissue from control (corn oil-treated) sections. (Figure 3.1, E-F 
compared to G-H).  Six and 12 hours after treatment with E2 there was intense 
staining of cyclin D1 mRNA in the luminal epithelium of the uterus with low levels 
of generalized staining in the stroma (Figure 3.1, I-J v. K-l and M-N v. O-P).  
These data are consistent with a study showing increased cyclin D1 mRNA 
levels by Northern blot analysis 6 and 12 hours after treatment with E2 (Geum et 
al., 1997).  Furthermore, previous studies have shown that although cell 
proliferation is primarily observed in the luminal epithelium in the adult uterus, 
proliferation is seen in both the stroma and the epithelium of the immature uterus 
(Quarmby and Korach, 1984).  Therefore, the induction of cyclin D1 in the 
stroma and the luminal epithelium seen in this study is consistent with studies 
that show proliferation of cells in both the stroma and epithelium in the immature 
uterus. 
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Figure 3.1: Time-dependent expression of cyclin D1 mRNA after treatment with 
E2 in B6C3F1 mice.  Twenty-five day old female B6C3F1 mice were treated with 
the corn oil vehicle (A-B, E-F, I-J, M-N) or 200 ng of E2 in corn oil (C-D, G-H, K-
L, O-P) (n=4 per treatment).  Cyclin D1 mRNA levels were determined by in situ
hybridization of uterine sections taken 1 hour (A-D), 3 hours (E-H), 6 hours (I-L), 
and 12 hours (M-P) after treatment utilizing [35S]-labeled cRNA sense or 
antisense probes for cyclin D1 mRNA.  Stained sections were analyzed by 
brigthfield (A, C, E, G, I, K, M, O) and darkfield (B, D, F, H, J, L, N, P) 
microscopy.  A representative section of each treatment and time point is shown.   
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The growth factor, VEGF, is involved in embryonic vascular development 
and postnatal angiogenesis and studies in the rat uterus have shown that 
treatment with E2 results in rapid upregulation of VEGF mRNA in the stromal 
compartment within 1 hour after treatment.  Furthermore, it has been shown in 
humans and non-human primates that VEGF expression in the uterus is 
hormonally regulated throughout the menstrual cycle and induction of VEGF by 
E2 in breast cancer cell lines is context dependent (Stoner et al., 2000; Nayak 
and Brenner, 2002; Sugino et al., 2002; Stoner et al., 2004).  Analysis of the 
human VEGF promoter shows that E2 downregulates VEGF mRNA levels and 
promoter activity in Hec1A endometrial cancer cells whereas hormone-induced 
transactivation was observed in ZR-75 breast cancer cells with treatment 
(Stoner et al., 2000; Stoner et al., 2004).  In the present studies an early 
induction of VEGF mRNA in stromal cells of the uterus was observed as 
previously reported in the rat uterus (Hyder et al., 2000).  As shown in Figure 
3.2, within 1 hour after treatment with E2 there was an increase in staining of 
VEGF mRNA in the stromal compartment (Figure 3.2, A-B vs. C-D).  The 
increased staining was also seen 3 hours after treatment with E2 (Figure 3.2, E-
F vs. G-H).  VEGF mRNA staining decreased after 6 hours and returned to 
control levels 12 hours after treatment with hormone (Figure 3.2, I-J vs. K-L and 
M-N vs. O-P).   
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Figure 3.2: Time-dependent expression of VEGF mRNA after treatment with E2 
in B6C3F1 mice.  Twenty-five day old female B6C3F1 mice were treated with 
the corn oil vehicle (A-B, E-F, I-J, M-N) or 200 ng of E2 in corn oil (C-D, G-H, K-
L, O-P) (n=4 per treatment).  VEGF mRNA levels were determined by in situ
hybridization of uterine sections taken 1 hour (A-D), 3 hours (E-H), 6 hours (I-L), 
and 12 hours (M-P) after treatment utilizing [35S]-labeled cRNA sense or 
antisense probes for VEGF mRNA.  Stained sections were analyzed by 
brightfield (A, C, E, G, I, K, M, O) and darkfield (B, D, F, H, J, L, N, P) 
microscopy.  A representative section of each treatment and time point is shown.   
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 DNA polymerase α, which is necessary for DNA synthesis in S phase of 
the cell cycle, is also induced by E2 in vitro in breast cancer cell lines (Samudio 
et al., 2001); however, the involvement of DNA polymerase α in E2-induced 
proliferation in the mouse uterus has not previously been characterized.  An 
initial time course study showed that E2 induced expression of the 180 kd 
catalytic subunit of DNA polymerase α in the mouse uterus and the temporal 
pattern of expression was similar to that of cyclin D1.  One and 3 hours after 
treatment with E2 there was a consistent staining of the DNA polymerase α 180 
kd catalytic subunit mRNA in the stromal cells compared to control sections 
(Figure 3.3, A-B vs. C-D and E-F vs. G-H).  Six and 12 hours after hormonal 
treatment there was an increase in staining of the DNA polymerase α 180 kd 
catalytic subunit mRNA in the uterine luminal epithelial cells compared to 
controls and the general staining of the stroma was also observed (Figure 3.3, I-
J vs. K-L and M-N vs O-P).  The time course of E2-induced expression of the 
catalytic subunit of DNA polymerase α was consistent with the timing of E2-
induced cell cycle progression shown in previous studies in which [3H]thymidine 
incorporation (and DNA synthesis) was initiated approximately 6 hours after 
treatment with E2 in the immature rat or mouse uterus and this response peaked 
around 16 hours after hormone treatment.   
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Figure 3.3: Time-dependent expression of DNA polymerase α catalytic subunit 
mRNA after treatment with E2 in B6C3F1 mice.  Twenty-five day old female 
B6C3F1 mice were treated with the corn oil vehicle (A-B, E-F, I-J, M-N) or 200 
ng of E2 in corn oil (C-D, G-H, K-L, O-P) (n=4 per treatment).  DNA polymerase 
α catalytic subunit mRNA levels were determined by in situ hybridization of 
uterine sections taken 1 hour (A-D), 3 hours (E-H), 6 hours (I-L), and 12 hours 
(M-P) after treatment utilizing [35S]-labeled cRNA sense or antisense probes for 
DNA polymerase α catalytic subunit mRNA.  Stained sections were analyzed by 
brigthfield (A, C, E, G, I, K, M, O) and darkfield (B, D, F, H, J, L, N, P) 
microscopy.  A representative section of each treatment and time point is shown.   
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3.1.2 Requirement of ERα for E2-induced gene expression in the mouse uterus 
E2-induced responses are mediated through steroid hormone receptors 
and to date, two estrogen receptors have been identified, estrogen receptor α
(ERα) and estrogen receptor β (ERβ).  Both ERα and ERβ are expressed in the 
uterus; however, the localization and levels of expression within uterine cell 
types are variable.  The generation of mice deficient in ERα (ERKO), 
ERβ (βERKO) and both receptors (αβERKO) have aided in deciphering the role 
of each receptor in the uterus.  αERKO mice have a hypoplastic uterus that is 
not responsive to E2 (Lubahn et al., 1993).  In contrast, βERKO mice have a 
normal uterus that undergoes cyclic changes with ovarian hormones; however, 
the immature uterus expresses increased proliferative markers and exaggerated 
responses to E2 (Krege et al., 1998a).  These data indicate that ERα is 
necessary for E2-induced responses in the uterus, whereas ERβ may play an 
inhibitory role.  Therefore, we used the ERKO mice to determine whether or not 
ERα is necessary for E2-induced gene expression of cyclin D1, VEGF and DNA 
polymerase α in the uterus characterized in Figures 3.1-3.3.   
Twenty-five day old ERKO+/+ (ERα wild-type) and ERKO-/- (ERα
knockout) were treated with E2 or corn oil and the uterus was removed at 1, 6 
and 12 hours later for analysis.  Overall, a loss of E2-induced gene expression 
was seen in the ERKO-/- mice (Figures 3.4-3.8):  The staining of cyclin D1 mRNA 
in the uterus differed between the ERKO+/+ mice and ERKO-/- mice.  As seen in 
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the control sections from the 6 hour timepoint, cyclin D1 probes exhibit a higher 
level of staining in the epithelium, stroma, and myometrium of the uterus in 
ERKO+/+ mice compared to ERKO-/- mice (Figure 3.4, A-B v. E-F); although no 
difference is seen between the controls from the 12 hour timepoint (Figure 3.5, 
A-B v. E-F).  Six hours and 12 hours after treatment with E2, an increase in 
staining of the luminal epithelium of the uterus is observed compared to control 
treatment in the ERKO+/+ mice, and this was comparable to that seen in the 
B6C3F1 mice after treatment with E2 (Figures 3.4 and 3.5, A-B v. C-D).  
However, the staining of the uterus from the E2 treated ERKO-/- mice does not 
differ from that of the ERKO-/- control mice after 6 or 12 hours of treatment 
(Figures 3.4 and 3.5, E-F v. G-H) showing that ERα is necessary for E2-induced 
cyclin D1 gene expression in the uterus.  A similar pattern of staining is seen for 
the 180 kd catalytic subunit of DNA polymerase α mRNA.  An increase in 
staining for the 180 kd catalytic subunit of DNA polymerase α mRNA is 
observed in all three uterine layers of control ERKO+/+ mice compared to 
control ERKO-/- mice from the 6 hour timepoint (Figure 3.6, A-B v. E-F);  
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although no difference is seen between the controls from the 12 hour timepoint 
(Figure 3.7, A-B v. E-F).  Furthermore, six and 12 hours after treatment with E2 
the ERKO+/+ mice exhibited an increased staining of the DNA polymerase α
catalytic subunit mRNA in the luminal epithelium compared to controls (Figures 
3.6 and 3.7, A-B v. C-D).  However, increased staining was not observed in the 
ERKO-/- mice after treatment with E2 (Figure 3.6 and 3.7, E-F v. G-H).  Uterine 
sections from ERKO+/+ and ERKO-/- mice stained for VEGF mRNA also 
demonstrated that ERα is necessary for E2-induced VEGF expression.  One 
hour after treatment with E2 the ERKO+/+ mice exhibited an increased staining 
for VEGF mRNA in the stromal cells (Figure 3.8, A-B v. C-D), however no 
difference in staining was observed in the ERKO-/- mice treated with E2 (Figure 
3.8, E-F v. G-H). 
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Figure 3.4: Expression of cyclin D1 mRNA six hours after treatment with E2 in 
ERKO+/+ and ERKO-/- mice. Twenty-five day old female ERKO+/+ (A-D) or 
ERKO-/- (E-H) mice were treated with the corn oil vehicle (A-B, E-F) or 200 ng of 
E2 in corn oil (C-D, G-H) (n is 3-5 per treatment).  Cyclin D1 mRNA levels were 
determined by in situ hybridization of uterine sections taken 6 hours after 
treatment utilizing [35S]-labeled cRNA sense or antisense probes for cyclin D1 
mRNA.  Stained sections were analyzed by brightfield (A, C, E, G) and darkfield 
(B, D, F, H) microscopy.  A representative section of each treatment and 
genotype is shown.   
143
Figure 3.5: Expression of cyclin D1 mRNA twelve hours after treatment with E2 
in ERKO+/+ and ERKO-/-  mice. Twenty-five day old female ERKO+/+ (A-D) or 
ERKO-/- (E-H) mice were treated with the corn oil vehicle (A-B, E-F) or 200 ng of 
E2 in corn oil (C-D, G-H) (n is 3 per treatment).  Cyclin D1 mRNA levels were 
determined by in situ hybridization of uterine sections taken 12 hours after 
treatment utilizing [35S]-labeled cRNA sense or antisense probes for cyclin D1 
mRNA.  Stained sections were analyzed by brigthfield (A, C, E, G) and darkfield 
(B, D, F, H) microscopy.  A representative section of each treatment and 
genotype is shown.   
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Figure 3.6: Expression of DNA polymerase α catalytic subunit six hours after 
treatment with E2 in ERKO+/+ and ERKO-/-  mice. Twenty-five day old female 
ERKO+/+ (A-D) or ERKO-/- (E-H) mice were treated with the corn oil vehicle (A-
B, E-F) or 200 ng of E2 in corn oil (C-D, G-H) (n is 3-5 per treatment).  DNA 
polymerase α catalytic subunit mRNA levels were determined by in situ
hybridization of uterine sections taken 6 hours after treatment utilizing [35S]-
labeled cRNA sense or antisense probes for DNA polymerase α catalytic 
subunit mRNA.  Stained sections were analyzed by brightfield (A, C, E, G) and 
darkfield (B, D, F, H) microscopy.  A representative section of each treatment 
and genotype is shown.   
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Figure 3.7: Expression of DNA polymerase α catalytic subunit twelve hours after 
treatment with E2 in ERKO+/+ and ERKO-/-  mice. Twenty-five day old female 
ERKO+/+ (A-D) or ERKO-/- (E-H) mice were treated with the corn oil vehicle (A-
B, E-F) or 200 ng of E2 in corn oil (C-D, G-H) (n is 3 per treatment).  DNA 
polymerase α catalytic subunit mRNA levels were determined by in situ
hybridization of uterine sections taken 12 hours after treatment utilizing [35S]-
labeled cRNA sense or antisense probes for DNA polymerase α catalytic 
subunit mRNA.  Stained sections were analyzed by brightfield (A, C, E, G) and 
darkfield (B, D, F, H) microscopy.  A representative section of each treatment 
and genotype is shown.   
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Figure 3.8: Expression of VEGF one hour after treatment with E2 in ERKO+/+
and ERKO-/-  mice. Twenty-five day old female ERKO+/+ (A-D) or ERKO-/- (E-
H) mice were treated with the corn oil vehicle (A-B, E-F) or 200 ng of E2 in corn 
oil (C-D, G-H) (n is 3-4 per treatment).  VEGF mRNA levels were determined by 
in situ hybridization of uterine sections taken 1 hour after treatment utilizing 
[35S]-labeled cRNA sense or antisense probes for VEGF mRNA.  Stained 
sections were analyzed by brightfield (A, C, E, G) and darkfield (B, D, F, H) 
microscopy.  A representative section of each treatment and genotype is shown.   
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3.1.3 Inhibition of E2-induced gene expression in the mouse uterus by AhR 
agonist TCDD 
 Crosstalk between AhR and ER has been characterized in vitro in breast 
cancer cell lines and in vivo in various rodent models.  Research in several 
laboratories has demonstrated that TCDD inhibits estrogen-induced responses 
in the rodent uterus, carcinogen-induced rodent mammary tumors and human 
breast/endometrial cancer cell lines.  Activation of the AhR through agonists 
such as TCDD has been shown to downregulate induction of several E2-
responsive genes including those required for cell proliferation.  Therefore, we 
further investigated inhibitory AhR-ERα crosstalk in the mouse uterus to 
determine whether TCDD would inihibit the E2-induced gene expression of 
cyclin D1, VEGF or DNA polymerase α as characterized above.   
 Twenty-five day old B6C3F1 mice were treated with corn oil, E2, TCDD (1 
µg) or E2+TCDD and 1, 3, 6, and 12 hours later the uterus was removed for  
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analysis.  Previous studies have shown that treatment with TCDD inhibits E2-
induced increase in uterine wet weights.  Therefore, uterine wet weights were 
used as a positive control for the activity of TCDD as an inhibitor of E2-induced 
responses.  As shown in Figure 3.9, uterine wet weights were similar between 
treatment groups after compound administration for 1 hour.  Three, 6 and 12 
hours after treatment with E2 uterine weights were increased compared to 
control mice and wet weights of uteri from animals treated with E2+TCDD were 
decreased compared to mice treated with E2 alone at 6 and 12 hours.  
Therefore, our TCDD dose and treatment regimen showed that within the 12 
hour treatment period TCDD inhibited the E2-induced increase in uterine wet 
weights.  These data are comparable to previous studies where longer treatment 
periods of E2 and TCDD were used to study inhibitory AhR-ERα interactions in 
the uterus (Ramamoorthy et al., 1999). 
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Figure 3.9: Uterine weights after treatment with E2 and TCDD in B6C3F1 mice.  
Twenty-five day old female B6C3F1 mice were treated with the corn oil vehicle, 
200 ng of E2, 1 µg of TCDD, or E2 + TCDD (n=4 per treatment).  Mice were 
weighed and uteri were removed and weighed 1, 3, 6, and 12 hours after 
treatment.  Uterine weights are presented as mean + SE and are a percentage 
of total body weight.  Significant (p<0.05) induction by E2 (*) and inhibition in the 
cotreatment (ET) (**) groups is indicated. 
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 The ability of TCDD to inihibit E2-induced cyclin D1, VEGF and DNA 
polymerase α expression was also investigated.  Six hours after treatment, 
cyclin D1 probes stained intense areas of the stroma, localizing to the glandular 
epithelium in the sections from control mice and TCDD treated mice (Figure 
3.10, A-B and C-D) and staining of cyclin D1 mRNA of the luminal epithelium is 
increased in uterine sections from E2 treated and E2 + TCDD treated mice 
compared to the sections from controls (Figure 3.10, A-B v. E-F or G-H).  
However, the intensity of staining in the luminal epithelial cells is slightly higher 
in the E2 sections compared to sections from animals treated with E2 + TCDD 
(Figure 3.10, E-F v. G-H).  Twelve hours after treatment, uteri from control and 
TCDD treated mice still showed intense areas of cyclin D1 mRNA staining that 
localized to glandular epithelium (Figure 3.11, A-B and C-D); the luminal 
epithelial staining of cyclin D1 mRNA was increased in E2 and E2+TCDD 
treated mice compared to control and TCDD treated mice (Figure 3.11, A-B and 
C-D v. E-F or G-H).  However, the differences in staining intensities of cyclin D1 
mRNA in the luminal epithelium between the E2 and E2+TCDD treated mice is 
greater after cotreatment for 12 hours compared to the 6 hour treatment group 
(Figure 3.11, E-F v. G-H compared to Figure 3.10, E-F v. G-H).  These data 
demonstrate that TCDD decreased induction of cyclin D1 gene expression by E2 
in the luminal epithelium of the mouse uterus and the inhibitory response was 
highest 12 hours after cotreatment with E2 + TCDD.   
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Figure 3.10: Expression of cyclin D1 mRNA six hours after treatment with E2 
and TCDD in B6C3F1 mice.  Twenty-five day old female B6C3F1 mice were 
treated with the corn oil vehicle, (A-B) 1 µg of TCDD (C-D), 200 ng of E2 (E-F), 
or E2 + TCDD (G-H) (n=4 per treatment).  Cyclin D1 mRNA levels were 
determined by in situ hybridization of uterine sections taken 6 hours after 
treatment utilizing [35S]-labeled cRNA sense or antisense probes for cyclin D1 
mRNA.  Stained sections were analyzed by brightfield (A, C, E, G) and darkfield 
(B, D, F, H) microscopy.  A representative section of each treatment is shown. 
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Figure 3.11: Expression of cyclin D1 mRNA twelve hours after treatment with E2 
and TCDD in B6C3F1 mice.  Twenty-five day old female B6C3F1 mice were 
treated with the corn oil vehicle, (A-B) 1 µg of TCDD (C-D), 200 ng of E2 (E-F), 
or E2 + TCDD (G-H) (n=4 per treatment).  Cyclin D1 mRNA levels were 
determined by in situ hybridization of uterine sections taken 12 hours after 
treatment utilizing [35S]-labeled cRNA sense or antisense probes for cyclin D1 
mRNA.  Stained sections were analyzed by brightfield (A, C, E, G) and darkfield 
(B, D, F, H) microscopy.  A representative section of each treatment is shown. 
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 Uterine sections from control and TCDD treated mice showed similar low 
levels of staining of the 180 kd catalytic subunit of DNA polymerase α mRNA 
throughout the stromal cells 6 and 12 hours after treatment (Figures 3.12 and 
3.13, A-B and C-D).  Uterine sections from mice treated with E2 alone and 
E2+TCDD showed an increase in staining of DNA polymerase α catalytic 
subunit mRNA in the luminal epithelial cells compared to controls (Figures 3.12 
and 3.13, A-B v. E-F or G-H).  However, the sections from E2+TCCD treated 
mice had a much lower staining intensity the luminal epithelium when compared 
to the staining intensity in sections from the E2-treated mice (Figures 3.12 and 
3.13, E-F v. G-H).  An increase in staining of DNA polymerase α catalytic 
subunit mRNA in the stroma is also seen in the sections from E2-treated mice 
when compared to control and E2+TCDD mice (Figures 3.12 and 3.13, E-F v. A-
B or G-H).  Therefore, as with cyclin D1, TCDD inhibited E2-induced expression 
of the 180 kd catalytic subunit of DNA polymerase α gene in the mouse uterus.  
However, six hour after cotreament TCDD inhibits E2-induced expression of the 
DNA polymerase α gene to a greater extent than observed for inhibition of E2-
induced cyclin D1 expression at the same time point. 
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Figure 3.12: Expression of DNA polymerase α catalytic subunit mRNA six hours 
after treatment with E2 and TCDD in B6C3F1 mice.  Twenty-five day old female 
B6C3F1 mice were treated with the corn oil vehicle (A-B), 1 µg of TCDD (C-D), 
200 ng of E2 (E-F), or E2 + TCDD (G-H) (n=4 per treatment).  DNA polymerase 
α catalytic subunit mRNA levels were determined by in situ hybridization of 
uterine sections taken 6 hours after treatment utilizing [35S]-labeled cRNA 
sense or antisense probes.  Stained sections were analyzed by brightfield (A, C, 
E, G) and darkfield (B, D, F, H) microscopy.  A representative section of each 
treatment is shown. 
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Figure 3.13: Expression of DNA polymerase α catalytic subunit mRNA twelve 
hours after treatment with E2 and TCDD in B6C3F1 mice.  Twenty-five day old 
female B6C3F1 mice were treated with corn oil (A-B), 1 µg of TCDD (C-D), 200 
ng of E2 (E-F), or E2 + TCDD (G-H) (n=4 per treatment).  mRNA levels were 
determined by in situ hybridization utilizing [35S]-labeled cRNA sense or 
antisense probes for DNA polymerase α catalytic subunit.  Stained sections 
were analyzed by brightfield (A, C, E, G) and darkfield (B, D, F, H) microscopy.  
A representative section of each treatment is shown. 
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The timing and localization of E2-induced VEGF gene expression is 
different from that observed for cyclin D1 and DNA polymerase α and the ability 
of TCDD to inhibit the E2-induced response in our model is also different.  One 
and 3 hours after treatment both the control and TCDD treated mice show low 
levels of staining of VEGF mRNA throughout the stroma (Figures 3.14 and 3.15, 
A-B and C-D).  Treatment with E2 induced an increase in staining of VEGF 
mRNA throughout the stroma when compared to the control and TCDD treated 
mice and, as observed for the B6C3F1, the increase was higher 1 hour after 
treatment than after 3 hours (Figures 3.14 and 3.15, A-B and C-D v. E-F).  
E2+TCDD treatment showed a similar increase in staining of VEGF mRNA in 
the stroma compared to the control and TCDD treated mice (Figures 3.14 and 
3.15, A-B and C-D v. G-H) and no difference in staining intensity was seen 
between the E2 and E2+TCDD treatment groups after 1 and 3 hours of 
treatment (Figures 3.14 and 3.15, E-F v G-H).  Thus TCDD did not inhibit E2-
induced VEGF gene expression one hour after cotreatment with both 
compounds.     
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Figure 3.14: Expression of VEGF mRNA one hour after treatment with E2 and 
TCDD in B6C3F1 mice.  Twenty-five day old female B6C3F1 mice were treated 
with the corn oil vehicle (A-B), 1 µg of TCDD (C-D), 200 ng of E2 (E-F), or E2 + 
TCDD (G-H) (n=4 per treatment).  VEGF mRNA levels were determined by in 
situ hybridization utilizing [35S]-labeled cRNA sense or antisense probes.  
Stained sections were analyzed by brightfield (A, C, E, G) and darkfield (B, D, F, 
H) microscopy.  A representative section of each treatment is shown. 
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Figure 3.15: Expression of VEGF mRNA three hours after treatment with E2 and 
TCDD in B6C3F1 mice.  Twenty-five day old female B6C3F1 mice were treated 
with the corn oil vehicle (A-B), 1 µg of TCDD (C-D), 200 ng of E2 (E-F), or E2 + 
TCDD (G-H) (n=4 per treatment).  VEGF mRNA levels were determined by in 
situ hybridization utilizing [35S]-labeled cRNA sense or antisense probes.  
Stained sections were analyzed by brightfield (A, C, E, G) and darkfield (B, D, F, 
H) microscopy.  A representative section of each treatment is shown. 
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3.1.4 Requirement of AhR for inhibition of E2-induced gene expression by AhR 
agonist 
 The AhR was initially identified as a receptor that bound the 
environmental toxicant 2,3,7,8-tetrachlorodobenzo-p-dioxin (TCDD) with high 
affinity and studies with AhR knockout mice have confirmed a role for this 
protein in mediating TCDD-induced toxicity (Fernandez-Salguero et al., 1995; 
Schmidt et al., 1996; Mimura et al., 1997).  AhRKO mice have also been used to 
determine the role of AhR in the ability of TCDD to inhibit E2-induced responses 
(Buchanan et al., 2000).  In this study, we have used AhRKO mice to investigate 
the role of the AhR in the mouse uterus in mediating the antiestrogenic effects of 
TCDD associated with inhibition of E2-induced cyclin D1 and DNA polymerase α
gene expression.  Twenty-five day old AhRKO females were treated with corn 
oil, E2, TCDD, or E2+TCDD and uteri were removed for analysis 6 and 12 hours 
after treatment.   
 In AhRKO mice, TCDD did not inhibit E2-induced cyclin D1 and DNA 
polymerase α gene expression.  As indicated in the control sections from the 6 
hour timepoint, probes for cyclin D1 mRNA stain intense areas of the stroma in 
uterine sections from AhRKO mice, generally localizing to the glandular 
epithelium (Figure 3.16, A-B).  Six hours after treatment, cyclin D1 probes 
intensely stain the luminal epithelium of uterine sections from E2 and E2 + 
TCDD treated mice compared to sections from control mice (Figure 3.16, A-B v. 
C-D, E-F) and there was no difference in staining intensities of the luminal 
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epithelium sections from E2 and E2+TCDD treatment groups (Figure 3.16, C-D 
v. E-F).   After 12 hours of treatment a similar staining pattern for cyclin D1 
mRNA in seen.  E2 and E2+TCDD increased staining of the luminal epithelial 
cells compared to controls (Figure 3.17, A-B v. C-D, E-F) and there is no 
difference in staining intensity between the two treatments (Figure 3.17, C-D v 
E-F).  Sections from the uteri of control and TCDD treated mice at 6 hours of 
treatment stained for the 180 kd catalytic subunit of DNA polymerase α mRNA 
show a low level of staining throughout the stroma (Figure 3.18, A-B and C-D).  
Sections from E2 and E2+TCDD treated mice six and 12 hours after treatment 
stained for the DNA polymerase α catalytic subunit mRNA exhibited a 
comparable increase in staining of the stroma as well as an increase in staining 
along the luminal epithelial cells compared to the controls (Figures 3.18 and 
3.19, A-B v E-F or G-H).  However, as observed for staining of cyclin D1 mRNA, 
differences in staining intensities of the DNA polymerase α catalytic subunit 
mRNA in the stroma or luminal epithelium were not observed in sections from 
E2 and E2+ TCDD treated mice (Figures 3.18 and 3.19, E-F v. G-H).  These 
results indicate that the AhR is necessary for inhibition of E2-induced cyclin D1 
and 180 kd catalytic subunit of DNA polymerase α gene expression by TCDD in 
the mouse uterus.         
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Figure 3.16: Expression of cyclin D1 mRNA six hours after treatment with E2 
and TCDD in AhRKO mice. Twenty-five day old female AhRKO mice were 
treated with the corn oil vehicle (A-B), 200 ng of E2 (C-D), or E2 + TCDD (E-F) 
(n is 5-6 per treatment).  Cyclin D1 mRNA levels were determined by in situ
hybridization of uterine sections taken 6 hours after treatment utilizing [35S]-
labeled cRNA sense or antisense probes for cyclin D1 mRNA.  Stained sections 
were analyzed by brightfield (A, C, E, G) and darkfield (B, D, F, H) microscopy.  
A representative section of each treatment is shown.  
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Figure 3.17: Expression of cyclin D1 mRNA twelve hours after treatment with E2 
and TCDD in AhRKO mice. Twenty-five day old female AhRKO mice were 
treated with the corn oil vehicle (A-B), 200 ng of E2 (C-D), or E2 + TCDD (E-F) 
(n is 2-3 per treatment).  Cyclin D1 mRNA levels were determined by in situ
hybridization of uterine sections taken 12 hours after treatment utilizing [35S]-
labeled cRNA sense or antisense probes for cyclin D1 mRNA.  Stained sections 
were analyzed by brightfield (A, C, E, G) and darkfield (B, D, F, H) microscopy.  
A representative section of each treatment is shown.  
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Figure 3.18: Expression of DNA polymerase α catalytic subunit mRNA six hours 
after treatment with E2 and TCDD in AhRKO mice. Twenty-five day old female 
AhRKO mice were treated with the corn oil vehicle (A-B), 1 µg of TCDD (C-D), 
200 ng of E2 (E-F), or E2 + TCDD (G-H) (n is 5-6 per treatment).  DNA 
polymerase α catalytic subunit mRNA levels were determined by in situ
hybridization of uterine sections taken 6 hours after treatment utilizing [35S]-
labeled cRNA sense or antisense probes for.  Stained sections were analyzed 
by brightfield (A, C, E, G) and darkfield (B, D, F, H) microscopy.  A 
representative section of each treatment is shown.  
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Figure 3.19: Expression of DNA polymerase α catalytic subunit mRNA twelve 
hours after treatment with E2 and TCDD in AhRKO mice. Twenty-five day old 
female AhRKO mice were treated with the corn oil vehicle (A-B), 200 ng of E2 
(C-D), or E2 + TCDD (G-H) (n is 2-3 per treatment).  DNA polymerase α
catalytic subunit mRNA levels were determined by in situ hybridization of uterine 
sections taken 12 hours after treatment utilizing [35S]-labeled cRNA sense or 
antisense probes for DNA polymerase α catalytic subunit.  Stained sections 
were analyzed by brightfield (A, C, E, G) and darkfield (B, D, F, H) microscopy.  
A representative section of each treatment is shown.  
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3.1.5 Stromal-epithelial interactions necessary for E2-induced gene expression 
and inhibition of E2-induced gene expression by AhR agonist 
There is evidence that E2 can bind to ER in stromal or epithelial cells of 
the uterus and induce expression of paracrine factors that then enhance 
proliferation in neighboring cells or other cell types.  Furthermore, Buchanan and 
coworkers have shown that in uterine tissue from adult mice AhR expression is 
necessary in the stromal cells and not the epithelial cells in order for AhR 
agonists to inhibit E2-induced responses of the epithelium (Buchanan et al., 
2000).  Therefore, in order to differentiate between direct induction of gene 
expression by E2 from indirect induction of gene expression by a paracrine 
factor we have used the protein synthesis inhibitor cycloheximide.  In addition 
this inhibitor was also used to distinguish between direct inhibition of E2-induced 
responses by AhR from indirect inhibition by paracrine factors.   
Treatment with TCDD induces high levels of protein synthesis of multiple 
drug metabolizing enzymes in the liver, including cytochrome p450 1A1 
(cyp1A1).  Therefore, the induction of cyp1A1 protein in the liver was used as a 
control for protein synthesis inhibition by cycloheximide and was determined by 
Western blot analysis of protein isolated from liver microsomes.  As seen in  
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Figure 3.20, mice that were not pretreated with cycloheximide exhibited high 
levels of cyp1A1 protein expression in the liver 12 hours after treatment with 
TCDD or E2+TCDD.  In contrast mice pretreated with cycloheximide for 1 hour 
exhibited little or no induction of cyp1A1 protein expression 12 hours after 
treatment with TCDD or E2+TCDD, except for mouse #2 in the E2+TCDD 
treatment group (Figure 3.20).  Uterine wet weights were also measured as an 
indication of general uterine responses to treatments.  Without cycloheximide 
pretreatment, uterine weights from mice treated with E2 for 12 hours were 
increased compared to control mice and mice treated with TCDD or E2+TCDD 
(Figure 3.21).  In mice pretreated with cycloheximide uterine weights were 
increased in mice treated with E2 and E2+TCDD but not changed in mice 
treated with TCDD alone suggesting that the protein synthesis inhibitor blocked 
the antiestrogenic effects of TCDD (Figure 3.21).   
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Figure 3.20: Cyp1A1 protein levels in liver microsomes 12 hours after treatment 
with E2 and TCDD with and without cycloheximide. Twenty-five day old female 
B6C3F1 mice were treated with the corn oil vehicle, 1 µg of TCDD, 200 ng of E2 
or E2 + TCDD with or without 1 hour pretreatment of 0.75 mg of cycloheximide 
(n is 4 per treatment).  Cyp1A1 protein levels were determined by Western blot 
analysis of protein isolated from liver microsomes.  
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Figure 3.21: Uterine weights after treatment with E2 and TCDD with and without 
cycloheximide.  Twenty-five day old female B6C3F1 mice were treated with the 
corn oil vehicle, 1 µg of TCDD, 200 ng of E2 or E2 + TCDD with or without 1 
hour pretreatment of 0.75 mg of cycloheximide (n is 4 per treatment).  Mice were 
weighed and uteri were removed and weighed 12 hours after treatment.  Uterine 
weights are presented as mean + SE and are a percentage of total body weight.  
Induction by E2 (*p<0.05) and inhibition in the cotreatment (ET) (**p<0.07) 
groups is indicated. 
As shown in Figures 3.22 and 3.23, pretreatment with cycloheximide did 
not affect E2 induction of cyclin D1 or 180 kD DNA polymerase α catalytic 
subunit mRNA in luminal epithelial cells of the uterus.  With and without 
cycloheximide pretreatment, after 12 hours of treatment with E2 there is a similar 
increase in staining of cyclin D1 mRNA in the luminal epithelial cells of the 
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uterus compared to sections of the uterus from control mice (Figure 3.22, A-D v. 
I-L).  Furthermore, with and without pretreatment of cycloheximide, treatment 
with E2 for 12 hours also resulted in similar increased staining of the luminal 
epithelial cells for 180 kD catalytic subunit of DNA polymerase α mRNA 
compared to uterine sections from the controls (Figure 3.23, A-D v. I-L).  
Pretreatment with cycloheximide also did not affect the inhibition of E2-
induced cyclin D1 and 180 kD DNA polymerase a catalytic subunit mRNA by 
TCDD.  With and without pretreatment of cycloheximide, treatment with 
E2+TCDD resulted in a slight increased staining for cyclin D1 mRNA in the 
stroma and luminal epithelial cells compared to control mice and mice treated 
with TCDD alone (Figure 3.22, A-D and E-H v. M-P), however the staining was 
less intense than the staining in uterine sections from mice treated with E2 alone 
(Figure 3.22, I-L v. M-P).  Similarly, with and without pretreatment of 
cycloheximide, staining for the 180 kD DNA polymerase a catalytic subunit was 
increased along the luminal epithelial cells of uterine sections from mice treated 
with E2+TCDD when compared to sections from control mice and mice treated 
with TCDD (Figure 3.23, A-D and E-H v. M-P); however, the intensity of staining 
was lower than the staining of the luminal epithithelial cells in sections from mice 
treated with E2 alone (Figure 3.23, I-L v. M-P).  
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Figure 3.22: Expression of cyclin D1 mRNA twelve hours after treatment with E2 
and TCDD with and without cycloheximide treatment. Twenty-five day old female 
B6C3F1 mice were treated with the corn oil vehicle, (A-D), 1 µg of TCDD (E-H), 
200 ng of E2 (I-L) or E2 + TCDD (M-P) (n is 4 per treatment) with (A-B, E-F, I-J, 
M-N) or without (C-D, G-H, K-L, O-P) 1 hour pretreatment of 0.75 mg of 
cycloheximide.  Cyclin D1 mRNA levels were determined by in situ hybridization 
of uterine sections taken 12 hours after treatment utilizing [35S]-labeled cRNA 
sense or antisense probes.  Stained sections were analyzed by brightfield and 
darkfield microscopy.  A representative section of each treatment is shown.  
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Figure 3.23: Expression of DNA polymerase α catalytic subunit mRNA twelve 
hours after treatment with E2 and TCDD with and without cycloheximide 
treatment. Twenty-five day old female B6C3F1 mice were treated with corn oil 
vehicle, (A-D), 1 µg of TCDD (E-H), 200 ng of E2 (I-L) or E2 + TCDD (M-P) (n is 
4 per treatment) with (A-B, E-F, I-J, M-N) or without (C-D, G-H, K-L, O-P) 1 hour 
pretreatment of 0.75 mg of cycloheximide.  DNA polymerase α catalytic subunit 
mRNA levels were determined by in situ hybridization utilizing [35S]-labeled 
cRNA sense or antisense probes.  Stained sections were analyzed by brightfield 
and darkfield microscopy.  A representative section of each treatment is shown. 
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3.2 ErbB2-induced tumor development and inhibition of ErbB2-mediated 
responses by 1,1’,2,2’-tetramethyldiindolylmethane (1,1’,2,2’-tetraMethDIM)  
3.2.1 Characterization of gene expression that leads to ErbB2-induced tumor 
development  
Overexpression and amplification of ErbB2 have been implicated in 
development of aggressive forms of human breast cancer and many other tumor 
types.  In vitro studies in BT-474 ErbB2 overexpressing human breast cancer 
cells indicate that modulation of cyclin D1 and p27 through both the MAPK and 
PI3K/Akt pathways allows G1 to S phase transition; and in vivo studies crossing 
MMTV-c-neu and cyclin D1-/- mice indicate that cyclin D1 is necessary for 
ErbB2 induced mammary tumor formation (Lenferink et al., 2001; Yu et al., 
2001).  However the mechanism of ErbB2 transformation of cells is not 
understood.  The MMTV-c-neu mouse mammary tumor model expresses a 
mutated form of the rat c-neu (ErbB2) protein under the mouse mammary tumor 
virus promoter and in this transgenic model there is a well established 
progression of mammary carcinogenesis with palpable mammary tumors 
forming around 25 weeks of age (Muller et al., 1988).  Therefore, analysis of 
gene expression profiles during the progressive stages of mammary 
carcinogenesis in MMTV-c-neu mice will provide insights on ErbB2-induced 
genes that contribute to enhanced tumor formation and growth. 
 Mammary glands have been removed for RNA isolation and 
histopathological analysis from female MMTV-c-neu and FVB control mice at 6, 
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12, and 18 weeks of age; however, only tissue from the 6 week old mice has 
been analyzed in preliminary studies.  The #1 and #2 mammary glands were 
isolated for histopathological analysis because the location of the glands makes 
it difficult to isolate the mammary tissue without muscle and other surrounding 
tissue included, and inclusion of surrounding tissue for RNA isolation and 
microarray analysis could alter gene expression profiles.  Histopathological 
analysis of mammary glands from the MMTV-c-neu mice and FVB mice showed 
no differences between the control and the transgenic mice at 6 weeks of age.  
The glands were normal with no indication of transformation in the mammary 
epithelium.  These results agree with the original description of the TG.NK line 
by Muller and coworkers in which stochastic expression of ErbB2 and mammary 
epithelial transformation was not observed until mice were older (Muller et al., 
1988).   
 Microarray analysis comparing gene expression in the mammary of FVB 
and MMTV-c-neu mice at 6 weeks of age was performed using the Affymetrix 
MG-U74Av2 chip.  A summary of the gene expression profiles is shown in Table 
3.1.  Thirty-two genes were up-regulated greater than 2 fold in the MMTV-c-neu 
mice compared to the FVB background mice and 23 genes were down-regulated 
greater than 2 fold.  The genes that were up-regulated or down-regulated 
greater than 2-fold were classified under molecular function/pathways based on 
gene ontology using tools from the web-based bioinformatics resource David 
(http://david.niaid.nih.gov/david/upload.asp).  The results (Tables 3.2 and 3.3) 
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indicate that catalytic activity and binding were the two classifications that 
contained most genes up-regulated and down-regulated.  Several up-regulated 
genes in the transgenic mice are also involved in development, signal 
transduction and transporter activity (Table 3.2) and multiple down regulated 
genes exhibited transporter activity and enzyme regulation (Table 3.3).  Further 
analysis of gene expression changes in the MMTV-c-neu mice compared to the 
FVB background at six weeks of age is in progress.   
Based on the minimal variation in gene expression found within the FVB 
and MMTV-c-neu groups at 6 weeks of age samples from 2 MMTV-c-neu and 2 
FVB mice 12 and 18 weeks will be analyzed in future studies.  Table 3.4 
indicates the detection of gene expression within the FVB and MTVV-c-neu 
groups and the scatter graphs in Figure 3.24 compare the three animals within 
the MMTV-c-neu group showing good correlation in gene expression between 
animals.  Similar correlation was found between the FVB animals.  Therefore, 2 
samples per group at each the 12 week and 18 week time points should allow 
delineation of differences in gene expression between the FVB and MMTV-c-
neu mice. 
175
Table 3.1: Summary of gene expression profiles in mouse mammary tissue at 6 wks based on 
analysis with GeneSpring software. RNA was isolated from mammary tissue of FVB and MMTV-
c-neu at 6 weeks of age and gene expression analyzed using the Affymetrix MG-U74Av2 
microarray chip.   
Total samples analyzed:                                          2 samples of FVB control 
                                          3 samples of MMTV-c-neu 
Total genes on Affytmetrix MG-U74Av2 chip:   12,520 
Total genes changed after removing genes with same levels under both 
conditions 1,187 
Total genes up-regulated among genes changed: 741 
Total genes down-regulated among genes changed: 446 
Total genes up-regulated greater than 2 fold: 32 
Total genes down-regulated greater than 2 fold: 23 
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Table 3.2: Classification of MMTV-c-neu genes up-regulated greater than 2 fold. RNA was 
isolated from mammary tissue of FVB and MMTV-c-neu at 6 weeks of age and gene expression 
analyzed using the Affymetrix MG-U74Av2 microarray chip and GeneSpring software comparing 
MMTV-c-neu and FVB mice. 
CLASSIFICATION
GENENAME GenBank 
Fold
Change
Catalytic Act. glucan (1,4-alpha-), branching enzyme 1 AI854404 2.03 
  ATP citrate lyase AW121639 2.2 
  ATP-binding cassette, sub-family D (ALD), member 2 Z48670 2.09 
  apolipoprotein B editing complex 2 AW124988 2.25 
  aldehyde dehydrogenase family 1, subfamily A7 U96401 2.1 
neural precursor cell expressed, developmentally down-regulted 
gene 4 AV365271 4.07 
  ELOVL family member 6, elongation of long chain fatty acids  AW122523 2.72 
  ELOVL family member 6, elongation of long chain fatty acids  AI839004 2.5 
  methylmalonyl-Coenzyme A mutase X51941 2.13 
  malic enzyme, supernatant J02652 2.37 
Binding ATP citrate lyase AW121639 2.2 
  ATP-binding cassette, sub-family D (ALD), member 2 Z48670 2.09 
  nuclear receptor subfamily 1, group D, member 1 AI834950 2.07 
  apolipoprotein B editing complex 2 AW124988 2.25 
  growth differentiation factor 8 U84005 2.34 
neural precursor cell expressed, developmentally down-regulted 
gene 4 AV365271 4.07 
  retinol binding protein 4, plasma U63146 2.34 
Development frizzled homolog 4 (Drosophila) U43317 3.23 
  RIKEN cDNA A430096B05 gene AV373294 2.28 
  patched homolog AI848841 2.94 
  angiomotin like 2 AI854404 2.03 
Signal Transducer  nuclear receptor subfamily 1, group D, member 1 AI834950 2.07 
  frizzled homolog 4 (Drosophila) U43317 3.23 
  growth differentiation factor 8 U84005 2.34 
  patched homolog AI848841 2.94 
Transporter Act. ATP-binding cassette, sub-family D (ALD), member 2 Z48670 2.09 
  retinol binding protein 4, plasma U63146 2.34 
  hemoglobin alpha, adult chain 1 AV003378 2.45 
Behavior nuclear receptor subfamily 1, group D, member 1 AI834950 2.07 
Cell Adhesion Mol.  RIKEN cDNA A430096B05 gene AV373294 2.28 
Transcript. Regulator  nuclear receptor subfamily 1, group D, member 1 AI834950 2.07 
Unclassified interferon-induced protein with tetratricopeptide repeats 1 U43084 3.27 
  pentaxin related gene X83601 3.06 
  RIKEN cDNA 2310034L04 gene AI839116 2.07 
  RIKEN cDNA 2700089E24 gene AI131982 2.14 
  RIKEN cDNA 6330514M23 gene AW048944 2.09 
  RIKEN cDNA B430320C24 gene AI606967 2.79 
  cytotoxic T lymphocyte-associated protein 2 beta X15592 2.17 
  beta-1-globulin V00722 2.6 
  small inducible cytokine A2 M19681 2.36 
  small inducible cytokine A7 X70058 2.3 
  hemoglobin beta, adult major chain  J00413 2.18 
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Table 3.3: Classification of MMTV-c-neu genes down-regulated greater than 2 fold. RNA was 
isolated from mammary tissue of FVB and MMTV-c-neu at 6 weeks of age and gene expression 
analyzed using the Affymetrix MG-U74Av2 microarray chip and GeneSpring software comparing 
MMTV-c-neu and FVB mice. 
CLASSIFICATION GENENAME GenBank Fold Change
Binding glycerol kinase U48403 2.1 
  casein gamma D10215 7.87 
  nuclear factor I/A D90173 2.04 
  myeloblastosis oncogene M12848 2.07 
  capping protein (actin filament) muscle Z-line, beta U10407 2.56 
  fatty acid binding protein 3, muscle and heart X14961 3.57 
  chemokine (C-C motif) ligand 19 AW120505 2.15 
  apolipoprotein D X82648 2.02 
Catalytic Act. glycerol kinase U48403 2.1 
  reelin U24703 2.1 
  solute carrier family 27 (fatty acid transporter), member 2 AF072757 3.46 
  solute carrier family 27 (fatty acid transporter), member 1 U15976 2.04 
  phosphoglycerate mutase 2 AF029843 2.12 
  cyclin B2 X66032 2.42 
  creatine kinase, mitochondrial 2 AI181132 2.51 
Transporter Act. fatty acid binding protein 3, muscle and heart X14961 3.57 
  solute carrier family 27 (fatty acid transporter), member 1 U15976 2.04 
  apolipoprotein D X82648 2.02 
Enzyme Regulator Act. cyclin B2 X66032 2.42 
  extracellular proteinase inhibitor X93037 2.28 
Behavior reelin U24703 2.1 
Cell Adhesion Mol. Act. reelin U24703 2.1 
Cellular Process antigen identified by monoclonal antibody Ki 67 X82786 2.38 
Chaperone Act. DnaJ (Hsp40) homolog, subfamily B, member 1 AB028272 2.27 
Development reelin U24703 2.1 
Signal Transducer Act. chemokine (C-C motif) ligand 19 AW120505 2.15 
Structural Molecule Act. reelin U24703 2.1 
Transcription Regulator nuclear factor I/A D90173 2.04 
Unclassified H19 fetal liver mRNA X58196 4.18 
  casein alpha M36780 3.28 
  casein beta X04490 8.83 
  unncoupling protien, mitochondrial M21247 2.5 
  small proline-rich protein 2a AJ005559 2.35 
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Table 3.4. Detection of gene expression among animals within the FVB and the MMTV-c-neu 
groups. RNA was isolated from mammary tissue of FVB and MMTV-c-neu at 6 weeks of age and 
gene expression analyzed using the Affymetrix MG-U74Av2 microarray chip.   
Animals % Present % Absent % Marginal 
    
FVB1 47.2 50.2 2.6 
FVB2 44.1 53.2 2.7 
    
MMTV-c-neu1 48.3 49.1 2.5 
MMTV-c-neu2 41.7 55.9 2.4 
MMTV-c-neu3 47.4 50.1 2.5 
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Figure 3.24: Scatter graphs comparing gene expression within the MMTV-c-neu 
and FVB groups. RNA was isolated from mammary tissue of FVB and MMTV-c-
neu at 6 weeks of age and gene expression analyzed using the Affymetrix MG-
U74Av2 microarray chip.  Scatter graphs were plotted to compare gene 
expression patterns between animals within the groups. 
180
3.2.2 Inhibition of ErbB2-induced growth in vitro by 1,1’,2,2’-tetraMethDIM, an 
AhR agonist 
Recently, it has been reported that 1,1’,2,2’-tetraMethDIM, an AhR 
agonist, inhibited DMBA-induced mammary tumor growth in rats (McDougal et 
al., 2001) and in in vitro studies, this compound inhibited constitutively active 
MAPK and p110 (catalytic subunit of PI3-K).  Breast cancer cell lines that 
overexpress ErbB2 exhibit constitutive activation of both the MAPK and PI3K 
pathways. Therefore, the ability of 1,1’,2,2’-tetraMethDIM to inhibit the growth of 
ErbB2 overexpressing cells in vitro was investigated.  Initial studies examined 
the ability of 1,1’,2,2’-tetraMethDIM to inhibit growth of BT-474 and MDA-MB-
453 human breast cancer cell lines, which overexpress ErbB2, and also 
determine their effects on E2- and heregulin (an ErbB2 agonist)- induced growth 
in MCF-7 human breast cancer cells.  All three cell lines express a functional 
AhR.   
BT-474 and MDA-MB-453 cells were grown over a 5-7 day period in 
media containing 2.5 or 5% charcoal-stripped fetal bovine serum or 10% 
untreated fetal bovine serum and treated with various concentrations of 1,1’,2,2’-
tetraMethDIM.  The ability of 1,1’,2,2’-tetraMethDIM to inhibit the growth of both 
BT-474 and MDA-MB-453 cells was dependent upon the serum in the treatment 
media.  BT-474 and MDA-MB-453 cells cultured in 10% serum grew at a much 
higher rate than cells grown in the other media; moreover, 1,1’,2,2’-
tetraMethDIM did not inhibit the growth at the concentrations (2.5 to 10 µM)
181
used in this study (Figure 3.25).  After treatment of BT-474 cells grown in media 
containing 5% charcoal-stripped serum with 1,1’,2,2’-tetraMethDIM growth was 
inhibited 5 and 7 days after treatment with 10 µM 1,1’,2,2’-tetraMethDIM.  In 
contrast 2.5 or 5 µM 1,1’,2,2’-tetraMethDIM did not affect growth over the time 
course of this study (Figure 3.26).  MDA-MB-453 cells grown in media containing 
5% charcoal-stripped serum were treated with 5 and 10 µM 1,1’,2,2’-
tetraMethDIM and cell growth was inhibited after 7 days; 5 and 10 mM 1,1’,2,2’-
tetraMethDIM did not significantly inhibit growth at earlier time points and 2.5 µM
1,1’,2,2’-tetraMethDIM had no effect on cell growth over the 7 day period (Figure 
3.26).  The highest inhibition of growth by 1,1’,2,2’-tetraMethDIM was observed 
in cells grown in media containing 2.5% charcoal-stripped serum.  Five and 10 
µM 1,1’,2,2’-tetraMethDIM inhibited growth of BT-474 cells after 5 and 7 days in 
media containing 2.5% charcoal-stripped serum (Figure 3.27).  Growth of MDA-
MB-453 cells was also inhibited by different concentrations of 1,1’,2,2’-
tetraMethDIM when cells are grown in 2.5% charcoal-stripped serum (Figure 
3.27).   
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Figure 3.25: BT-474 and MDA-MB-453 cell proliferation in media containing 10% 
FBS. Cells were seeded in media containing 10% FBS and treated with DMSO, 
2.5, 5.0 or 10.0 µM 1,1’,2,2’,tetraMethDIM over 5 days.  Cells were counted 
everyday.  The mean + SE is plotted (n=3) and significant (p<0.05) changes are 
indicated (*). 
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Figure 3.26: BT-474 and MDA-MB-453 cell proliferation in media containing 5% 
charcoal-stripped FBS. Cells were seeded in media containing 5% charcoal-
stripped FBS and treated with DMSO, 2.5, 5.0 or 10.0 µM 1,1’,2,2’,tetraMethDIM 
over 7 days.  Cells were counted on day 2, 5, and 7.  The mean + SE is plotted 
(n=3) and significant (p<0.05) changes are indicated (*). 
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Figure 3.27: BT-474 and MDA-MB-453 cell proliferation in media containing 
2.5% charcoal-stripped FBS. Cells were seeded in media containing 2.5% 
charcoal-stripped FBS and treated with DMSO, 2.5, 5.0 or 10.0 µM
1,1’,2,2’,tetraMethDIM over 7 days.  Cells were counted on day 2, 5, and 7.  The 
mean + SE is plotted (n=3) and significant (p<0.05) changes are indicated (*). 
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The ability a 1,1’,2,2’-tetraMethDIM to inhibit baseline, as well as, E2- and 
heregulin-induced growth was investigated in MCF-7 cells.  MCF-7 cells were 
grown in serum-free media alone or in serum-free media plus 1 nM E2 or 2.5 
ng/ml heregulin and the growth inhibitory effects of 0, 2.5, 5, or 10 µM 1,1’,2,2’-
tetraMethDIM over a six day period were determined.  MCF-7 cells treated with 
0 or 2.5 µM 1,1’,2,2’-tetraMethDIM had similar growth curves, whereas 5 and 10 
µM 1,1’,2,2’-tetraMethDIM inhibited growth of MCF-7 cells (Figure 3.28).  One 
nanomolar E2 induced growth of MCF-7 cells compared to solvent treated MCF-
7 cells and 1,1’,2,2’-tetraMethDIM inhibited E2-induced growth of MCF-7 cells in 
a concentration-dependent manner (Figure 3.28).  An induction of growth was 
not seen in the heregulin treated MCF-7 cells compared to the solvent-treated 
control cells until 6 days after treatment.  Similarly, inhibition of growth by all 
three doses of 1,1’,2,2’-tetraMethDIM was not observed until 6 days of treatment 
(Figure 3.28).  Although heregulin did not induce growth of MCF-7 cells after 2 
and 4 days of treatment, cells treated with 5 and 10 µM 1,1’,2,2’-tetraMethDIM + 
heregulin showed an increased growth, whereas cells treated with 5 and 10 µM
1,1’,2,2’-tetraMethDIM alone did not (Figure 3.28). 
186
                 
0
40
80
120 DMSO
Heregulin 2.5 ng/ml
Heregulin 2.5 ng/ml +
2.5 uM 1,1',2,2'tetraMethDIM
Heregulin 2.5 ng/ml + 
Heregulin 2.5 ng/ml +
5 uM 1,1',2,2'tetraMethDIM
10 uM 1,1',2,2'tetraMethDIM
0
50
100
150
200
250
c
e
ll
s
/w
e
ll
 (
x
1
0
0
0
) DMSO
E2 1 nM
E2 1 nM + 2.5 uM
1,1',2,2' tetraMethDIM
E2 1 nM + 5 uM
E2 1 nM + 10 uM
1,1',2,2' tetraMethDIM
1,1',2,2' tetraMethDIM
0
20
40
60
80
2 4 6
DMSO
2.5 uM
1,1',2,2' tetraMethDIM
5 uM
10 uM
1,1',2,2' tetraMethDIM
1,1',2,2' tetraMethDIM
Days
* *
*
*
*
*
*
*
*
*
**
**
**
**
**
****
*
*
**
**
**
**
** **
**
**
Figure 3.28: MCF-7 cell proliferation in serum-free media. Cells were seeded in 
media containing 2.5% charcoal-stripped FBS and dosed in serum-free media 
with DMSO, E2 or heregulin plus 2.5, 5.0 or 10.0 µM 1,1’,2,2’,tetraMethDIM over 
6 days.  Cells were counted on day 2, 4, and 6.  The mean + SE is plotted (n=3) 
and significant (p<0.05) changes are indicated (*). 
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3.2.3 Mechanism of growth inhibition by 1,1’,2,2’-tetraMethDIM in BT-474 and 
MDA-MB-453 cells – cytotoxicity, induction of apoptosis, or cell cycle arrest 
 Cancer cell growth is inhibited either by cell death or inhibition of cell 
division or both, and cell death occurs through cytotoxicity, induction of 
apoptosis, or a combination of the two processes.  We investigated whether 
treatment of BT-474 or MDA-MB-453 cells with 1,1’,2,2’-tetraMethDIM resulted 
in cytotoxicity, cell cycle arrest , or apoptosis (measured by induction of caspase 
3 activity or cleavage of PARP protein).  BT-474 and MDA-MB-453 cells were 
cultured in media containing 2.5% charcoal-stripped serum and treated with 
1,1’,2,2’-tetraMethDIM (Figure 3.27).  Cytotoxicity was measured using the 
lactose dehydrogenase (LDH) cytoxicity assay.  The amount of LDH in the 
media provides a relative measure of cells that have lysed due to cytotoxicity.  
The LDH released from these cells is determined by measuring the conversion 
of NADH+ + pyruvate to NAD+ + lactate and the subsequent decrease in the 
absorbance of NADH+.  Therefore, a decrease in absorbance from the pyruvate 
+ NADH+ control indicates the presence of LDH in the sample and thus 
cytoxicity.  Cytotoxicity was measured 2 and 4 days after treatment of BT-474 
cells with 2.5, 5, and 10 µM 1,1’,2,2’-tetraMethDIM.  Treatment with 0.005, 0.05 
and 5 mM phenol was used as a positive control for cytotoxicity in the assay and 
Triton-X was used as a measure of the maximum decrease in absorbance with 
complete cell lysis.  Treatment with 5 mM phenol for 2 days resulted in 
cytotoxicity as indicated by a decrease in absorbance compared to the pyruvate 
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+ NADH+ control and after 4 days all three doses of phenol induced cytoxicity 
(Figure 3.29).  There was no indication that 1,1’,2,2’-tetraMethDIM was cytotoxic 
at any dose (Figure 3.29).  Similarly, after 2 days of treatment of MDA-MB-453 
cell with 1,1’,2,2’-tetraMethDIM there was no indication of cytoxicity at any dose 
(Figure 3.30).   
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Figure 3.29: LDH cytotoxicity assay in BT-474 cells. Cells were seeded in media 
containing 2.5% charcoal-stripped FBS and dosed with DMSO; 2.5, 5.0 or 10.0 
µM 1,1’,2,2’,tetraMethDIM; 0.005, 0.05 or 5 mM phenol over 4 days.  Aliquots of 
media were removed from the cells on day 2 and 4 and analyzed using the LDH 
cytotoxicity assay.  The mean + SE is plotted (n=3) and significant (p<0.05) 
changes are indicated (*). 
189
              
0
0.1
0.2
0.3
P
y
ru
v
a
te
P
y
ru
v
a
te
+
 N
A
D
H
D
M
E
/F
-1
2
D
M
S
O
2
.5
 u
M
1
,1
',
2
,2
't
e
tr
a
M
e
th
D
IM
5
 u
M
1
,1
'2
,2
't
e
tr
a
M
e
th
D
IM
1
0
 u
M
1
,1
',
2
,2
't
e
tr
a
M
e
th
D
IM
A
b
s
o
rb
a
n
c
e
Figure 3.30: LDH cytotoxicity assay in MDA-MB-453 cells. Cells were seeded in 
media containing 2.5% charcoal-stripped FBS and dosed with DMSO, 2.5, 5.0 or 
10.0 µM 1,1’,2,2’,tetraMethDIM over 2 days.  Aliquots of media were removed 
from the cells on day 2 and analyzed using the LDH cytotoxicity assay.  The 
mean + SE is plotted (n=3) and significant (p<0.05) changes are indicated (*). 
190
In order to determine whether inhibition of cell growth by 1,1’,2,2’-
tetraMethDIM was due to cell cycle arrest, cell cycle progression was measured 
4 days after treatment of BT-474 and MDA-MB-453 cells with 1,1’,2,2’-
tetraMethDIM.  Cells were stained with propidium iodide to measure DNA 
content and analyzed by flow cytometry.  The percentage of cells in G0/G1 
phase of the cell cycle after 4 days of treatment was increased in BT-474 cells 
treated with 10 µM 1,1’,2,2’-tetraMethDIM and the percentage of cells in S and 
G2/M phases of the cell cycle was decreased (Figure 3.31).  Treatment of BT-
474 cells with 5 µM 1,1’,2,2’-tetraMethDIM showed a trend similar to that 
observed with 10 µM 1,1’,2,2’-tetraMethDIM (Figure 3.31).  Therefore, inhibition 
of BT-474 cell growth by 1,1’,2,2’-tetraMethDIM is at least partially due to an 
increase in the percentage of cells in G0/G1 phase of the cell cycle.  This effect 
may be related to an increase in time that the overall cell population spends in 
G0/G1, thereby extending the time for cell division.  It is also possible that a 
certain cell population exits from the cell cycle and arrests in G0/G1 so that 
fewer cells are undergoing cell division.  1,1’,2,2’-tetraMethDIM treatment did not 
result in a change in the percentage of MDA-MB-453 cells in G0/G1 at any dose 
(Figure 3.32).  In contrast a doubling of the percentage of MDA-MB-453 cells in 
G2/M phase of the cell cycle occurred after treatment with 10 µM 1,1’,2,2’-
tetraMethDIM (Figure 3.32).  Therefore, the effect of 1,1’,2,2’-tetraMethDIM on 
percent distribution of MDA-MB-453 cells in phases of the cell cycle is different 
from that observed for BT-474 cells. 
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Average Std. Error
G0/G1 DMSO 62.61 0.560
2.5 uM 1,1',2,2'tetraMethDIM 64.51 2.016
5 uM 1,1',2,2'tetraMethDIM 68.50 1.066
10 uM 1,1',2,2'tetraMethDIM 76.18 1.444
S DMSO 30.28 0.282
2.5 uM 1,1',2,2'tetraMethDIM 30.96 1.415
5 uM 1,1',2,2'tetraMethDIM 28.15 0.788
10 uM 1,1',2,2'tetraMethDIM 21.12 1.490
G2/M DMSO 7.10 0.825
2.5 uM 1,1',2,2'tetraMethDIM 4.54 0.694
5 uM 1,1',2,2'tetraMethDIM 3.35 0.373
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Figure 3.31: Cell cycle analysis in BT-474 cells. Cells were seeded in media 
containing 2.5% charcoal-stripped FBS and dosed with DMSO; 2.5, 5.0 or 10.0 
µM 1,1’,2,2’,tetraMethDIM over 4 days.  Cells were stained with propidium iodide 
and DNA content was analyzed by flow cytometry.  The mean + SE is plotted 
(n=3) and significant (p<0.05) changes are indicated (*). 
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Average Std. Error
G0/G1 DMSO 76.26 1.561
2.5 uM 1,1',2,2'tetraMethDIM 73.80 0.747
5 uM 1,1',2,2'tetraMethDIM 74.84 0.706
10 uM 1,1',2,2'tetraMethDIM 74.14 0.858
S DMSO 20.75 1.581
2.5 uM 1,1',2,2'tetraMethDIM 22.64 1.580
5 uM 1,1',2,2'tetraMethDIM 20.36 1.192
10 uM 1,1',2,2'tetraMethDIM 18.53 0.522
G2/M DMSO 2.99 0.101
2.5 uM 1,1',2,2'tetraMethDIM 3.56 1.036
5 uM 1,1',2,2'tetraMethDIM 4.81 0.709
10 uM 1,1',2,2'tetraMethDIM 7.33 0.402
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Figure 3.32: Cell cycle analysis in MDA-MB-453 cells. Cells were seeded in 
media containing 2.5% charcoal-stripped FBS and dosed with DMSO; 2.5, 5.0 or 
10.0 µM 1,1’,2,2’,tetraMethDIM over 4 days.  Cells were stained with propidium 
iodide and DNA content was analyzed by flow cytometry.  The mean + SE is 
plotted (n=3) and significant (p<0.05) changes are indicated (*). 
 Caspase 3 activity and cleavage of the PARP protein were used as 
indicators of 1,1’,2,2’-tetraMethDIM-mediated apoptosis as a mechanism for 
inhibition of BT-474 or MDA-MB-453 cell growth.  As an early indicator of 
apoptosis, caspase 3 activity was measured 24, 48, and 72 hours after 
treatment.  Caspase 3 activity was determined using the Ac-DEVD-AMC 
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fluorogenic substrate that fluoresces when cleaved by active caspase 3 protein, 
and camptothecin was used as a positive control for induction of apoptosis.  
After treatment for 24 hours neither camptothecin nor any dose of 1,1’,2,2’-
tetraMethDIM resulted in increased fluorescence indicating that caspase 3 
activity was not increased in BT-474 or MDA-MB-453 cells (Figures 3.33 and 
3.34).  In contrast, treatment with camptothecin for 48 and 72 hours increased 
caspase 3 activity, whereas 1,1’,2,2’-tetraMethDIM did not affect caspase 
activity in BT-474 or MDA-MB-453 cells (Figures 3.33 and 3.34).  Cleavage of 
the PARP protein is also an indicator of apoptosis and a downstream substrate 
of the caspase cascade.  Cleavage of PARP was determined by Western blot 
analysis of whole cell lysates isolated after treatment of BT-474 or MDA-MB-453 
cells with 1,1’,2,2’-tetraMethDIM for 40 hours.  Treatment with 10 µM 1,1’,2,2’-
tetraMethDIM did not result in cleavage of the PARP protein in either BT-474 or 
MDA-MB-453 cells, whereas okadaic acid, a known inducer of apoptosis, 
induced cleavage of PARP (Figure 3.35).  Therefore, these data suggest that 
1,1’,2,2’-tetraMethDIM does not induce apoptotic pathways associated with 
PARP cleavage in BT-474 or MDA-MB-453 cells.  The data suggests that the 
growth inhibitory effects of 1,1’,2,2’-tetraMethDIM must be associated with other 
pathways.   
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Figure 3.33: Induction of caspase 3-dependent activity in BT-474 cells. Cells 
were seeded in media containing 2.5% charcoal-stripped FBS and dosed with 
DMSO; 2.5, 5.0 or 10.0 µM 1,1’,2,2’,tetraMethDIM; 0.1 µM okadaic acid; or 3 µM
camptothecin.  On days 1, 2, and 3 after treatment cells were lysed and assayed 
for caspase 3 activity.  The mean + SE is plotted (n=3) and significant (p<0.05) 
changes are indicated (*).   
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Figure 3.34: Induction of caspase 3-dependent activity in MDA-MB-453 cells.
Cells were seeded in media containing 2.5% charcoal-stripped FBS and dosed 
with DMSO; 2.5, 5.0 or 10.0 µM 1,1’,2,2’,tetraMethDIM; 0.1 µM okadaic acid; or 
3 µM camptothecin.  On days 1, 2, and 3 after treatment cells were lysed and 
assayed for caspase 3 activity.  The mean + SE is plotted (n=3) and significant 
(p<0.05) changes are indicated (*). 
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Figure 3.35: Induction of PARP cleavage in MDA-MB-453 and BT-474 cells.
Cells were seeded in media containing 2.5% charcoal-stripped FBS and dosed 
with DMSO; 2.5, 5, or 10.0 µM 1,1’,2,2’,tetraMethDIM; 1, 5, or 10 µM compound 
#9; 5 µM CHX; 0.1 or 0.2 µM  okadaic acid (OA); or 0.5 or 5 µM camptothecin 
(Camp).  Forty hours after treatment the cells and pelleted supernatant were 
treated with high salt lysis buffer and protein used for Western blot analysis of 
PARP.    
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3.3.5 No evidence for inhibition of MAPK or PI3K pathways by 1,1’,2,2’-
tetraMethDIM in BT-474 or MDA-453 cell lines 
Previous studies in BT-474 cells indicate that modulation of cyclin D1 and 
p27 through both the MAPK and PI3K/Akt pathways allows G1 to S phase 
transition (Lenferink et al., 2001).  In our studies 1,1’,2,2’-tetraMethDIM 
increases the percentage of BT-474 cells in G0/G1; therefore, we investigated 
whether or not 1,1’,2,2’-tetraMethDIM inhibits the MAPK or PI3K/Akt pathways 
or affects downstream activation of cyclin D1 and p27.  Western blots were used 
determine phosphorylation of ErbB2 as an initial step in the activation of both the 
MAPK and PI3K/Akt pathways, and the phosphorylation of ERK1/2 and Akt1 as 
downstream components of each pathway, respectively.  After treatment of BT-
474 cells with 1,1’,2,2’-tetraMethDIM, U0126 (an inhibitor of the MAPK pathway), 
or LY294002 (an inhibitor of the PI3K/Akt pathway) for 4 days, protein was 
isolated and immunoprecipitated with antibodies to ErbB2 or IgG as a control.   
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The precipitated protein was probed with an antibody to phosphorylated tyrosine 
(p-tyr) to determine the level of ErbB2 phosphorylation on tyrosine residues.  
After 4 days of treatment with 1,1’,2,2’-tetraMethDIM, U0126, or LY294002 BT-
474 cells did not exhibit any change in phosphorylation of ErbB2 on tyrosine 
residues and none of the treatments affected overall ErbB2 protein levels 
(Figure 3.36).  Immunoprecipitation with the control IgG antibody did not pull 
down non-specific proteins with p-try residues.  Aliquots from the same protein 
samples were also used in Western blots analysis for phosphorylated ERK1/2 
(p-ERK1/2), ERK1/2, phosphorylated Akt1 (p-Akt1), and Akt.  1,1’,2,2’-
tetraMethDIM did not affect the phosphorylation of ERK1/2 or Akt1 or the overall 
level of the ERK1/2 or Akt proteins (Figure 3.36).  LY294002, a specific inhibitor 
of the PI3K/Akt pathway, decreased phosphorylation of Akt, and U0126, a 
specific inhibitor of MAPK pathway, decreased the phosphorylation ERK1/2.   
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Figure 3.36: ErbB2, ERK, and Akt phosphorylation in BT-474 cells. Cells were 
seeded in media containing 2.5% charcoal-stripped FBS and dosed with DMSO 
(Lanes 1, 6, 11); 10.0 µM 1,1’,2,2’,tetraMethDIM (Lanes 2, 7, 12); 1 nM E2 
(Lanes 3, 8, 13), 10 µM U0126 (Lanes 4, 9, 14) or 10 µM LY294002 (Lanes 5, 
10, 15).  After 4 days of treatment, the cells were lysed in high salt lysis buffer 
and proteins used for immunoprecipitation and Western blot analysis.  
Representative Western blots are shown.   
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In a separate experiment BT-474 and MDA-453 cells were treated with 
2.5, 5, and 10 µM 1,1’,2,2’-tetraMethDIM for 4 days and ERK and Akt 
phosphorylation and cyclin D1 and p27 protein levels were determined by 
Western blot analysis of whole cell lysates.  As indicated in Figure 3.36, 
1,1’,2,2’-tetraMethDIM does not affect ERK1/2 or Akt1 phosporylation, whereas 
the specific inhibitors, U0126 and LY294002 decreased constitutive levels of 
ERK1/2 and Akt1 phosphorylation, respectively, in BT-474 cells (Figure 3.37).  In 
MDA-MB-453 cells 1,1’,2,2’-tetraMethDIM did not affect the phosphorylation of 
ERK1/2 or Akt1; suprisingly, U0126 and LY294002 also did not inhibit the 
phosphorylation of ERK1/2 and Akt (Figure 3.38).  ERK1/2 phosphorylation was 
actually increased in MDA-MB-453 cells by treatment with 10 µM 1,1’,2,2’-
tetraMethDIM, U0126 and LY294002 for 4 days.  Cyclin D1 protein levels were 
not affected after treatment of BT-474 cell with 1,1’,2,2’-tetraMethDIM for 4 days; 
however, treatment with LY294002 decreased cyclin D1 protein (Figure 3.37).   
201
In MDA-MB-453 cells treated with 10 µM 1,1’,2,2’-tetraMethDIM cyclin D1 
protein levels were slightly increased and LY294002 treatment decreased cyclin 
D1 protein as observed in BT-474 cells (Figure 3.38).  p27 protein levels were 
slightly increased in both BT-474 and MDA-MB-453 cells by treatment with 
1,1’,2,2’-tetraMethDIM in a dose dependent manner, as well as by L294002 
treatment in BT-474 cells and DIM treatment in MDA-MB-453 cells after 4 days 
(Figures 3.37 and 3.38). 
In order to determine whether an early change in cyclin D1 or the cell 
cycle inhibitors p21 or p27 correlated with the decrease in cell growth, cyclin D1, 
p21 and p27 protein levels were determined by Western blot analysis using 
whole cell lysates from BT-474 and MDA-MB-453 cells treated with 5 and 10 µM
1,1’,2,2’-tetraMethDIM.  However, after 12 and 24 hours of treatment with 
1,1’,2,2’-tetraMethDIM cyclin D1, p21 and p27 protein levels changed minimally 
(Figures 3.39 and 3.40). 
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Figure 3.37: MAPK, PI3-K and cell cycle protein levels after 4 days of treatment  
in BT-474 cells. Cells were seeded in media containing 2.5% charcoal-stripped 
FBS and dosed with DMSO; 2.5, 5, or 10.0 µM 1,1’,2,2’,tetraMethDIM; 10 µM
U0126; 1 nM E2; or 10 µM LY294002.  After 4 days of treatment, the cells were 
lysed in high salt lysis buffer and proteins used for Western blot analysis.  
Representative Western blots are shown.   
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Figure 3.38: MAPK, PI3-K and cell cycle protein levels after 4 days of treatment  
in MDA-MB-453 cells. Cells were seeded in media containing 2.5% charcoal-
stripped FBS and dosed with DMSO; 2.5, 5, or 10.0 µM 1,1’,2,2’,tetraMethDIM; 
10 µM U0126; 1 nM E2; or 10 µM LY294002.  After 4 days of treatment, the cells 
were lysed in high salt lysis buffer and proteins used for Western blot analysis.  
Representative Western blots are shown.   
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Figure 3.39: Cell cycle protein levels after 12 and 24 hours of treatment in BT-
474 cells. Cells were seeded in media containing 2.5% charcoal-stripped FBS 
and dosed with DMSO; 5 or 10.0 µM 1,1’,2,2’,tetraMethDIM; or 10 nM TCDD.  
After 12 and 24 hours of treatment, the cells were lysed in 1X laemmli buffer and 
whole cell lysates used for Western blot analysis.  Representative Western blots 
are shown.   
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Figure 3.40: Cell cycle protein levels after 12 and 24 hours of treatment in MDA-
MB-453 cells. Cells were seeded in media containing 2.5% charcoal-stripped 
FBS and dosed with DMSO; 5 or 10.0 µM 1,1’,2,2’,tetraMethDIM; or 10 nM 
TCDD.  After 12 and 24 hours of treatment, the cells were lysed in 1X laemmli 
buffer and whole cell lysates used for Western blot analysis.  Representative 
Western blots are shown.   
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1,1’,2,2’-tetraMethDIM did not inhibit the phosphorylation of ErbB2 in BT-
474 cells and inhibition of downstream components, ERK1/2 and Akt, also was 
not observed in BT-474 or MDA-MB-453 cells by Western blots.  It is possible 
that 1,1’,2,2’-tetraMethDIM is acting downstream of activated ERK1/2 and Akt.  
Therefore, we examined the effects of 1,1’,2,2’-tetraMethDIM on activation of 
Elk-1 and Srf using chimeric GAL4-fusion proteins and a construct containing 5 
tandem GAL4 response elements (pGAL4).  Elk-1 and Srf are downstream 
targets of MAPK and Akt respectively and activation of these transcription 
factors is required for induction of several growth-regulatory genes (references).  
MDA-MB-453 cells were used for the transfection studies due to poor 
transfection efficiencies observed in BT-474 with several transfection reagents 
including calcium phosphate, Lipofectamine (Invitrogen), and Superfect 
(Qiagen).  MDA-MB-453 cells were transfected with pGAL4 and either an empty 
pM (GAL4) expression vector or one expressing a Srf-GAL4 fusion protein or an 
Elk1-GAL4 fusion protein.  Active Srf- or Elk1-GAL4 fusion proteins will bind to 
the GAL4 promoter and induce expression of luciferase protein, therefore a 
luciferase assay can be used as an indirect measure of Srf and Elk1 activation.  
The Elk1-GAL4 fusion vector did not increase luciferase activity above the empty 
pM vector control (Figure 3.41).  The assay depends on activation of the Srf-
GAL4 and Elk1-GAL4 fusion proteins by constitutively active PI3K/Akt and  
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MAPK pathways in the MDA-MB-453 cells.  Because the Elk1-GAL4 fusion 
protein was not activated by the MAPK pathway in the MDA-MB-453 cells, we 
were unable to further determine inhibition of Elk1-dependent activity by 
1,1’,2,2’-tetraMethDIM using this assay.  The Srf-GAL4 fusion vector showed 
increased luciferase activity above the empty pM vector and treatment with 
LY294002 inhibited luciferase activity; however treatment with 1,1’,2,2’-
tetraMethDIM increased luciferase activity above the DMSO control (Figure 
3.41).  Therefore, 1,1’,2,2’-tetraMethDIM does not inhibit activation of Srf in 
MDA-MB-453 cells in transfection studies, but surprisingly induces activity.  
These results indicate that activation of Srf and Elk-1 was not inhibited by 
1,1’,2,2’-tetraMethDIM suggesting that the growth inhibitory effects of this 
compound were not related to direct inhibition of ErbB2, Akt, or MAPK kinase 
signaling pathways.   
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Figure 3.41: Srf and Elk1 activity in transient transfection assays with MDA-MB-
453 cells. Cells were seeded in media containing 2.5% charcoal-stripped FBS 
and transfected with the empty pM vector, the Srf-Gal4 expression plasmid or 
the Elk1-Gal4 expression plasmid and the Gal4 promoter-luciferase reporter 
plasmid using the standard calcium phosphate method.  The transfected cells 
were dosed with DMSO; 5.0 or 10.0 µM 1,1’,2,2’,tetraMethDIM; 10 µM U0126; 
10 µM LY294002; or 10 µM 1,1-bis(3’-indolyl)-1-(phenyl)methane (c-phenDIM).  
Thirty-six hours after treatement the cells were lysed and assayed for luciferase 
activity and total protein concentration.  Luciferase activity was normalized to 
total protein concentration for each sample and mean + SE is plotted (n=3).  
Significant (p<0.05) changes are indicated (*).   
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TGFβ1 induces growth arrest and apoptosis in many cell types and these 
effects are mediated through kinase receptors and downstream intracellular 
effectors termed SMADs.  TGFβs activate serine/threonine kinase receptors that 
propagate the signal through phosphorylation of SMAD2 and 3.  Active SMAD2 
and 3 then bind to SMAD4 and the resulting complexes localize to the nucleus 
and interact with specific promoter sequences to control gene expression.  
Therefore, the potential role of the TGFβ/SMAD pathway in mediating inhibition 
of cell proliferation by 1,1’,2,2’-tetraMethDIM was further investigated using a 
mammalian one-hybrid system to determine the activation of SMAD2- and 
SMAD4-GAL4 fusion proteins.  MDA-MB-453 cells were transfected with pGAL4 
and either an empty pM expression vector or vectors expressing SMAD2-GAL4 
or SMAD4-GAL4 fusion proteins.  Transfection with the SMAD2 and SMAD4 
fusion proteins increased the luciferase activity above that of the pM empty  
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vector, with higher activities observed for SMAD4 compared to SMAD2 (Figure 
3.42).  TGFβ1 was used as a positive control to show that activation of the 
SMAD pathway in the MDA-MB-453 cells leads to activation of the transfected 
fusion proteins and thus increased luciferase activity.  Treatment of MDA-MB-
453 cells with 10 ng/ml TGFβ1 induced transactivation in cells transfected with 
SMAD2-GAL4 whereas 5 or 10 µM 1,1’,2,2’-tetraMethDIM, DIM, and MCDF had 
minimal effects (Figure 3.42).  Ten ng/ml TGFβ1 also induced luciferase activity 
in cells transfected with SMAD4-GAL4 and 5 and 10 µM 1,1’,2,2’-tetraMethDIM 
(but not DIM or MCDF) also induced transactivation.  These results indicate that 
one mechanism of growth inhibition of MDA-MB-453 cells by 1,1’,2,2’-
tetraMethDIM may be through activation of the TGFβ1/SMAD pathway 
downstream of SMAD2 and upstream of SMAD4. 
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Figure 3.42: SMAD2 and SMAD4 activity in transient transfection assays with 
MDA-MB-453 cells. Cells were seeded in media containing 2.5% charcoal-
stripped FBS and transfected with the empty pM vector, the SMAD2-Gal4 
expression plasmid or the SMAD4-Gal4 expression plasmid and the Gal4 
promoter-luciferase reporter plasmid using the standard calcium phosphate 
method.  The transfected cells were dosed with DMSO; 2ng/ml or 10 ng/ml 
TGFβ1 (PeproTech, Inc.); 5.0 or 10.0 µM 1,1’,2,2’,tetraMethDIM; 5 or 10 µM
DIM; or 5 µM 6-MCDF.  Thirty-six hours after treatment the cells were lysed and 
assayed for luciferase activity and total protein concentration.  Luciferase activity 
was normalized to total protein concentration for each sample and mean + SE is 
plotted (n=3).  Significant (p<0.05) changes are indicated (*).   
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3.3.6 Downregulation of the AhR and induction of cyp1A1 by 1,1’,2,2’-
tetraMethDIM compared to other AhR agonists in MCF-7, BT-474 and MDA-MB-
453 cells  
 AhR agonists exhibit different receptor binding affinities as well as 
different potencies as inducers of AhR-dependent responses such as 
downregulation of the receptor itself and induction of cyp1A1 protein.  These 
studies compared the effects of TCDD, 6-MCDF, DIM and 1,1’,2,2’-
tetraMethDIM on downregulation of the AhR and induction of cyp1A1 protein in 
MCF-7, BT-474 and MDA-MB-453 cells.  Cells were treated for 24 hours and 
whole cell lysates were analyzed by Western blot analysis to compare AhR, 
cyp1A1 and ERα protein levels in the various treatment groups.  Treatment of 
MCF-7 cells with TCDD and 6-MCDF resulted in a high induction of cyp1A1 
protein accompanied by downregulation of AhR protein (Figure 3.43).  1,1’,2,2’-
tetraMethDIM exhibited minimal induction of cyp1A1 in MCF-7 cells; however, 
this was not accompanied by downregulation of AhR protein.  DIM and E2 had 
no effect on cyp1A1 or AhR proteins; however, treatment with TCDD, 6-MCDF, 
DIM, and E2 all enhanced downregulation of ERα in MCF-7 cells compared to 
untreated controls.  In contrast, treatment with 1,1’,2,2’-tetraMethDIM did not 
affect ERα levels (Figure 3.43).  In BT-474 cells all the AhR agonists induced  
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cyp1A1 protein expression with similar induction potencies for 10 nM TCDD, 10 
µM 1,1’,2,2’-tetraMethDIM, and 5 µM 6-MCDF, whereas lower levels were 
observed in cells treated with DIM.  In contrast, only TCDD and 6-MCDF 
downregulated AhR protein (Figure 3.44).  DIM treatment did not induce 
downregulation of AhR.  BT-474 cells did not express levels of ERα protein as 
determined in Western blot analysis.  Previous reports of ERα expression in BT-
474 cells are conflicting, some studies report expression of low levels of ERα
and others refer to BT-474 cells as ERα negative cells lines (Elstner et al., 1995; 
Grunt et al., 1995; Magklara et al., 2000).  MDA-MB-453 cells exhibited the 
lowest level of response to the AhR agonists.  Only TCDD induced cyp1A1 
protein and downregulated AhR protein (Figure 3.45).  MDA-MB-453 cells have 
previously been characterized as an ERα negative cell line, and ERα was not 
detected in this study.    
214
               
D 6-MCDF DIMTCDD E2
Loading
Cyp 1A1
AhR
ERα
10 µM
1,1’,2,2’tretaMethDIM
                
Figure 3.43: AhR downregulation and Cyp1A1 induction in MCF-7 cells. Cells 
were seeded in media containing 2.5% charcoal-stripped FBS and dosed with 
DMSO; 10.0 µM 1,1’,2,2’,tetraMethDIM; 10 nM TCDD, 5 µM 6-MCDF, 10 µM
DIM, or 1 nM E2.  After 24 hours of treatment, the cells were lysed in 1X laemmli 
buffer and whole cell lysates used for Western blot analysis.  Representative 
Western blots are shown.   
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Figure 3.44: AhR downregulation and Cyp1A1 induction in BT-474 cells. Cells 
were seeded in media containing 2.5% charcoal-stripped FBS and dosed with 
DMSO; 10.0 µM 1,1’,2,2’,tetraMethDIM; 10 nM TCDD, 5 µM 6-MCDF, 10 µM
DIM, or 1 nM E2.  After 24 hours of treatment, the cells were lysed in 1X laemmli 
buffer and whole cell lysates used for Western blot analysis.  A sample of DMSO 
treated MCF-7 whole cell lysates is also loaded as a positive control for ERα
protein.  Representative Western blots are shown.   
216
                
D 6-MCDF DIMTCDD E2
Loading
Cyp 1A1
AhR
ERα
10 µM
1,1’,2,2’tretaMethDIM
Figure 3.45: AhR downregulation and Cyp1A1 induction in MDA-MB-453 cells.
Cells were seeded in media containing 2.5% charcoal-stripped FBS and dosed 
with DMSO; 10.0 µM 1,1’,2,2’,tetraMethDIM; 10 nM TCDD, 5 µM 6-MCDF, 10 
µM DIM, or 1 nM E2.  After 24 hours of treatment the cells were lysed in 1X 
laemmli buffer and whole cell lysates used for Western blot analysis.  
Representative Western blots are shown.   
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3.3.7 Inhibition of tumor development and growth in MMTV-c-neu mice by 
1,1’,2,2’-tetraMethDIM 
 The MMTV-c-neu mouse mammary tumor model expresses a mutated 
form of the rat c-neu (ErbB2) protein under the mouse mammary tumor virus 
promoter.  This murine model exhibits well characterized morphological changes 
in the mammary gland with palpable mammary tumors forming around 25 weeks 
of age (Muller et al., 1988).  Recently it has been reported that 1,1’,2,2’-
tetraMethDIM inhibited DMBA-induced mammary tumor growth in rats 
(McDougal et al., 2001) and in vitro data in this study show that 1,1’,2,2’-
tetraMethDIM inhibits growth of breast cancer cell lines that overexpress ErbB2 
(Figures 3.26 and 3.27).  Therefore, an initial study examined the potential 
antitumor activity of 1,1’,2,2’-tetraMethDIM as an inhibitor of development and 
growth of tumors in MMTV-c-neu mice.  MMTV-c-neu mice were dosed with 
1,1’,2,2’-tetraMethDIM (10 mg/kg) or a corn oil control every other day for 4 
weeks starting at 22 weeks of age.  Mice were palpated for tumors at each 
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dosing and after initial detection tumors volumes were determined every second 
day.  After 4 weeks, tumors were removed for final measurement and fixed for 
analysis and further studies.  The results (Figure 3.46) show that a mouse from 
the control group developed a tumor within 2 days after initiating treatment and 
after 4 weeks all the control (untreated) mice developed at least one tumor.  
Tumors did not appear in the 1,1’,2,2’-tetraMethDIM treatment group until 14 
days after initial treatment and one of the mice treated with 1,1’,2,2’-
tetraMethDIM did not develop mammary tumors by the end of the study.  Two of 
the control mice developed fast growing tumors 12 and 24 days into the study 
compared to the slow growing tumors that appeared in the 1,1’,2,2’-
tetraMethDIM treated mice, only one of which grew to more than 200 cm3 after 
12 days of growth (Figure 3.46).  This initial study indicates that 1,1’,2,2’-
tetraMethDIM may decrease the incidence and growth of mammary tumors in 
MMTV-c-neu mice and warrants further research.  
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Figure 3.46: Tumor incidence and growth in MMTV-c-neu mice.  Twenty-two 
week old MMTV-c-neu mice were treated with 10 mg/kg 1,1’,2,2’-tetraMethDIM 
or corn oil by gavage and palpable mammary tumor were measured and 
recorded every other day for 28 days.  The percent tumor free mice and tumor 
volumes are plotted.  (n=3 control, n=4 1,1’2,2’tetraMethDIM). 
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS
4.1 AhR-ERα crosstalk in uterine gene expression 
 Hormone or mitogenic polypeptide stimulation of the rodent female 
reproductive tract has been extensively investigated in both immature and 
ovariectomized rodents and in ERα and ERβ knockout mouse models.  A 
comparison of E2-responsiveness in uteri from ERKO and βERKO mice 
suggests that ERα plays a dominant role in normal uterine development 
(Lubahn et al., 1993; Krege et al., 1998a; Couse and Korach, 1999; Hewitt and 
Korach, 2003).  Moreover, there is evidence from studies in βERKO mice that 
ERβ may inhibit ERα-induced responses; for example, in βERKO mice 
(compared to wildtype mice) enhanced E2-responsiveness and higher levels of 
progesterone receptor and Ki-67, a proliferation associated protein, were 
observed (Weihua et al., 2000).  In contrast, uteri from ERKO mice are poorly 
developed and hypoplastic, and after treatment with E2 the prototypical increase 
in uterine wet weight and vaginal cornification are not observed (Lubahn et al., 
1993).  Growth factors such as EGF also activate ERα-dependent 
pathways/genes in the mouse uterus and EGF induces increases in uterine DNA 
synthesis and progesterone receptor mRNA levels in wildtype but not ERKO 
mice (Curtis et al., 1996).  In contrast, some estrogenic responses such as 
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induction of c-fos are induced by EGF in both wildtype and ERKO mice 
demonstrating an ERα-independent pathway for c-fos gene expression by EGF 
in the mouse uterus.  Recent studies show that E2, estrogenic metabolites, or 
synthetic estrogens also induce expression of multiple genes that are 
independent of ERα and ERβ and their induction is not inhibited by ‘pure’ 
antoestrogens such as ICI 182,780 (Das et al., 1997; Banerjee et al., 2003; Lee 
et al., 2003). 
 Cyclin D1 plays a critical role in cell proliferation and progression of cells 
from G0/G1 through S phase of the cell cycle and DNA polymerase α is 
necessary for DNA synthesis in S phase of the cell cycle.  Both genes are 
induced by E2 and cotreatment with TCDD inhibits the E2-induced response in 
vitro in breast cancer cell lines through ERα.  E2-induced cyclin D1 expression 
in the mouse uterus has also been demonstrated (Geum et al., 1997; Wang et 
al., 1998; Castro-Rivera et al., 2001; Samudio et al., 2001; Buchanan et al., 
2002).  Therefore, we hypothesized that cyclin D1 and DNA polymerase α would 
be appropriate model genes for investigating inhibitory AhR-ERα crosstalk in 
wildtype and transgenic mice.  The results in Figure 3.1 and 3.3 demonstrate 
that treatment with E2 induced uterine cyclin D1 and the 180 kDa catalytic 
subunit of DNA polymerase α gene expression in B6C3F1 mice, and maximal 
expression was observed 6-12 h after treatment with E2 in the luminal epithelial 
cells.  These results for cyclin D1 gene expression agree with previous studies 
that demonstrated maximal increase in total uterine cyclin D1 expression 6-12 h 
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after treatment with E2 and the time course of both cyclin D1 and 180 kDa 
catalytic subunit of DNA polymerase α gene expression correlates with previous 
studies showing maximal proliferation 12 to 24 hours after single treatment with 
E2 (Quarmby and Korach, 1984; Couse et al., 1997; Geum et al., 1997).  
Furthermore, the lack E2-induced cyclin D1 and DNA polymerase a catalytic 
subunit mRNA expression in uteri from ERKO-/- mice (Figures 3.4-3.7) 
demonstrate the requirement for ERα in the E2-induced response.    
A slight induction of cyclin D1 and DNA polymerase α catalytic subunit 
gene expression was seen in the stromal compartment 3 h after treatment and 
persisted through 12 h in the B6C3F1 mice (Figures 3.1 and 3.3).  In contrast, 
there was considerable diffuse background staining and staining of glands for 
cylin D1 mRNA in the uterine stroma of untreated ERKO+/+ mice and AhRKO 
mice at 6 hours after treatment (Figures 3.4 and 3.16) and for DNA polymerase 
α catalytic subunit mRNA in the uterine stroma of untreated ERKO+/+ mice 
(Figure 3.6) and this did not change after treatment with E2.  Similarly, after 12 h 
treatment in the ERKO +/+ and AhRKO mice, although the overall staining of the 
uterine tissue for cyclin D1 and DNA polymerase α catalytic subunit was weaker, 
an induction of cyclin D1 gene expression was not seen in the stromal 
compartment of the uterus with hormone treatment in either mouse model 
(Figure 3.5 and 3.17).  Induction of DNA polymerase α catalytic subunit gene 
expression was not observed in the stromal compartment of ERKO+/+ mice 
(Figures 3.7).  In contrast, DNA polymerase α catalytic subunit mRNA was 
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induced in uterine stromal cells of AhRKO mice after 6 h treatment and some 
induction was also detected after 12 h (Figures 3.18 and 3.19).  Since ERα is 
expressed in both uterine stromal and epithelial cells (Couse and Korach, 1999) 
and E2 induces proliferation in both stromal and epithelial cells of the immature 
mouse uterus (Quarmby and Korach, 1984), it is not surprising that hormone-
induced cyclin D1 and DNA polymerase a catalytic subunit gene expression is 
observed primarily in luminal epithelium but also noted in stromal uterine cells of 
the immature mouse uterus in B6C3F1 mice.  Higher glandular development and 
glandular epithelial staining for cyclin D1 mRNA were observed in the uteri from 
ERKO+/+ and AhRKO mice (Figures 3.4, 3.5, 3.16, and 3.17) and even the 
B6C3F1 mice used for E2 and TCDD cotreatment studies (Figures 3.10 and 
3.11) compared to the uteri from B6C3F1 mice used in the initial timecourse 
studies (Figure 3.1).  Proliferation is seen only in the luminal epithelium of 
mature adult uteri, and since glandular development is a sign of maturation, 
perhaps the uteri of these mice are slightly more developed and thus E2-induced 
proliferation and the need for cyclin D1 and DNA polymerase α catalytic subunit 
expression in the stroma is reduced.   
Previous studies using tissue recombination of stromal and epithelial cells 
from wildtype and ERKO mice show that in ovariectomized nude mice bearing 
stromal and epithelial tissue recombinants as subrenal capsule grafts, hormone-
induced DNA synthesis /proliferation was primarily dependent on stroma from 
ER-postive animals (Cooke et al., 1997; Buchanan et al., 1999).  It was 
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concluded that “epithelial ER is neither necessary nor sufficient for E2-induced 
uterine epithelial proliferation” (Cooke et al., 1997), and the proposed model for 
epithelial cell proliferation was associated with a paracine pathway and 
dependent on induction of ERα-dependent stromal factors.  Nevertheless, other 
E2-induced genes such as lactoferrin and complement C3 can be induced 
directly in uterine epithelial cells (Buchanan et al., 1999).   
Previous studies by Geum and coworkers (Geum et al., 1997) show that 
E2 induced cyclin D1 mRNA levels in uterine tissue of immature female ICR 
mice, and their time course study for cyclin D1 mRNA was comparable to the 
results illustrated in Figure 3.1 with maximal induction observed after 6-12 hours.  
Moreover, since induction of cyclin D1 mRNA is primarily localized to the luminal 
epithelial cells with only slight induction in the stromal cells (Figure 3.1), induced 
cyclin D1 mRNA in whole uterine extracts must be primarily due to increased 
cyclin D1 mRNA in epithelial cells (Geum et al., 1997).  It was also reported that 
the protein synthesis inhibitor cycloheximide did not affect hormonal activation of 
uterine cyclin D1 (Geum et al., 1997) suggesting that induction of cyclin D1 by 
E2 in luminal epithelial cells observed in this study may be due to a direct effect 
on the epithelial cells and not related to ERα-dependent stromal paracrine 
factors.  Similarly, our studies demonstrate that treatment with cycloheximide 
does not affect E2-induced cyclin D1 or DNA polymerase α catalytic subunit 
gene expression in the luminal epithelial cells (Figures 3.22 and 3.23) or E2-
induced increase in uterine wet weights (Figure 3.21).  This suggests that the 
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stromal cell-dependent proliferation of uterine epithelial cells observed in tissue 
recombination studies may not involve cyclin D1 or DNA polymerase α but other 
genes/proteins critical for cell proliferation.  However, the tissue recombination 
studies use stromal and epithelial cells from adult mice and our study as well as 
the study by Guem and coworkers used immature mice (Cooke et al., 1997; 
Geum et al., 1997; Buchanan et al., 1999).  Therefore, the difference in the 
requirement for paracrine factors from the stromal for epithelial responses could 
also be due to the different developmental stages of the uterine tissue studied.  
Differences in the ability of the adult and immature uterus to respond to 
treatment with E2 have been demonstrated previously.  Stromal and epithelial 
uterine tissue proliferate in response to E2 in the immature mouse, whereas 
stromal uterine tissue in adult mouse loses the ability to respond and only the 
epithelium proliferates in response to hormone.  Therefore, ERα signaling in the 
mature adult uterus differs from that of the immature uterus and could account 
for the difference in direct vs. indirect action of E2 on the luminal epithelial cells.   
Insufficient inhibition of protein synthesis by cycloheximide treatment may 
also have allowed a high enough level of paracrine factors to be produced to 
elicit an E2-induced response in the luminal epithelial cells of the uterus.  Guem 
and coworkers (Geum et al., 1997) did not include a positive control in their 
study demonstrating that the dose of cycloheximide was sufficient to inhibit 
protein synthesis (Geum et al., 1997).  We used the inhibition of TCDD-induced 
cyp1A1 protein expression in the liver as a control for cycloheximide treatment.  
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Protein expression of cyp1A1 was inhbited in the TCDD and TCDD+E2 mice 
treated with cyclohexmide compared to those not treated with cylcloheximide; 
however, 4 out of the 8 TCDD and TCDD+E2 animals treated with 
cycloheximide do show a low level of cyp1A1 expression compared to the 
absence of any cyp1A1 protein without TCDD treatment (Figure 3.20).  
Therefore, a low level of protein synthesis occurred in the livers of some animals 
treated with cycloheximide and may also have occurred in the uterus.  It could 
be argued that even partial inhibiton of protein synthesis would lead to lower 
levels of paracrine factors produced and a decrease in the luminal epithelial 
response to E2; however, a threshold level may be all that is necessary for a full 
luminal epithelial response.  Many in vivo studies with cycloheximide treatment 
limit the time course to 6 hours to ensure that maximal inhibiton of protein 
synthesis throughout the study because the effectiveness of cycloheximide may 
decrease at later timepoints.  
Previous studies have demonstrated that activation of the AhR complex 
by TCDD and related compounds results in inhibitory AhR-ERα crosstalk in the 
rodent uterus and in breast cancer cells (Wang et al., 1998; Safe and McDougal, 
2002).  The results in Figures 3.10 and 3.11 show that in B6C3F1 mice 
cotreated with E2+TCDD, there was decreased luminal epithelial cyclin D1 
mRNA expression after 6 or 12 h compared to animals treated with E2 alone, 
and the inhibitiory response was more pronounced after 12 h.  Similarly, Figures 
3.12 and 3.13 show that cotreatment with E2+TCDD in B6C3F1 mice resulted in 
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a decreased luminal epithelial DNA polymerase α catalytic subunit mRNA 
expression at 6 and 12 h compared to animals treated with E2 alone; moreover, 
the inhibitory response was as effective at 6 h as it was at 12 h.  In contrast, 
TCDD did not inhibit activation of cyclin D1 or DNA polymerase a catalytic 
subunit gene expression in AhRKO mice (Figures 3.16-3.19) confirming a role 
for the AhR in mediating this inhibitory response.  Using the tissue 
recombination approach with uterine stroma and epithelium from wildtype and 
AhRKO mice, Buchanan and coworkers showed that inhibition of E2-induced 
uterine epithelial cell proliferation and lactoferrin mRNA levels by TCDD was 
dependent on the stromal AhR (Buchanan et al., 2000).  We have demonstrated 
that in the immature female mouse model, E2 acts directly on the luminal 
epithelial cells and does not require paracrine factors from the stroma; therefore, 
if the AhR is required in the stroma then stromal-epithelial cell interactions are 
necessary for the inhibitory response.   
Several possible mechanisms of inhibitory AhR-ERα crosstalk have been 
described including direct interaction of the AhR complex with 5’-promoter 
inhibitory dioxin response elements, competition with ERα for common 
coregulatory proteins, activation of proteasome-dependent degradation of ERα,
or induction /activation of nuclear factors that inhibit hormone activation of gene 
expression (Gierthy et al., 1988; Badawi et al., 2000; Klinge et al., 2000; Carlson 
and Perdew, 2002; Ohtake et al., 2003; Wormke et al., 2003).  Most of these 
inhibitory pathways are intracellular, whereas a stromal influence on the 
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inhibitory AhR-ERα crosstalk must induce other paracrine-dependent inhibitory 
pathways.  In contrast, Figures 3.22 and 3.23 show that inhibition of protein 
synthesis by cycloheximide treatment does not affect the inhibition of E2-
induced cyclin D1 or DNA polymerase α catalytic subunit gene expression by 
TCDD.  Therefore, the inhibitory AhR-ERα crosstalk for gene expression in 
these studies most likely involves an intracellular mechanism rather than a 
paracrine dependent pathway.   
The conflicting results between our AhR-ERα cross talk studies and the 
tissue recombination studies are analogous to the differences between the 
results of our studies on E2-induced luminal epithelial responses and the tissue 
rescombination studies.  Primarily, the uteri used were at different levels of 
development and the requirements for AhR-ERα crosstalk may change as ERα
signaling changes in the maturing uterus.  It could be that the AhR is required in 
the stroma of adult tissue because E2-induced responses depend on stromal 
ERα and induced stromal factors.  Tissue recombination studies in the adult 
uterus have demonstrated that ERα and the AhR are necessary in the stroma 
for E2-induction of luminal epithelial responses and for inhibition of the 
responses by TCDD.  Therefore, ERα and AhR receptors are required in the 
same cell types and the mechanism of AhR-ERα crosstalk could be one of the 
intracellular inhibitory mechanisms that have been described.  However, if E2 is 
acting directly on the luminal epithelial cells in the immature uterus to induce a 
response, then tissue recombination studies with immature uteri may show that 
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the AhR is required in the luminal epithelial cells to inhibit the E2-induced 
response through one of the intracellular inhibitory mechanisms described.  
Furthermore, as described above for E2-induced responses in the luminal 
epithlelium, incomplete inhibtion of protein synthesis could also account for the 
conflicting results.  A low level of paracrine factors produced in the stroma may 
be sufficient to inhibit E2-induced responses in the luminal epithelial cells.   
The growth factor VEGF is involved in postnatal angiogenesis and studies 
in humans and non-human primates have shown regulation of VEGF throughout 
the menstrual cycle to prepare the stromal compartment of the uterus for 
implantation (Nayak and Brenner, 2002; Sugino et al., 2002).  Previous studies 
in the rat uterus have shown that treatment with E2 results in rapid upregulation 
of VEGF mRNA in the stromal compartment within 1 hour after treatment.  The 
localization and timing of E2-induced VEGF expression in the uterus described 
in previous reports differed from that of cyclin D1 and therefore, it was used as a 
third model gene to investigate AhR-ERα crosstalk in wildtype and transgenic 
mice.  Initial studies in B6C3F1 mice demonstrated E2-induced expression 
patterns similar to that seen previously in the rat (Figure 3.2).  VEGF mRNA was 
induced throughout the stroma of the uterus with maximal expression 1 and 3 h 
after treatment.  Similarly, VEGF gene expression was induced by E2 in the 
stroma of ERKO+/+ uteri; however, no induction of VEGF gene expression was 
seen with hormone treatment in ERKO-/- mice (Figure 3.8) demonstrating the 
requirement for ERα in the E2-induced gene expression in the stromal tissue.  In 
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contrast to the ability of TCDD to inhibit E2-induced cyclin D1 and DNA 
polymerase α gene expression, TCDD did not inhibit E2-induced VEGF gene 
expression in the uterine stroma after 1 or 3 h (Figures 3.14 and 3.15).  The 
induction of VEGF mRNA by E2 differed from E2-induced cyclin D1 and DNA 
polymerase α gene expression in both timing, with maximal induction at 1 to 3 h 
vs. 6 to 12 h, and localization, with strong stromal induction vs. slight stromal 
induction and strong luminal epithelial induction.  TCDD inhibited E2-induced 
DNA polymerase α catalytic subunit gene expression in the stromal cells of 
B6C3F1 mice (Figures 3.12 and 3.13); therefore the lack of TCDD inhibition of 
E2-induced VEGF gene expression is likely not due to the stromal location of the 
mRNA induction.  However, the rapid induction of VEGF mRNA by E2 could 
account for the inability of TCDD to inhibit the response in our experimental 
model.  Mice were cotreated with TCDD and E2 at the same time.  It is possible 
that AhR-mediated inhibition of hormone-induced VEGF expression requires 
more prolonged treatment with TCDD and induction of inhibitory factors.  Future 
studies will investigate this possibility.   
4.2 ErbB2-induced tumor development in MMTV-c-neu mice 
ErbB2 and the ErbB family of receptors are involved in normal growth and 
differentiation of the breast (Carraway et al., 1997) and have been implicated in 
carcinogenesis as well (Slamon et al., 1989).  Activation via the tyrosine kinase 
region of the receptors mediates cell proliferation, differentiation, and survival 
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(Salomon et al., 1995; Schlessinger, 2000; Simon, 2000).  Dysregulation of 
ErbB2 signaling pathways can result from receptor gene amplifications or 
mutations that lead to an increase in receptor transcription, translation, or 
stability altering the receptor protein expression levels in the cells.  ErbB2 
overexpression in observed in 20-30% of breast tumors (van de Vijver et al., 
1987; McCann et al., 1991) and is associated with aggressive tumor behavior 
and poor prognosis (Hynes and Stern, 1994).  One study showed that 92% of 
overexpression of ErbB2 in breast cancer was due to gene amplification 
(Pauletti et al., 1996) and overexpression is found in all stages of tumor 
development, but not in benign tissue (Allred et al., 1992).  However, the role of 
ErbB2 in tumor formation is unclear.   
Transgenic mice provide a useful model to assess the role of oncogenes 
in tissue-specific tumor induction and growth in vivo.  To study the contribution of 
an oncogene to mammary tumor formation, a gene can be fused to the MMTV 
promotor, which drives expression in mammary tissue, and the construct 
introduced into the genome of mice.  Tumor formation and growth can then be 
assessed to determine the effects of overexpression of the oncogene.  Studies 
of transgenic mice carrying MMTV-c-myc and MMTV-v-Ha-ras fusion contructs 
have shown development of solitary mammary adenocarcinomas in a stochastic 
manner that appear clonal in origin (Stewart et al., 1984; Leder et al., 1986; Sinn 
et al., 1987).  This indicates that the expression of c-myc or v-Ha-ras alone is not 
sufficient for transformation of mammary epithelial cells, additional events are 
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necessary for malignant transformation.  Multiple transgenic lines carrying 
MMTV-c-neu (ErbB2), either an activated or a wildtype c-neu, have been 
developed to assess the role of ErbB2 expression and activation in mammary 
tumor formation.  Some transgenic MMTV-c-neu lines indicate that further 
events in addition to expression of an activated ErbB2 are necessary for 
mammary epithelial cell transformation; however, multiple other lines indicate 
that overexpression of an activated ErbB2 receptor is sufficient for mammary 
epithelial cell transformation (Muller et al., 1988; Bouchard et al., 1989; Guy et 
al., 1992).   
For these studies we used an MMTV-c-neu line expressing an activated 
ErbB2 receptor available from Charles River Laboratories that was developed by 
Muller and coworker (Muller et al., 1988) and designated TG.NK in the original 
publication.  Studies of this line and others developed by Muller and coworkers 
indicated that expression of the activated ErbB2 receptor is sufficient for 
transformation and tumor development in mammary epithelium (Muller et al., 
1988).  Expression of activated ErbB2 is found in transformed epithelium but not 
in normal mammary epithelium in these mice and expression of the activated 
ErbB2 receptor occurs in a stochastic manner as the mice age so that 
transformed epithelium and tumors are found surrounded by normal mammary 
epithelium (Muller et al., 1988).  These transgenic mice provide a consistent 
model in which activated ErbB2 leads to transformation of the mammary 
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epithelium and eventual tumor formation around 25 weeks of age in 100% of the 
animals.   
In order to better understand how ErbB2 leads to transformation of the 
mammary epithelium we wanted to determine changes in gene expression 
profiles that occur during transformation in these MMTV-c-neu mice.  Therefore, 
mammary glands were collected at 6, 12 and 18 weeks of age from MMTV-c-
neu mice and from FVB mice, which is the background strain of the MMTV-c-
neu transgenic line.  Theoretically, in the mammary gland of young mice the 
activated ErbB2 is not expressed and the mammary epithelium is normal, as the 
mice age activated ErbB2 begind to be expressed in certain mammary epithelial 
cells leading to changes in gene expression that result in transformation of the 
cells, and the older the mice, the more cells expressing activated ErbB2 and the 
higher the levels of changes in gene expression.  For these studies we are 
assuming the expression of the activated ErbB2 is random throughout the 
mammary epithelium of all the mammary glands.  Mammary glands #1 and #2 
were used for histological analysis because their location made isolation of 
mammary tissue without other contaminating tissue difficult and mammary gland 
#3, #4, and #5 were used for RNA isolation and microarray analysis of gene 
expression.  Histological analysis of serial sections of the mammary gland can 
assess the level of transformation of the mammary epithelium at each time point 
and the changes in the histopathology can be correlated with changes in gene 
expression profiles in the mammary glands at each time point.  Because ErbB2 
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is not available on the commercial Affymetrix or CodeLink microarray chips it is 
necessary to also analyze ErbB2 expression levels by RT-PCR and 
immunohistochemistry to compare differences in ErbB2 expression between 
mice and mammary glands with differences in gene expression profiles.    
Initial histopathological analysis of the mammary glands of 6 week old 
MMTV-c-neu and FVB found no differences between the transgenic and the 
background mice.  There was no indication of transformation in the mammary 
epithelium of the MMTV-c-neu mice.  Furthermore, there was little change in the 
gene expression profies of the mammary glands between the MMTV-c-neu and 
FVB mice based on microarray analysis using the Affytmetrix MG-U74Av2 chip 
and expression analysis using GeneSpring expression analysis software.  As 
shown in Table 3.1, of the 12,520 genes only 32 were upregulated greater than 
two fold and only 23 were downregulated greater than two fold when comparing 
three MMTV-c-neu and two FVB mice and few of these genes were changed 
greater than 3 fold (Tables 3.2 and 3.3).  Initial analysis has demonstrated little 
variation in gene expression within the MMTV-c-neu and FVB mice indicating 
that two animals per group may be enough for analysis at the 12 and 18 week 
time points (Table 3.4, Figure 3.24).  However, the 12 and 18 week old animals 
will also be going through the estrous cycle and changes in hormone levels may 
lead to changes in mammary gland gene expression profiles within the MMTV-c-
neu and FVB groups resulting in more variation and the need for more animals 
within each group for analysis.  Further analysis of gene expression changes at 
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6 weeks of age and analysis of gene expression in the mammary glands of mice 
at 12 and 18 weeks of age will increase our understanding of ErbB2-induced 
mammary epithelial cell transformation.   
4.3 Inhibition of ErbB2-mediated responses by 1,1’,2,2’-tetraMethDIM, an 
AhR agonist  
The antiestrogenic properties as well as the possible downregulatory 
effect on the ErbB family of receptors by AhR agonist warrant the further 
development SAhRMs for breast cancer chemotherapy where the compounds 
exhibit minimal toxicity but retain the antiestrogenic/antitumorigenic effects.  One 
series of SAhRMs our lab has focused on is ring-substituted diindolylmethanes 
(DIMs) that are able to inhibit mammary tumor growth in rodent models while 
exhibiting relatively low toxicity (McDougal et al., 1997; Chen et al., 1998a; 
McDougal et al., 2000; McDougal et al., 2001).  Recently it has been reported 
that the SAhRM 1,1’,2,2’-tetraMethDIM inhibited DMBA-induced mammary 
tumor growth in rats and also inhibited constitutively active MAPK and p110 
(catalytic subunit of PI3-K) in vitro in MCF-7 human breast cancer cells.  Several 
ErbB2-overexpressing breast cancer cells such as the BT-474 and MDA-MB-
453 cell lines express a functional AhR and exhibit constitutive activation of both 
the MAPK and PI3K pathways.  Therefore we investigated inhibitory AhR-ErbB2 
interactions of 1,1’,2,2’-tetraMethDIM in BT-474, MDA-MB-453 and MCF-7 cells 
lines.   
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Initially we determined whether 1,1’,2,2’-tetraMethDIM would inhibit the 
growth of BT-474 or MDA-MB-453 cells in presence of low levels (2.5% and 5%) 
of charcoal-stripped fetal bovine serum or high levels (10%) of untreated fetal 
bovine serum, and whether 1,1’,2,2’-tetraMethDIM would inhibit the basal, E2-
induced or heregulin-induced growth of MCF-7 cells.  Results in Figures 3.25-
3.27 show that 1,1’,2,2’-tetraMethDIM inhibits the growth of both BT-474 and 
MDA-MB-453 cells in low levels of serum, but not in the presence of 10% FBS.  
Most likely the high level of growth stimulatory factors present in that amount of 
untreated FBS masked the inhibitory actions of 1,1’,2,2’-tetraMethDIM in the 
cells.  Furthermore, as seen in Figure 3.28, 1,1’,2,2’-tetraMethDIM was able to 
inhibit basal growth of MCF-7 cells, as well as E2 and heregulin induced growth.   
Cell growth can be inhibited by cytotoxicity leading to cell lysis, alterations 
in the cell cycle leading to increases in the length of stages of the cell cycle or 
cell cycle arrest, or induction of apoptosis leading to cell death.  Results in 
Figures 3.29 and3.30 show that 1,1’,2,2’-tetraMethDIM did not induce 
cytotoxicity at any of the doses used in either cell line.  Analysis of apoptosis 
induction demonstrated that 1,1’,2,2’-tetraMethDIM did not activate apoptosis 
pathways that involved caspase-3 activation or PARP cleavage in either the BT-
474 or the MDA-MB-453 cells (Figures 3.33-3.35).  However, in order to fully 
exclude apoptosis as one of the mechanisms of 1,1’,2,2’-tetraMethDIM growth 
inhibition, further analysis with other apoptosis assays is necessary.   
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Alterations in the timing of the cell cycle are apparent by changes in the 
percentage of cells in each stage of the cycle at a particular time.  We analyzed 
cell cycle progression after 4 days of treatment because this time point was just 
prior to time points in which increasing differences in cell numbers were seen in 
the cell proliferation assays (Figure 3.27).  As seen in Figure 3.31, treatment 
with 1,1’,2,2’-tetraMethDIM resulted in an increase in the percentage of BT-474 
cells in G0/G1 stage of the cell cycle.  These results indicate that 1,1’,2,2’-
tetraMethDIM alters cell cycle progression in BT-474 cells resulting in a longer 
time spent in G0/G1 for the overall cell population or an arrest of a small 
population of the cells in G0/G1.  In contrast, 1,1’,2,2’-tetraMethDIM did not affect 
the cell cycle progression in MDA-MB-453 cells (Figure 3.32).  The cell cycle 
proteins cyclin D1, p21 and p27 were also analyzed to determine any effects 
1,1’,2,2’-tetraMethDIM had on the cell cycle.  Although cyclin D1 and p21 levels 
were not affected by treatment with 1,1’,2,2’-tetraMethDIM, p27 levels were 
increased in a dose dependent manner after 4 days of treatment in both BT-474 
and MDA-MB-453cells (Figure 3.37 and 3.38).  Therefore, it seems that one 
mechanism of growth inhibition by 1,1’,2,2’-tetraMethDIM could be through 
increased expression of the inhibitory protein p27.  In BT-474 cells the increased 
p27 levels could be the cause of the altered cell cycle progression detected in 
BT-474 cells with an increase in cells in G0/G1.  However, previous studies in 
BT-474 cells have shown that modulation of both cyclin D1 and p27 was 
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necessary for inhibition of cell growth by the ErbB kinase inhibitor AG1478 
(Lenferink et al., 2001).   
 Both BT-474 and MDA-MB-453 cells have constituitively active MAPK 
and PI3-K pathways that regulate cell proliferation and apoptosis and inhibition 
of cell proliferation in these cells is likely due to inhibition of one of the kinase 
pathways.  We analyzed phosphorylation of ErbB2, ERK1/2, and Akt to 
determine if 1,1’,2,2’-tetraMethDIM inhibited either of these kinase pathways 
leading to decreased phosphorylation of the receptor or signaling molecules.  
However, 1,1’,2,2’-tetraMethDIM did not decrease phosphorylation of ErbB2 
receptor or ERK or Akt signaling molecules (Figures 3.36-3.38).  Furthermore, 
MDA-MB-453 cells were used in transfections for the mammalian one-hybrid 
assay with Srf and Elk fusion proteins to determine if 1,1’,2,2’-tetraMethDIM 
acted downstream of ERK and Akt to inhibit either kinase pathway.  Srf and Elk 
are transcription factors downstream of the PI3-K and MAPK pathways; 
however, Elk was not activated in the MDA-MB-453 cells and Srf activation was 
not affected by 1,1’,2,2’-tetraMethDIM treatment (Figure 3.41).  Therefore, we 
found no evidence that 1,1’,2,2’-tetraMethDIM was inhibiting cell growth in BT-
474 or MDA-MB-453 cells through inhibition of either the MAPK or PI3-K 
pathways.   
 TGFβ1 is an inhibitor of the cell proliferation as well as an inducer of 
apoptosis in many cell types.  The intracellular SMAD proteins mediate the 
downstream signal of TGFβ1 with SMAD2 and 3 activated through 
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phosphorylation and binding to SMAD4 to regulate transcription.  In our studies 
using the SMAD2 and SMAD4 fusion protein with the mammalian one-hybrid 
assay in MDA-MB-453 cells, 1,1’,2,2’-tetraMethDIM increased the activity of 
SMAD4, but did not affect SMAD2 activity (Figure 3.42).  Therefore, 1,1’,2,2’-
tetraMethDIM may inhibit cell growth through induction of TGFβ1/SMAD 
signaling downstream of SMAD2 and upstream of SMAD4.  However, a better 
system to test the activity of the SMAD proteins may be necessary because the 
basal activity and the induction by TGFβ1 of the SMAD2 fusion protein were 
relatively low.   
 Ongoing studies with several ring-substituted DIMs and DIM indicate that 
these compounds inhibit growth of ER-negative breast cancer cells and other 
ER-independent cell lines.  Minimal effects on cell cycle genes and kinase 
pathways have been observed as reported in this study for 1,1’,2,2’-
tetraMethDIM in BT-474 and MDA-MB-453 cells.  Recent data suggests that the 
DIM group of compounds may target the mitochondria and induce apoptotic or 
necrotic death pathways and these are currently being investigated.   
 1,1’,2,2’-tetraMethDIM and other methyl-substituted DIM analogues are 
classified as SAhRMs.  The compounds bind the AhR transforming the rat 
hepatic AhR into a DNA binding form and inhibit E2-induced cell proliferation in 
T47D cells as well as certain E2-induced uterine responses in mice; however, 
they do not induce cyp1A1 promoter activity in vitro in T47D cells (McDougal et 
al., 2001).  We wanted to determine the AhR agonist activity of 1,1’,2,2’-
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tetraMethDIM and other AhR ligands such as TCDD, 6-MCDF, and DIM in BT-
474 and MDA-MB-453 cells because differential activation of the AhR could 
account for different mechanisms of growth inhibition between the cell lines.  
Downregulation of AhR protein and induction of cyp1A1 protein were used as 
measures of AhR agonist activity.  As seen in Figure 3.44, TCDD, 1,1’,2,2’-
tetraMethDIM, 6-MCDF, and DIM induced cyp1A1 protein with TCDD as the 
most potent inducer and DIM as the weakest inducer in BT-474 cells.  TCDD, 6-
MCDF, and 1,1’,2,2’-tetraMethDIM also downregulated AhR protein levels in BT-
474 cells; however, the downregulation by 1,1’,2,2’-tetraMethDIM was very 
slight.  In contrast, only TCDD induced cyp1A1 protein and downregulated AhR 
protein in MDA-MB-453 cells (Figure 3.45).  The AhR agonist activity of the 
compounds in MCF-7 cells fell between activity in the BT-474 and MDA-MB-453 
cells.  TCDD and 6-MCDF induced high increases in cyp1A1 protein and easily 
detectable decreases in AhR protein, whereas 1,1’,2,2’-tetraMethDIM induced 
very low levels of cyp1A1 protein and did not downregulate the AhR in MCF-7 
cells (Figure 3.43).  Furthermore, ERα downregulation was induced by  
treatment with TCDD, 6-MCDF and DIM, but not 1,1’,2,2’-tetraMethDIM in MCF-
7 cells.  The differences in AhR agonist activity in the cell lines could be caused 
by varying levels of AhR or cofactor expression in the cells and could result in 
activation of differential signaling and thus different mechanisms of cell growth 
inhibition. 
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In addition to the in vitro studies, a preliminary study using MMTV-c-neu 
transgenic mice that overexpress ErbB2 in the mammary gland was also carried 
out to determine the inhibitory effects of 1,1’,2,2’-tertaMethDIM on ErbB2-
induced tumor formation.  Although the number of mice used for the study was 
low, the results in Figure 3.46 indicate that 1,1’,2,2’-tetraMethDIM may inhibit 
ErbB2-induced tumor growth in mice.  Future studies using more mice should 
focus on earlier treatment with 1,1’,2,2’-tetraMethDIM or related compounds to 
determine if the compounds are able to decrease tumor incidence or on 
treatment once palpable tumors arise to determine whether or not the 
compounds are able to inhibit the growth of detectable tumors.   
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